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CHAPER 1. INTRODUCTION 
1.1 Carbohydrates as energy sources and structural materials 
Carbohydrates, also known as saccharides, are literally hydrates of carbon, with 
empirical formula Cx(H2O)y. The prefix glyco- is used to denote carbohydrates or 
carbohydrate-containing substances, or carbohydrate-related fields of research, while 
the suffix -ose is part of the nomenclature of simple carbohydrates such as glucose, 
fructose, sucrose and lactose. The term “sugar” is almost an equivalence of 
carbohydrate. “Glycan” is always used as the name for carbohydrate polymers. 
Structurally it is more accurate to view carbohydrates as polyhydroxy aldehydes and 
ketones (Scheme 1), modified with chemical groups such as N-acetyl, sulfate, 
carboxylic acid and deoxy units. A simple straight-chain carbohydrate molecule exists 
in equilibration with its cyclic forms via the reversible formation of hemiacetal or 
hemiketal. This process creates one more stereogenic center, i.e. the anomeric carbon, 
with two possible configurations, which leads to the categorization of α and β anomers 
(Figure 1). Natural carbohydrates are usually found in polymeric form as 
polysaccharides with the linkage involving the anomeric carbon, while the 
monosaccharides are the simple carbohydrates that cannot be further hydrolyzed into 
smaller building blocks. Similarly, disaccharides and oligosaccharides are terms used 
for the polysaccharide with the appropriate degrees of polymerization. 
 




As one of the four major types of biological macromolecules, carbohydrates are 
regarded as energy storage and supply substances, and as structural components in 
biological systems. In particular, carbohydrates are the direct products of 
photosynthesis, the fundamental process that converts light energy into chemical 
energy and reduces inorganic carbon dioxide into organic carbohydrates. The initially 
formed carbohydrates such as glucose are then used as fuel to drive metabolism, or as 
the precursors for the biosynthesis of other biologically important molecules including 
lipids and amino acids. Or else, the carbohydrates together with their potential chemical 
energy are fixed into polysaccharides. Starch, which is a polymer of glucose with 
1,4-α-glycosidic linkages, serves as the main way of storing energy in plants. When the 
glucose monomers are linked through 1,4-β-glycosidic bonds, cellulose fibers are 
produced for use as the ubiquitous structural component of the plant. This serves as 
the start of the food chain and supplies all of the organic materials and most of the 
energy necessary for life on earth.1 The consumption of these polysaccharides by 
animals and bacteria requires their digestion into monomeric glucose units, which are 
readily absorbed and used as instant energy sources. Similar to the strategy adopted 
by the plants, excess amounts of glucose is stored in mammals in the form of 
polysaccharides (i.e. glycogen). When it is needed, these polysaccharides are quickly 
hydrolyzed into monosaccharides, which can then release their chemical energy via a 
process called cellular respiration to generate ribose (a pentose)-containing adenosine 
triphosphate (ATP) (Figure 1). Structurally comparable to cellulose, chitin is 




exoskeletons of arthropods. As is found in ATP, ribose and deoxyribose also find their 
roles in the formation of the backbone of the genetic molecules RNA and DNA. 
 
Figure 1. Structure of Adenosine triphosphate (ATP). 
While all of the functions in energy transportation and structure demonstrate the 
importance of carbohydrates in biological systems, their versatility was largely 
underestimated compared to the other two major types of biological materials—proteins, 
which mediate most of the chemical reactions inside living organisms, and nucleic 
acids which carry genetic information. The situation only changed with the realization 
that carbohydrates are the keys to deciphering cellular recognition phenomena. 
1.2 Carbohydrates in cellular recognition processes 
Compared with nucleic acids and proteins, carbohydrates display extraordinary 
structural diversity, and possess incomparable capacity to form isomers in chain 
elongation. For example, due to the multifunctionality of carbohydrate molecules, two 
identical monosaccharide molecules can be attached in two different ways (leading to α 
and β anomers) at several different positions (leading to regioisomers) (Figure 2). 
Moreover, only twenty different amino acids are encoded by genetic code that is made 
out of four types of nucleotides, whereas over 300 naturally occuring monosaccharides 
have been identified, with 22 of them being used for the biosynthesis of most of the 
oligosaccharides and polysaccharides.2 This diversity is very well illustrated by a recent 




diversification can be derived from the covalent attachment of functionalities (such as 
sulfate, phosphate, and acetyl groups) and the formation of branched structures. 
Therefore, at least in theory, carbohydrates far surpass amino acids and nucleotides in 
information-storing capacity. Together with the complexity of the families of 
glycosyltransferases and glycan-modifying enzymes, such structural diversity arouses 
much speculation that beyond their unspecific4 structural and energy-related functions, 
carbohydrates may also play roles in specific biological processes where small 
changes in structures are recognized and vital to the function of other specific 
compounds in living systems. 
 
Figure 2. Examples of Regio- and Stereoisomers of Dimeric Glucosides. 
The directional property of cell and microorganism migration has long been 
observed. For example, blood cells circulating in the blood are able to leave the blood 
vessels and accumulate at the sites of inflammation. Different lymphocytes migrate 
selectively towards particular lymphoid organs, a process called lymphocyte homing. 
Infectious microorganisms including bacteria and viruses adhere to organs and tissues 
selectively. Apparently, the operation of the biological system depends on the precise 
communication between cells from the same or different organisms. Therefore, 
deciphering the mechanisms that cells employ in interacting with each other is of critical 




ailments. The role of carbohydrates in this process was not recognized until the late 
1960s, when two developments changed the situation: the first was the realization that 
the outer surface of all cell membranes is covered with sugar coats, mostly in the forms 
of glycoproteins and glycolipids; the other was the study of carbohydrate binding 
proteins, known as lectins. Lectins and cell surface carbohydrates act like locks and 
keys that pass information from one cell to another and mediate relevant biological 
consequences. 
1.2.1 The Fischer’s lock and key theory and the induced fit theory 
The classic lock and key theory was first postulated by Emil Fischer while 
investigating the stereospecificity of the enzyme emulsin towards amygdalin.5 An 
enzymatically catalyzed reaction begins with the binding of the substrates to the active 
sites of the enzyme, which has a unique geometric shape that is complementary to the 
geometric shape of the substrate molecule. According to Fischer’s theory, the enzyme 
is the lock and the substrate is the key. Only the correctly shaped and sized key 
(substrate) opens (binds to) a particular lock (enzyme). Later Paul Ehrlich6 extended 
the lock and key theory to the field of immunity. Frank Rattray Lillie7 also invoked it to 
describe the recognition between sperm and eggs. By the 1920s the lock and key 
theory had become one of the major theoretical assumptions of cellular biology.  
However, many experimental observations appeared that cannot be perfectly 
explained by the lock and key theory. For example, Koshland questioned why the APT 
that hexokinases normally use to phosphorylate the substrate hexoses is not 
hydrolyzed (which would lead to the great loss of enzyme activity and enormous waste 




usually occupied by water molecules.8 The lock and key theory was also unsuccessful 
in explaining why some competitive inhibitors of enzyme with high affinity (with the right 
geometric shape that can fit into the active site) failed to react on the enzyme’s 
surface.8 In 1958, Koshland9 proposed the induced fit theory that introduced the 
concept of a flexible enzyme, in contrast to the model of rigid enzymes implied in the 
lock and key theory. Over the years, especially with the direct evidences from protein 
X-ray crystallography, it is now widely accepted that essentially all enzymes undergo 
substrate-induced conformational change to some extent. This is not a refutation of 
Fischer’s lock and key theory; as Koshland pointed out, it still lives on, but just in an 
extension of it.8 It still guides research in cellular biology, as will be seen in the 
uncovering of the mechanism of cell-cell interaction. 
1.2.2 Cell surface carbohydrates – glycoproteins and glycolipids 
As mentioned earlier, one of the stimuli for the advancement of the field of 
glycobiology was the realization of the ubiquity of carbohydrates in living systems. 
Carbohydrates are found not only in the cellular machinery responsible for energy 
storage and release and structural support; most of the secretory proteins in eukaryotic 
cells are also heavily glycosylated. Proteins and peptides that are synthesized in the 
ribosome are transported by the endoplasmic reticulum to the Golgi apparatus, the 
organelle that is responsible for the most of the post-translational modification of 
proteins. The post-translational modifications of proteins in the Golgi apparatus include 
the addition of phosphates (phosphorylation) and, for the most part, the addition or the 
removal of carbohydrates. By doing so, the cargo proteins acquire the proper 




biological activities. In addition, the attached carbohydrates serve as labels that direct 
the proteins to different parts of the cells or to the extracellular space. For example, a 
mannose-6-phosphate is appended to the proteins (lysosomal enzymes) destined for 
lysosomes. Proteoglycans, which are the major component of the mammalian 
extracellular matrix, are formed by the attachment of glycosaminoglycans (GAGs) to 
the core proteins.10 
The classical model of plasma membranes, which puts emphasis on the lipid 
nature of the structure, had been so prevalent that the role of carbohydrates had been 
largely ignored. Even though scattered work, for example, the study of blood-group 
substances by Watkins and Morgan,11,12 pointed to the carbohydrates as components 
of plasma membrane, it was not until the 1960s, when electrophoresis13-16 and 
microscopic techniques17-20 were employed in the electrokinetic and histochemical 
studies of cells, that carbohydrates (and carbohydrate containing molecules, i.e. 
glycoproteins and glycolipids) received consideration as necessary parts of a complete 
model of the plasma membrane. More specifically, cell electrophoresis enabled a 
change of scientific opinion on the molecular origin of the ubiquitous net negative 
surface charge21 on all animal cells from the phosphate group of the bilayer 
phospholipids to the carboxylic acid group of sialic acids (a family of 9-carbon sugar 
acids). On the other hand, the advance of microscopy involving a variety of staining 
methods (periodic acid-Schiff stain, Hale stain, colloidal iron hydroxide, ferritin-labelled 
lectins and so on) specific for carbohydrates led to the demonstration of the existence 




these carbohydrates were exclusively distributed in the outer leaflet of the plasma 
membrane (Figure 3).19 
 
Figure 3. Structure of the Plasma Membrane. 
Remarkably, it is now known that every cell, no matter whether from a 
single-celled organism or a multicellular organism, carries a dense and complex coat of 
carbohydrates. Literally, the extracellular matrix which contains glycosaminoglycans 
(GAGs), proteoglycans and proteins falls into the category of cell surface 
carbohydrates. Unlike other GAGs, hyaluronic acid is neither covalently bound to 
proteins nor sulfated. Structurally, hyaluronic acid is a polymer of disaccharides 
consisting of N-acetyl-D-glucosamine and D-glucuronic acid linked by alternating β-(1,4) 
and β-(1,3) glycosidic bonds (Figure 4).23 Other proteoglycans include heparan sulfate, 
chondroitin sulfate, and kerantan sulfate. These proteoglycans are various GAGs 
bound to core proteins, formed in the Golgi apparatus via the process mentioned earlier. 
Due to the wide existence of carboxylic acid and sulfate functionalities, the negatively 
charged proteoglycans attract positively charged sodium ions, which leads to the 
absorption of large amounts of water molecules via osmosis. The pressure generated 




matrix (such as collagen and elastin) determines the stiffness and elasticity of the 
extracellular matrix, which in turn defines the mechanical properties of the extracellular 
environment. It is reported that the changes of these mechanical properties can be 
sensed by cells and leading to the regulation of many important cellular processes.24  
 
Figure 4. Structure of Hyaluronic Acid. 
While the carbohydrate components of the extracellular matrix may be 
considered to have limited association with the plasma membrane, the other group of 
cell surface carbohydrates consisting of glycoproteins and glycolipids constitutes an 
integral part of the plasma membrane. The term “glycoprotein” can be used in a broad 
context to represent any macromolecules that contain carbohydrates and proteins, as 
such the proteoglycans would also fall into its category. More specifically, a 
glycoprotein molecule found as part of the plasma membrane usually contains a 
transmembrane protein backbone to which one or more oligosaccharide chains are 
covalently bonded. Monosaccharides such as D-galactose, D-mannose, L-fucose, 
2-amino-2-deoxy-D-glucose, 2-amino-2-deoxy-D-galactose and the sialic acids are 
common members of the oligosaccharide chains. 
Glycolipids are those molecules in which there is one monosaccharide molecule 
or a chain of oligosaccharide covalently attached to a lipid backbone. The two major 
types of glycolipids found on the plasma membrane are glyceroglycolipids and 
glycosphingolipids, with the former containing glycosylated glycerol molecules acylated 




Sphingolipids have received tremendous attention because of their enrollment in signal 
transmission and cell recognition. A ceramide is formed when the sphingosine base is 
N-acylated with a fatty acid chain. On the backbone of ceramides, head groups 
including non-carbohydrate moieties (phosphocholine or phosphoethanolamine), 
monosaccharides (galactose or glucose) and oligosaccharides (usually containing sialic 
acid) can be attached at the 1-hydroxy group, leading to sphingomyelins, cerebrosides, 
and gangliosides, respectively. 
 
Figure 5. Structure of Sphingosine. 
In the early stages of research in this area, the structural information of the cell 
surface carbohydrates was gained without knowing their biological function.  Later the 
realization of the ubiquitous existence of the cell surface carbohydrates as well as the 
advances in research on their biosynthesis25-27 raised interest in the search of their 
function. The hypothesis had been made that carbohydrates serve as recognition 
markers at the cell surface based on their ubiquitous existence and information-storing 
capability. Early evidence came from the study of the effect of glycosidases on the fate 
of transfused lymphocytes by Gesner and coworker,28 and from the observation of the 
quick clearance of sialic acid-free ceruloplasmin molecules from the circulatory system 
and their accumulation in the liver cells.29 However, the link needed to turn structural 
information of cell surface carbohydrates into biological response was still missing. 
Intuitively, if the information-carrying carbohydrates (the keys) are located at the cell 




also be present at the cell surfaces or in the extracellular fluid. Finally in 1967, when 
Burger and coworkers30 isolated and characterized the glycoprotein from wheat germ 
lipase that was responsible for the agglutination of tumor cells, lectins, the non-immune 
and enzymatically inactive carbohydrate-binding proteins were taken into account 
regarding the recognition of cell surface carbohydrates.31 
1.2.3 Lectins as cell surface carbohydrate-binding proteins 
Long before the realization of lectins’ role in cellular recognition, the 
hemagglutination activity of agglutinins from rattlesnake venom,32 castor beans extract 
(ricin) and bovine serum had been observed.33 The richness of agglutinins in plant 
extracts facilitated the purification of such a protein (concanavalin A, from jack bean) 
and subsequent demonstration of its interaction with carbohydrates (starch, glycogen 
and mucins).34,35 Later, the specificity of interactions of several hemagglutinins with 
erythrocytes of different ABO blood groups invoked the features of immunoglobulins, 
and hemagglutinins were therefore regarded as antibody-like substances that 
specifically bind to carbohydrates. However, the non-immune origin of hemagglutinins 
led to the introduction of the term “lectin” by Boyd36 in 1954. The original definition of 
the term “lectin” emphasized the carbohydrate binding specificity and the distinction 
from antibodies. Currently, the lectin family excludes any enzymes (such as 
glycosyltransferase, glycosidase and sulfotransferase) that bind and modify their 
substrate carbohydrates and any transport proteins (such as the bacterial periplasmic 
receptors) of free mono- or oligosaccharides.33 Furthermore, the activities of 
agglutinating cells are no longer required as several lectins possess only one 




in nature. They are found in all types of living organisms and together with surface 
carbohydrates, exert biological functions that are vital to almost all processes based on 
cell-cell interactions, such as microbial infection, cell migration, immune defense, 
fertilization and embryogenesis. 
Plant lectins. Due to their richness and ease of isolation, more plant lectins have 
been characterized than from other sources. Due to the same reasons, plant lectins 
have been widely used as research tools in the field of biochemistry and cell biology.33 
The versatility of plant lectins is exemplified by their application in purification and 
quantification of glycoconjugates (affinity chromatography and enzyme-linked 
lectin-binding assays (ELLA), for example), glycome analysis by lectin microarrays, 
characterization of cell surface presentation of glycoconjugates in normal and 
genetically engineered cells, etc.37 
These applications exploit the affinity, specificity and stability of plant lectins 
towards carbohydrates under different chemical environments. However, despite their 
versatility as research tools, the physiological role of plant lectins is not known with 
certainty. It’s hypothesized that plant lectins serve as storage substances of nitrogen 
since they are usually rich in the storage organs and seeds of plants.38 More 
interestingly, plant lectins are also considered as part of plant defense systems, 
involving their carbohydrate binding properties.38 The toxicity of plant lectins toward 
higher animals is well known. For example, the phytohemagglutinin (PHA) in raw or 
insufficiently cooked beans causes nausea followed by vomiting and diarrhea of 
humans. Certain lectins are also demonstrated to be toxic to phytophagous insects.39 




are directly exposed to the contents of the diet and their surface carbohydrates render 
plant lectins the possible targets for binding, and thus causes the disturbance of their 
normal function. 
Plant lectins are also hypothesized to be involved in the symbiotic interaction of 
leguminous plants with nitrogen-fixing bacteria, particularly rhizobia,40 and this 
interaction displays high specificity. A lectin from a particular legume binds specifically 
to its rhizobial symbiont, but not the symbiont of other legume species.41 The host 
specific nodulation genes in rhizobia have been identified. Transfer of these genes to 
an uninfective strain of rhizobia enabled its infection and nodulation of the legume host 
of the donor rhizobial strain. More importantly, it has been observed that the 
recombinant hybrid strain produced the donor strain-type polysaccharide and displayed 
high affinity to the lectins from the legume host of the donor strain.42 
Animal lectins. Animals also produce a variety of lectins. Although animal lectins 
and their activities have been known for more than a century since the observation of 
Charcot-Leyden crystal (galectin-10) in the 1850s and the observation of the activities 
of rattlesnake venoms (agglutinins) towards blood cells by Mitchell,43 the pace of 
research of animal lectins only started to increase dramatically thanks to a series of 
work since 1950s. These work include the use of eel agglutinin for the study of the 
carbohydrate nature of the blood group O antigens by Watkins and Morgan,11 and the 
discovery of the mammalian hepatic lectins when studying the carbohydrate-dependent 
mechanisms that control the lifetime of glycoproteins in blood circulation by Morell and 




identification and characterization of surface carbohydrates on normal and malignant 
cells. 
A large number of animal lectins now have been discovered and classified into 
groups. However, the classification of animal lectins is rather difficult and not always 
straightforward. Initially, they were classified on the basis of binding characteristics into 
two families: the C-type lectins (requiring calcium for binding activity) and the S-type 
lectins (sulfhydryl-dependent binding, also known as galectins).45 The carbohydrate 
binding activities of a lectin can usually be attributed to a single protein module, which 
is usually referred to as the carbohydrate recognition domain (CRD), within the lectin 
polypeptide. Currently, more structural information is available and the classification is 
based on primary structural homology of the CRDs and more than ten families can be 
listed in addition to the C-type lectins and galectins.46 Each family contains several 
members which are found at different cellular locations and execute different functions. 
Animal lectins were shown to participate in a wide variety of biological processes. 
For example, the expression and secretion of many galectins is developmentally 
regulated, suggesting that they may play a role in the control of differentiation and 
organ formation.40,47 Two related transmembrane lectins (MPRs) that recognize the 
mannose 6-phosphate (Man-6-P) residues on lysosomal emzymes have been 
discovered, one of which also binds the insulin-like growth factor II (IGF-II) at the 
plasma membrane48. IGF-II is a polypeptide with growth-promoting function in vivo.49 
The role of IGF-II and the Man-6-P/IGF-II receptor in embryonic growth and 
development was suggested by their high expression in fetal tissues, which declines 




domains.51,52 The other MPR is a cation-dependent receptor (CD-MPR). Both MPRs 
exist in equilibrium between different membrane-bounded compartments in the cells 
(trans Golgi network, endosomes and plasma membrane) and are responsible for the 
delivery of Man-6-P marked lysosomal hydrolases to lysosomes and the endocytosis of 
Man-6-P-containing ligands.53 
Another well studied function of animal lectins lies in their role in the immune 
system. For example, the -1,3-glucan binding lectins found on the surface and in the 
plasma of hemocytes of several insect species enhance the activation of 
prophenoloxidase (proPO) by laminarin (-1,3-glucan-type polysaccharide), suggesting 
its involvement in defending against yeast and bacterial infection.54 Five types of 
tachylectins showing different levels of specificity were purified from the Japanese 
horseshoe crab, Tachypleus tridentatus. It is suggested that these tachylectins are 
enrolled in the crab’s innate immune system by recognizing the carbohydrates exposed 
on invading pathogens through a combinatorial method.55 In higher animals, there are 
collectins and ficolins that possess very similar functions. They recognize and bind to 
oligosaccharide structures on the surface of microorganisms, leading to the killing of 
pathogens through complement activation and phagocytosis.56 In higher animals, the 
lectin-carbohydrate directed interactions are not confined to pathological phenomena. 
They are also the basis of a series of healthy operations of the immune system, 





1.2.4 Nature of interactions between carbohydrates and lectins 
Carbohydrates interact with lectins through noncovalent bonds.60 Having 
multiple hydroxy groups, the interaction of carbohydrates with lectins through the 
formation of a hydrogen bonding network is of crucial importance to the transfer of 
structural information. The ubiquitous amide bonds in the peptide backbone and the 
polar side chains of many amino acids (such as the carboxylate group of aspartic acid 
and glutamic acid, and the amide group of asparagine and glutamine) are the usual 
counterparts of the hydrogen bonding in the lectins.61 The interaction through hydrogen 
bonding is directional, thus provides basis for the specificity of lectins toward different 
monosaccharides.60 
In addition to the multiple hydrophilic hydroxy groups, the two faces of the 
carbohydrate ring also display hydrophobic C—H bonds. The hydrophobic nature of the 
faces is thus frequently exploited in the establishment of hydrophobic interactions 
between the carbohydrate ligands and the aromatic amino acids in the binding sites of 
lectins. Methyl groups in 6-deoxy and N-acetylated sugars are also observed as the 
sources of hydrophobic interactions.60 An entropically favorable desolvation of water 
molecules from the binding pocket has been suggested as the driving force of this 
hydrophobic interaction.62 
Ionic interactions of charged carbohydrate molecules (for example, sialic acid, 
phosphorylated and sulfated sugars) with amino acid residues containing electrically 
charged side chains are also observed.61 Moreover, carbohydrates can also bind to 




These interactions set up the foundation for the binding of carbohydrates with 
lectins in physiological conditions. However, it’s frequently reported that the binding 
affinity of lectins for their monovalent ligands is low in vitro. For example, the binding 
affinity expressed as I50 of rat and chicken hepatic lectins (RHL and CHL) and 
mannose-binding protein (MBP) for their respective target monosaccharide galactose, 
N-acetylglucosamine and mannose are approximately 0.5, 0.4, and 1 mM, and are 
biologically insignificant.64 How does the low affinity of lectins toward the monovalent 
ligands meet the requirement for high strength and specificity in physiological 
environments? It’s now believed that the successful functioning of carbohydrate-lectin 
interaction is also dependent on their multivalent presentation. For the lectins 
mentioned above, the binding affinity increases geometrically with a linear increase in 
the sugar density of sugar-derivatized bovine serum albumin molecules as ligand.65 
This important phenomenon is called the glycoside cluster effect or multivalent effect.66 
In physiological conditions, the carbohydrate epitopes and lectins are arranged in such 
a way that the simultaneous interaction of multiple ligands with receptors can occur.67 
The answer to the question of why evolution selected the multivalent mode of binding 
may remain unknown, but studies of the binding properties of synthetic multivalent 
ligands have shown this type of interaction to be highly specific and versatile.68 In 
addition, the low affinity but multivalent interaction conveys greater reversibility, 
reducing the chance of trapping cells in unproductive binding events.69 The binding 
achieved by multiple interactions is also demonstrated to be more resistant to the shear 
stress that a cell encounters in the flowing blood stream.70 These properties of 




importance in mediating processes that depend on cell-cell interaction, and can surely 
be exploited to achieve a wide variety of applications. 
1.3 Carbohydrates in drug development 
1.3.1 The implications of carbohydrates in therapies 
Although the development of various antibiotics has improved our ability to 
defeat most bacterial infections, the increase of antibiotic resistance is always calling 
for new approaches to fight bacteria. As cell surface carbohydrates and lectins are 
involved in the early stages of bacterial infection, that is the attachment or adhesion of 
the bacteria to host tissues, drugs that mimic the cell-surface carbohydrates and bind 
competitively for the bacteria lectins might serve as anti-adhesion therapy agents 
without issues like resistance and toxicity because they are not bactericidal.71 
As early as the 1960s, it had been discovered that the carbohydrate patterns on 
the membrane surface of carcinogenic agent-transformed cells were much different 
from those on the membranes of normal cells, which suggested that carbohydrates 
may be crucial in understanding and thus controlling diseases like cancer.72 These 
alternated carbohydrate patterns aid in the survival and spread of the cancer cells by 
interacting with lectins on the lining of blood vessels, granting them the ability to 
circulate throughout the body.72 Therefore, the glycosylation differences in tumor cells 
are useful markers that can be exploited in designing highly selective anti-cancer 
agents such as vaccines. The ability of carbohydrates to induce an immune response 
was reported at the beginning of last century.73 However, it was not until recently that 
the interest in carbohydrate vaccines was aroused, following revolutionary advances in 




Glycosyltransferases and glycosidases are groups of enzymes that nature has 
developed to achieve the biosynthesis, degradation and modification of carbohydrates 
and glycoconjugates. Some natural products are known as inhibitors of 
glycosyltransferases, for example, nikkomycins found in Streptomyces are inhibitors of 
chitin synthase;74 echinocandins are found to be inhibitors of fungal -1,3-glucan 
synthases.75 Many synthetic or semi-synthetic compounds such as ethambutol, 
caspofungin and lufenuron possess inhibitory properties that have already found 
clinical applications. The glycosidic bond is the point at which these enzymes exert 
their activities. Therefore, specific carbohydrate derivatives with modification of the 
glycosidic bond may also be used as competitive inhibitors to control the activity of 
glycosyltransferases and hence affect the oligosaccharide pattern of a given system.76 
The change in the oligosaccharide pattern can subsequently have a profound effect on 
cell-cell interaction and thus is promising in treating diseases like metastatic cancer and 
bacterial infections.77,78 
1.3.2 Glycoconjugate vaccines 
Glycoconjugate vaccines consist of carbohydrate antigens that are chemically 
linked to the carrier proteins. The carbohydrate antigens are usually bacterial capsular 
polysaccharides (CPSs) and are considered to be T cell-independent antigens, which 
induce the IgM responses but not IgM-to-IgG switching.79,80 Coupling of the CPSs to 
carrier proteins converts the polysaccharides to T cell-dependent antigens, which elicit 
T cell help for B cells that produce IgG antibodies to the conjugated polysaccharides 




The first carbohydrate vaccine, PneumoVax was commercialized in 1983. It was 
composed of an unconjugated capsular polysaccharide isolated from the pathogen. 
Nowadays, glycoconjugate vaccines find their applications in preventing infectious 
diseases caused by pathogens such as Haemophilus influenza type b, Streptococcus 
pneumonia and Neisseria meningitides.79 Even though the problem of low 
immunogenicity associated with unconjugated polysaccharide vaccines was largely 
overcome by the covalent coupling to an immunogenic protein carrier,82 the high cost 
and limited availability of capsular polysaccharides from natural sources still puts 
limitations on the research and widespread use of carbohydrate vaccines. Synthetic 
carbohydrate antigen-based vaccines are a potential solution to this problem, with 
several synthetic carbohydrate-based vaccines now in clinical trials.83 
1.3.3 Glycomimetics 
While much effort has been devoted to improving the efficiency of 
oligosaccharide synthesis for constructing glycoconjugates, carbohydrate mimetics 
provide us with an alternative way to achieve the same goal and avoid the inherent 
challenges in making conventional glycosidic bonds. Glycomimetics are often simpler 
and more stable than their parent models. With optimized structures, they also often 
bind more tightly to receptors and are therefore potential pharmaceutical 
candidates.84,85 
In preparing the glycomimetics, the focus has been mainly on the glycosidic 
bond and the endocyclic oxygen of the pyranose or furanose ring. Thus, three major 
types of glycomimetics were reported (Figure 6). The first type involves the 




and nitrogen (N-glycosides).87,88 The second type of glycomimetics has the endocyclic 
oxygen atom substituted by sulfur,89,90 carbon (carbaglycosides),91,92 or nitrogen 
(azaglycosides),93,94 with the azaglycosides being perhaps the most widely studied. 
The third type of glycomimetics involves the modification on the anomeric carbon. 
Among them, phosphinosugars (phostines),95 phosphonosugars (phostones),96,97 and 
the hydroxylamine based analogs98 are the most common. 
 
Figure 6. Structures of Glycomimetics. 
1.4 Recent progress in oligosaccharide synthesis 
Carbohydrates play important roles in cell-cell interactions and have great 
potential in drug development. Besides the efforts that have been devoted to 
developing novel glycomimetics, a better understanding of their functions and the 
construction of pharmaceutically important glycoconjugates requires pure samples of 
oligosaccharides as indispensable research tools or building blocks. Pure 
oligosaccharides have been traditionally obtained from natural sources, i.e., the 
pathogen itself. But not all pathogens can be cultured, and the purification process is 
always complicated and even impossible sometimes.99,100 Therefore, a lot of effort has 




1.4.1 Facile synthesis of oligosaccharides 
The successful synthesis of oligosaccharides requires the precise control of the 
stereochemistry and regiochemistry of the formation of a broad range of glycosidic 
bonds (a process called glycosylation). In this sense, the stereo- and regioselective 
enzymatic synthesis of oligosaccharides from unprotected carbohydrate molecules is 
particularly attractive, thanks to the strict substrate specificity of enzymes.101 Meanwhile, 
because most enzymatic reactions operate under standard physiological conditions, 
multicomponent preparation of oligosaccharides in one-pot can be carried out.102 
However, the limitation of this method is also obvious. It requires expensive 
nucleotide-activated glycosides as glycosyl donors; and glycosyltransferases for 
different carbohydrate substrates are not always available.100 The remaining task is to 
identify enzymes for a broad scope of substrates in order to achieve a wider structural 
diversity. Another solution is to use a combinatorial approach of chemical and 
enzymatic glycosylation, where more versatile chemical glycosylation can be carried 
out either before (to provide the substrate) or after (to give the final product) the 
enzymatic glycosylation.103 
The chemical synthesis of oligosaccharides is based on the numerous chemical 
glycosylation methods developed over the past few decades.104 To streamline the 
assembly of oligosaccharides, one-pot methods have been developed. For example, 
programmable one-pot oligosaccharide synthesis (Scheme 2a) uses a computer 
program to assist in selecting building blocks from a database of glycosyl donors (can 
also serve as glycosyl acceptors in the presence of free hydroxy groups) whose relative 




of a more reactive glycosyl donor (with higher RRV) in the presence of a less reactive 
glycosyl donor (with lower RRV). Therefore, successive addition of suitably protected 
building blocks with decreasing RRVs enables the synthesis of oligosaccharides.105 
This method harnesses the difference in reactivities of sugars with different protecting 
group patterns and, therefore, requires careful design and installation of protecting 
groups on each building block. A protocol based on the preactivation of glycosyl donors 
(Scheme 2b) was subsequently reported.106 This method relies on the irreversible 
activation of the glycosyl donors prior to the addition of the glycosyl acceptors and 
therefore addresses the problem of the need for meticulous protecting group 
manipulation. However, the one-pot oligosaccharide synthesis still suffers several 
problems, one of which is the difficulty in purifying the desired product from a very 
complicated mixture. Inspired by the synthesis of oligonucleotides and peptides, 
automated solid-phase oligosaccharide synthesis (Scheme 2c) has been developed.107 
Just like it’s nucleotide and peptide counterparts, this method involves the iterative 
assembly of different carbohydrate building blocks to a linker attached to a polymer 





Scheme 2. Oligosaccharide Synthesis Strategies. 
The efficiency of these oligosaccharide synthesis protocols has been 
demonstrated and improved over the past few years. Improvements have benefited 
from, and will always depend on advances in the construction of every particular type of 
glycosidic bond. While many chemical glycosylation methods104 are available now, 
some glycosidic bonds such as these represented by the -galactosides, -manosides 
and -sialosides are still difficult to achieve. And more importantly, an agreement on 
the general mechanism of a glycosylation reaction, which is of fundamental importance 
in optimizing the existing methodology and developing new methodology, has not been 
reached. 
1.4.2 Understanding of the mechanism of chemical glycosylation reactions  
A typical glycosylation reaction (Scheme 3) involves the nucleophilic substitution 
of a leaving group on the anomeric carbon of a glycosyl donor by a glycosyl acceptor to 
give a glycoside as the product. A promoter capable of activating the anomeric leaving 
group is usually employed. The newly formed glycosidic bond can exist in two 




Since the interactions of carbohydrates with lectins and carbohydrate-processing 
enzymes are highly specific, the mechanism and factors that determine the facial 
selectivity of the glycosylation reaction have been the central theme in carbohydrate 
chemistry. 
 
Scheme 3. The Glycosylation Reaction. 
When a nucleophilic substitution reaction at an sp3 carbon is considered, two 
limiting mechanisms are usually invoked: the unimolecular dissociative SN1 mechanism, 
and the bimolecular associative SN2 mechanism, the gap between which is generally 
considered to be spanned by a continuum of more or less tightly associated ion pair 
mechanisms. Being essentially a nucleophilic substitution reaction, the same situation 
should apply to the glycosylation reaction (Scheme 4).108,109 
 




However, the presence of not only an -oxygen, but also several other 
heteroatom (oxygen in most of the cases) substituents on the postulated cyclic 
carbenium ion (known as the glycosyl oxocarbenium ion) complicates the situation. 
Oxocarbenium ions are considered as stabilized carbenium ions due to the resonance 
delocalization of the -oxygen lone pair electrons. Therefore, the mechanisms of 
glycosylation reactions had been widely considered to proceed through dissociative 
glycosyl oxocarbenium ion intermediates and the stereoselectivity of the glycosylation 
reaction was usually rationalized on the basis of sterically or stereoelectronically 
dictated SN1-type attack of glycosyl acceptors on the glycosyl oxocarbenium ion in a 
specific conformation. Indirect evidences supporting the involvement of oxocarbenium 
ions in glycosylation reactions had come from several experiments.110-112 In contrast, 
the direct observation of these species was not achieved until very recently when 
Blériot and coworkers reported the NMR spectra of the per-O-acetyl 
2-deoxy-glucopyranosyl and 2-bromo-2-deoxyglucopyranosyl oxocarbenium ions, albeit 
generated in superacidic medium (Scheme 5).113,114 The absence of direct evidence for 
these species in common organic solvents testifies to their short lifetime in these 
conditions, presumably due to the rapid decomposition or combination with nucleophilic 
counterions in situ to form covalent species. When the presence of several substituents, 
which are mostly electron-withdrawing in nature, on a typical carbohydrate molecule is 
taken into consideration, the short lifetime of glycosyl oxocarbenium ions and 






Scheme 5. Generation of Glycosyl Oxocarbenium Ions in Superacidic Media. 
In fact, compared with discrete glycosyl oxocarbenium ions, covalent species 
formed in situ (Figure 7) have far more experimental support. Glycosyl halides, which 
themselves were widely used as stable glycosyl donors, were observed as reaction 
intermediates when halide ions are present in the activation systems.115,116 In addition, 
glycosyl perchlorates,117 sulfonates, phosphates,118 and sulfonium119, and uronium 
salts,120 and so on have been characterized in respective glycosylation reactions. 
Particular solvents such as acetonitrile in which the glycosylation reactions were 
performed were also demonstrated to associate with the transient glycosyl 
oxocarbenium ions.121-123 In a different scenario, the promoter has been found to attach 
to the anomeric leaving group, directly leading to an activated glycosyl donor.124 This 
was attributed to the weaker nucleophilicity of the counterions, which was insufficient 
for them to displace the activated anomeric leaving group or to associate with the 
transient oxocarbenium ions. Overall, a large amount of data exists for these covalently 
bonded active glycosyl intermediates formed in situ. This, together with an increasing 
amount of kinetic125,126 and KIE studies108,127 in this area provides strong evidence for 





Figure 7. Established Structures of Covalently-Bound Activated Glycosyl Donors. 
The determination of the position at which the mechanism of a particular 
glycosylation reaction lies on a SN1-SN2 mechanistic continuum seems to be taken on a 
case-by-case basis. A lot of factors including reaction conditions (solvent, temperature, 
etc.), nature of substrates (protecting group pattern, conformation of side chain, etc.) 
and activation system have to be taken into account when planning for a reaction 
favoring a particular anomer over the other. Nevertheless, there are some reliable 
strategies that can be applied routinely to obtain some specific stereochemical 
outcomes, with the neighboring group participation strategy being one of the most 
important among them. 
1.4.3 Neighboring group participation in glycosylation reactions 
The concept of neighboring group participation128 has been invoked in a wide 
variety of contexts.129,130 In carbohydrate chemistry, it refers to the stereoselective 
preparation of 1,2-trans-glycosides through a process involving the initial formation of 
an intermediate dioxalenium ion between a 2-O-carboxylate ester group and the 
anomeric carbon.131,132 The dioxalenium ion can then be captured by the acceptor 
alcohol to afford the 1,2-trans product (-glucosides and -mannosides and related 
glycosidic bonds) or it can be trapped as an orthoester, which then undergoes acid or 




The intermediate dioxalenium ions have been observed by X-ray crystallography134 as 
well as by NMR spectrometry.131 Rate acceleration (anchimeric assistance) in the case 
of weakly activated donors,135 and the high 1,2-trans stereo-selectivity are the features 
of reactions involving neighboring group participation. 
 
Scheme 6. Neighboring Group Participation Leading to the 1,2-trans Product. 
1.5 Overall goals 
The high demand for pure samples of oligosaccharides for research in 
glycobiology and for the development of carbohydrate-based drugs necessitates the 
development of efficient methods to construct glycosidic bonds with high 
stereo-selectivity. Currently, much progress has been made towards this goal, and a 
much better understanding of the general mechanism of the glycosylation reaction has 
been gained. However, there is still a long way to go for carbohydrate chemists to catch 
up with their colleagues working in the field of oligopeptide and oligonucleotide 
synthesis. Most of the current glycosylation methods require the presence of 
stoichiometric amount of additives, mainly in the forms of promoters, acid and 
electrophile scavengers, and drying agents. These additives, together with various 
undesired by-products complicate the reaction set-up and purification processes, and 
the reactions are by no mean efficient from the perspective of green chemistry. Another 




In view of these problems, the research described in this thesis set out to 
advance the state of the art in two distinct areas of glycosience. A first goal was to 
improve our knowledge and capability in making glycoconjugates by investigating into 
the possibility of stereo-directing participation by an ester functionality from a “remote” 
position in a glycosylation reaction, and by developing a new glycosylation 
methodology using photocatalysis concept. Second, the common medicinal chemistry 
approach was adopted to design and synthesize a series of natural oligosaccharide 
mimetics. The biological testing of these glycomimetics should provide meaningful 






CHAPTER 2. 2-O-ALKOXYCARBONYLMETHYL ETHERS AS PROBES 
FOR SIX-MEMBERED CYCLIC INTERMEDIATES IN 
STEREODIRECTING PARTICIPATION BY NON-VICINAL ESTERS 
2.1 Introduction 
As discussed in Chapter 1, the involvement of 2-O-acyl groups in neighboring 
group participation is supported by the isolation of crystalline salts of the 5-membered 
ring dioxalenium ions,134 by the spectroscopic observation of the same species (Figure 
8),131 and by computational works.132 Classical neighboring group participation is 
hampered by the formation of orthoesters as byproduct in some cases.136 Moreover, it 
is limited to the stereoselective synthesis of 1,2-trans glycosides.137 Several modified 
ester groups138-140 have been advanced to address the problem of orthoester formation, 
and to facilitate the deprotection after glycosylation. Participation of other non-ester 
type protecting groups,141-144 such as the 2-O-(2-pyridyl)-methyl group145 and the 
(S)-2-O-(phenylthiomethyl)-benzyl group146,147 has also been demonstrated by the 
observation of 6-membered ring intermediates spectroscopically (Figure 8). 
Interestingly, 1,2-cis glycosidic linkages can be achieved by employing the 
(S)-2-O-(phenylthiomethyl)-benzyl system. 
 
Figure 8. Participation Intermediates Observed by NMR Spectroscopy. 
In contrast to the presence of valid experimental support for the participation of 
2-O-acyl groups, the possibility of neighboring group participation by acyl groups 




or larger-membered cyclic intermediates is still under debate. In 2000, Crich and 
coworkers observed that the thioglycoside 16, with a 3-O-benzoate ester, gave 
exclusively the α-glycosylation product under standard preactivation conditions 
(Scheme 7a),148 whereas the corresponding 3-O-benzyl protected donor 20 was well 
known to display excellent β-selectivity under similar conditions (Scheme 7b).149 
Neighboring group participation involving the 3-O-benzoate group was initially invoked 
to explain the unusual α-stereoselectivity.148 However, a series of follow-up 
experiments from the same group demonstrated that the stereoselectivity of these 
4,6-O-benzylidene-protected β-mannosylations is highly sensitive to the steric and 
electronic nature of substituents at the 3-position,150-153 and many of these substituents 
are apparently nonparticipating. In addition, a dioxenium intermediate similar to 24 
(Figure 9) has never been identified. Similarly, Nifantiev and coworkers observed the 
effect of an equatorial 3-O-acetyl group in D-gluco and D-xylo systems in increasing the 
α-selectivity.154 Without observation of the key intermediates 25 or 26 (Figure 9), the 






Scheme 7. Glycosylation Reactions of 16 and 20 and Subsequent Deprotections. 
 
Figure 9. Putative Intermediates Resulting from Participation of 3-O-Acyl Groups. 
There also have been attempts to extend the phenomenon of stereodirecting 
neighboring group participation to ester groups located on the 4- and 6-positions.155 
Similar to the cases involving 3-O-acyl groups, the evidence rarely extends beyond 
modest changes in anomeric selectivity as compared with that observed in the 
presence of nonparticipating groups, and computational work.156-160 Nevertheless, in a 
few cases, cyclic intermediates have been trapped as stable bridging byproducts. 
By performing isotopic labeling experiments, Wilen has demonstrated that in 
simple model systems, participation by esters through the formation of six- and even 
seven-membered cyclic intermediates, although significantly slower than in the case of 
five-membered cyclic intermediates, is possible (Scheme 8).129 A bridged 




coworkers161 when a per-O-acetyl glucopyranosyl donor was activated. Isotopic 
labeling experiments indicated that the orthoacetate was derived from the 4-O-acetyl 
group by the initial formation of a seven-membered cyclic 1,4-dioxapenium 
intermediate. A bridged intermediate 36 resulting from participation by a 
tert-butoxycarbonyl (Boc) group at the 3-axial position in an allopyranosyl donor was 
trapped and isolated by Crich and coworkers (Figure 10).162 The Kim group trapped 
the bicyclic product 37 (Figure 10) from the activation of relevant D-mannosyl donor 
bearing a trichloroacetimidoyl group on the 3-O position, with the notable failure in 
trapping of similar bicyclic products when the same group or Boc was installed on 4-O 
and 6-O position.157 A similar bicyclic dihydro-1,3-oxazine was isolated as byproduct by 
Seeberger and coworkers during their synthesis of bacterial carbohydrate antigens.163 
While the isolation of these cyclic intermediates provides valuable insight into the 
various reactions taking place under particular glycosylation reaction conditions, the 
connection between the pathways leading to the formation of these intermediates and 
the pathways that lead to the glycosylation products is still not established. Meanwhile, 
results against the participation of the remote acyl group have also been reported.164 
Neither trapping experiments with Boc groups nor the isotopic labeling experiments 
employed by Crich and coworkers provided evidence in support of the participation 





Scheme 8. Participation by Esters Through the Formation of Six- and 
Seven-Membered Cyclic Intermediates in Simple Systems. 
 
Figure 10. Trapped Bridging Intermediates by Yu, Crich and Kim. 
As discussed in Chapter 1, the determination of the glycosylation reaction 
mechanism requires the careful examination of a series of factors. Therefore, it is a 
reasonable argument that, when protecting groups on a glycosyl donor become the 
subject, their ability of participation is not the only decisive forctor. In particular, 
protecting groups can have profound influence on the conformation that the reactive 
intermediates adopt.165,166 The equilibration between discrete oxocarbenium ions and 
covalently bound reactive glycosyl donors is also heavily dependent on the electronic 
properties of protecting groups.109 Furthermore, protecting group-induced changes in 
the extent of pre-association of the donors and acceptors through hydrogen 
bonding167,168 is known to affect the mechanism, and therefore, the stereochemical 
outcome of the glycosylation reactions. 
2.2 Hypothesis and goals 
The 4,6-O-benzylidene directed mannosylation developed by Crich and 




Extensive mechanistic studies have shown that a covalent α-triflate is the active 
glycosyl donor which undergoes SN-2 type of substitution with glycosyl acceptor to give 
the β-mannoside product (Scheme 7b).149 
Taking advantage of the nature of the 4,6-O-benzylidene directed mannosylation, 
and in view of the uncertainty about the remote ester participation, a series of 
2-O-(2-oxoethyl) ethers protected mannosyl donors (Scheme 9) were envisaged as 
ideal probes to study the possibility of remote participation by acyl functionalities (in 
ketones and esters) through six- or larger-membered cyclic intermediates. Specifically, 
the trans-diaxial 1,2-configuration would favour any possible participation by acyl 
groups on 2-position. If the stereodirecting participation is the major reaction pathway in 
glycosylation, α-mannosides would be expected to be the major glycosylation products 
(Scheme 9, Path B). On the other hand, if the association between the carbonyl 
oxygen and the anomeric carbon is too weak to be a major contributing factor in the 
reaction, direct substitution of the mannosyl triflate by acceptors in a SN-2 fashion 
would give the β-mannosides as major products (Scheme 9, Path A). Any weak 
associations might only be revealed by the use of esters with a weak exocyclic C-O 





Scheme 9. 4,6-O-Benzylidene Directed Mannosylation and Hypothesized Remote 
Participation. 
Therefore, performing glycosylation reactions with donors having the designed 
ether-type protecting groups, and examing the product composition, will allow to gain 
valuable information regarding the possibility of participation by remote esters through 
six-membered cyclic intermediates. 
2.3 Chemistry 
The key intermediate 40 for preparing the intended mannosyl donors was 
synthesized according to a well established procedure (Scheme 10).151 Thus, 
commercially available D-(+)-mannose was first treated with acetic anhydride in 
pyridine in the presence of a catalytic amount of 4-(dimethylamino)pyridine. The 
resulting pentaacetate was then reacted with thiophenol in the presence of Lewis acid 
boron trifluoride diethyl etherate to give the α-thioglycoside 39 as major product. 
Deacetylation with sodium methoxide followed by installation of the 4,6-O-benzylidene 
acetal furnished the 2,3-diol product, on which a benzyl ether was introduced at the 





Scheme 10. Synthesis of the Key Intermediate 40. 
The synthesis of mannosyl donors with phenacyl type protecting groups on the 
2-O position is shown in Scheme 11. Direct alkylation of the sodium salt of the 
thioglycoside 40 with 2-bromoacetophenone only led to the isolation of the desired 
product in low yields. Consistent with earlier results,174 2-bromoacetophenone was 
proven to be unstable under these alkylation conditions. Instead, the phenacyl ethers 
were introduced to the free 2-hydroxy group of 40 by alkoxide etherification with 
2-phenylallyl bromides (41, 42 and 43, Figure 11) followed by ozonolytic cleavage of 
the resulting alkenes 44, 45 and 46. While the allyl bromide 41 is commercially 
available, and the mono-trifluoromethyl-substituted bromide 42 has been synthesized 
by several groups,175-177 the bis-trifluoromethyl bromide 43 was conveniently prepared 
from a three-step procedure. Grignard reaction of the commercially available 
1-(2,4-bis(trifluoromethyl)phenyl)ethanone (Scheme 12, A) with methyl magnesium 
bromide gave the alcohol (not illustrated), which upon treatment with p-toluenesulfonic 
acid in reflux benzene led to the formation of alkene (Scheme 12, B) in 76% yield. A 
subsequent radical bromination reaction provided 43 in good yield. When the ozonolytic 
cleavage reactions are considered, it’s worth noticing that when the phenyl group was 
un-substituted or mono-substituted with trifluoromethyl group (44 and 45), the sulfide 
products bearing the relevant phenacyl ethers (47 and 48) were obtained in good yields, 
while the sulfoxide products (50 and 51) were isolated as minor products. However, 




groups (46), the sulfoxide 52 was obtained as the major product. The formation of the 
relatively higher amount of sulfoxide product 52 is presumably a result of the longer 
reaction time needed to cleave the less electron-rich alkene in 46. 
 
Scheme 11. Synthesis of the Mannosyl Donors with Phenacyl Type Protecting Groups 
at the 2-O Position. 
 
Figure 11. Structures of Aryl-Substituted Allyl Bromides. 
 
Scheme 12. Synthesis of the Allyl Bromide 43. 
Similarly, the 2-O-(alkoxycarbonylmethyl) derivertives 53 and 54 were obtained 
by alkylation of the sodium salt of 40 with methyl and t-butyl bromoacetates, 
respectively (Scheme 13). Then the corresponding sulfoxides 55 and 56 were 
prepared by treating the thioglycosides 53 and 54 with mCPBA in dichloromethane 
at -78 oC. Sulfoxides 50, 51 and 52 were also prepared following the same mCPBA 
oxidation procedure (Scheme 14). Interestingly, all the sulfoxides obtained from both 





Scheme 13. Synthesis of the Mannosyl Donors with Ester Type Protecting Groups at 
the 2-O Position. 
 
Scheme 14. Preparation of Sulfoxides by mCPBA Oxidation of the Sulfides. 
With the thioglycosides and sulfoxides bearing different substituents at 2-O 
position in hand, coupling reactions with glycosyl acceptors 57, 58 and 59 were 
attempted using the classical activation conditions for these glycosyl donors. Therefore, 
the thioglycosides were activated with either diphenyl sulfoxide (DPSO) or 
1-benzenesulfinyl piperidine (BSP)/triflic anhydride (Tf2O)/2,4,6-tri-tert-butylpyrimidine 
(TTBP) systems, and the sulfoxides were activated with Tf2O/TTBP system. All 
reactions were performed and quenched in dichloromethane (DCM) at -78 oC. The 





Table 1. Glycosylation Reactions. 
 
Entry Donor Acceptor Activation Products (% yield) 
1 47 57 DPSO, Tf2O, TTBP 63 (33) 
2 49 57 BSP, Tf2O, TTBP 61 (62), 3.8:1 β:α 
3 52 57 Tf2O, TTBP 61 (62), 7.9:1 β:α 
4 52 58 Tf2O, TTBP 64 (57), β-only 
5 53 57 BSP, Tf2O, TTBP 62 (79), 5:1 β:α 
6 53 58 BSP, Tf2O, TTBP 65 (83), β-only 
7 53 59 BSP, Tf2O, TTBP 67 (87), 2.6:1 β:α 
8 55 58 Tf2O, TTBP 65 (85), β-only 
9 55 59 Tf2O, TTBP 67 (59), β-only 
10 56 58 Tf2O, TTBP 66 (3), β-only + 68 (70) 
 
Attempted coupling of the phenacyl derivative 47 with adamantanol 57 on 
activation with DPSO and Tf2O in the presence of the hindered non-nucleophilic base 
TTBP in DCM at −78 °C gave a complex reaction mixture in which it was not possible 
to identify the anticipated glycosylation product 60 by ESI-mass spectrometry of the 
reaction mixture. The major isolated product from this reaction mixture was the tricyclic 
product 63, which was isolated in 33% yield (Table 1, entry 1). Coupling reactions of 
the glycosyl donors 48 and 51 bearing the 4-trifluoromethylphenacyl group at the 2-O 
position with 57 and rhamnose derived acceptor 58 gave complex reaction mixtures as 
demonstrated by TLC and mass spectrometric analysis. However, coupling reactions of 




acceptors 57 and 58 gave good yields of the glycosylation products 61 and 64 (Table 1, 
entries 2 - 4). 1H-NMR analysis of the crude reaction products revealed the β-isomers 
as the major products in all the cases. Similarly, coupling of the methoxycarbonylmethyl 
substituted thioglycoside 53 with acceptors 57−59 with activation by BSP gave the 
glycosides 62, 65, and 67 in good yield, with selectivities ranging from 2.6:1 for the less 
reactive acceptor 59 to complete with the rhamnoside 58 (Table 1, entries 5−7). 
Preactivation of the sulfoxide 55, followed by addition of acceptors 58 and 59 gave the 
glycosides 65 and 67 in good yield, both as single diastereomers (Table 1, entries 8 
and 9). Finally, preactivation of the sulfoxide 56 with Tf2O and TTBP followed by 
addition of acceptor 58 gave the tricyclic product 68 as the major product, with 3% of 
the β-glycoside 66 isolated. Careful examination of this reaction mixture with 1H-NMR 
and mass spectrometry found no evidence for α-glycoside or trans-fused lactone 
formation. 
 




Selective deprotection of the alkoxycarbonylmethyl ethers was exemplified by 
the treatment of glycosylation product 65 with potassium hexamethyldisilazide (KHMDS) 
in THF at −78 °C followed by addition of the Davis camphorsulfonyl oxaziridine. The 
deprotected product 69 was obtained in 64% yield. When glycosylation product 64 was 
treated with samarium iodide in THF at 0 °C, the alcohol 69 was isolated in 75% yield. 
The efficient deprotection of these ethers extends the possible use of these systems 
beyond that of simple mechanistic probes to potentially useful protecting groups in 
glycosylation reactions. 
 
Scheme 15. Deprotection Methods for Bis(trifluoromethyl)phenacyl and 
Methoxycarbonylmethyl Ethers. 
2.4 Discussion 
The various mannopyranosyl donors bearing substituted 2-O-(2-oxoethyl) ethers 
were prepared from the easily accessible 2-free hydroxy intermediate 40. While the 
ester-type substituents were conveniently installed by alkylation with 2-bromoacetates, 
the more enolizable nature of 2-bromoacetophenone derivatives necessitated the use 
of substituted allyl bromides (41-43) as surrogates. The subsequent ozonolysis or 
mCPBA oxidation furnished the sulfoxides as single diastereomers, to which the SR 




α-mannopyranosyl thioglycosides.178-180 Thus, as proposed by Crich and coworkers, 
consideration of the combined steric effect and the exo-anomeric effect would favor the 
conformation B (Scheme 16) where the bulky phenyl group is gauche to the relatively 
less sterically-demanding hydrogen, and the sulfur lone pair electrons would stabilize 
the σ* orbital of the endocyclic C-O bond through hyperconjugation. As seen from the 
Newman projection of B, the pro-R lone pair of the thioglycosides is exposed to attack 
by oxidants, whereas oxidation of the pro-S lone pair would be substantially hindered 
by the pyranose ring, and by the axial H-3 and H-5. 
 
Scheme 16. Equilibration of the Conformations of the Thioglycosides. 
Interestingly, a dichotomy arose when the glycosyl donors 47-52 were employed 
in glycosylation: good glycosylation yields and clean reaction mixtures were obtained 
with the donors 49 and 52 (Table 1, entries 2-4). In contrast, glycosylation with the 
unsubstituted or mono-CF3 substituted donors (47, 48, 50, and 51) led to complex 
reaction mixtures from which glycosylation products could not be identified. Instead, 
tricyclic product 63 was isolated in 33% yield from the reaction of 47 in the presence of 
the acceptor 57 (Table 1, entries 1). Mechanistically, the formation of tricycle 63 
requires the nucleophilic attack of the ketone oxygen at the anomeric carbon, which 
can happen either before (Scheme 17) or after sulfenylation. Nevertheless, the 
isolation of the tricyclic product 63 from the reaction of 47, although in low yield, 




intermediate in the mannopyranosyl system under study is stereoelectronically feasible. 
However, the absence of glycosylation product and generally complex reaction 
mixtures in the latter case, together with the good yields and high β-selectivity 
associated with the di-CF3 substituted donors 49 and 52 indicated the minor role of this 
participation in directing the stereoselectivity of the glycosylation reaction. 
 
Scheme 17. A Proposed Mechanism for the Formation of Tricyclic Product 63. 
The glycosylation reactions with donors 53-56 showed a similar pattern. While 
the donors (53 and 55) with the 2-O-(methoxycarbonylmethyl) protecting group reacted 
with all glycosyl acceptors (57-59) effectively, leading to the formation of β-glycosides 
as major products in all cases (Table 1, entries 5 - 9), the attempted glycosylation 
reactions with the 2-O-(t-butoxycarbonylmethyl) protected donors (54 and 56) resulted 
in the formation of tricyclic lactone 68 as the major product along with minor amount of 
β-glycoside 66 (Table 1, entries 10). These results are consistent with the conclusion 
drawn from the previous experiments that participation from the 2-position in 
mannopyranosyl system through the formation of six-membered cyclic intermediates is 
possible, but that the association between the carbonyl oxygen and the anomeric 
carbon is weak and insufficient to influence the attack of glycosyl acceptors on the 




which, upon cleavage, led to the formation of relatively stable t-butyl cation. Although 
not characterized in this study, the mannosyl triflates were implied in these β-selective 
reactions as the reactive intermediates. Therefore, the β-glycoside 66 is considered to 
arise from the triflate 73 via a SN2-type substitution with the glycosyl acceptor 58 
(Scheme 18). 
 
Scheme 18. Proposed Mechanism for the Formation of β-Glycoside 66 and Tricyclic 
Lactone 68. 
Above all, these experimental observations obtained from the glycosylation with 
both the 2-O-phenacyl and the 2-O-(alkoxycarbonylmethyl) containing systems 
suggested the absence of effective stereo-directing participation by these functionalities, 
despite their ideal trans-diaxial relationship with the anomeric leaving groups. These 
results also invite careful comparison with the proposed participation in systems 
involving non-vicinal esters. 
In the 2-O-(alkoxycarbonylmethyl) system, the putative participation would result 
in cyclic dioxenium ions taking either E,E- or Z,Z-configuration (Figure 13 A and B), 
depending on the conformation of the participating esters (cis or trans, respectively). 
On the other hand, the proposed participation by remote esters would afford the 




dialkoxycarbenium ions have shown that the E,Z-conformer is the major isomer at low 
temperature,181-183 and that the sterically unfavourable Z,Z-conformer was not observed 
in these acyclic systems.184 The rotation barrier about the cationic carbon-oxygen bond 
was estimated to be 11 ± 4 kcal·mol-1.181 DFT calculations have been carried out and 
show that the E,Z-configured dialkoxycarbenium is >2.5 more stable than the 
E,E-conformer.185 
 
Figure 13. Dialkoxycarbenium Ion Conformations. 
In addition, a DFT calculation conducted in the Crich group by the B3LYP 
method in the gas phase with the 6-31+G(d,p) basis set using the Gaussian 09W 
program suite186-189 indicated that participation by a non-vicinal ester via a 
six-membered ring (such as participation from the 3-position of a glycosyl 
oxocarbenium ion, Figure 14, B) is 1.74 kcal·mol-1 less favoured than the cyclization of 
an alkoxycarbonylmethyl ether onto an oxocarbenium ion (Figure 14, A), as required 





Figure 14. DFT Calculations for Participation by Esters Resulting in Six-Membered 
Ring Formation. 
Therefore, other factors being equal, there is no reason to expect that 
non-vicinal participation by a 3-O-ester via a six-membered ring intermediate will be 
intrinsically more favourable than that of the 2-O-alkoxycarbonylmethyl ethers 
investigated here. Overall the results argue that, in the absence of conformational 
predisposition, as with axial esters at the 3-position, effective stereodirecting 
participation by non-vicinal esters through the formation of six-membered intermediates 
is unlikely to be a serious contributing factor in glycosylation. 
2.5 Conclusion 
While the neighboring group participation by esters through the formation of 
five-membered ring intermediates is widely exploited in synthetic carbohydrate 
chemistry and firmly supported by various experimental evidences, the attempts to 
extend the concept to esters at a remote position aroused much speculation. 
Experiments have shown the capability of these remote esters to influence the 
stereoselectivity of glycosylation reactions, in some cases, in a way that could be 




that the putative dioxalenium ion intermediates have never been observed 
experimentally, and on the other hand, the five-membered counterparts have been 
crystallized for nearly half a century, the role of these putative intermediates in a 
glycosylation reaction is questionable. Not only the attempt to directly observe the 
dioxenium ion intermediates, but also the trapping experiment for these species led to 
negative results. 
This project used a series of mannosyl donors as probes to study this problem. 
The formation of cyclic products 63 and 68 demonstrated the stereoelectronical 
feasibility of participation through a six-membered cyclic intermediate in the system 
under study. Nevertheless, the moderate to high yields of glycosides favouring 
β-anomers in all other cases excluded the participation by these acyl functionalities as 
a major reaction pathway in their glycosylation reactions. Therefore, it is suggested that, 
without conformational predisposition, the more energy-demanding participation by 
non-vicinal esters through the formation of six- or larger membered intermediates is 





CHAPTER 3. DEVELOPMENT OF A NOVEL BLUE LIGHT 
PHOTOCATALYTIC GLYCOSYLATION METHOD 
3.1 Introduction 
The central role of glycosylation reactions in oligosaccharide synthesis has 
stimulated the development of many effective methodologies.104 The traditional ways of 
constructing glycosidic linkages usually require the assistance of strong acids or 
electrophiles, but little attention has been paid to the ecological efficiency of these 
reactions. In comparison, organic photochemistry converts clean light energy into 
tunable chemical reactivity, and over the past century, it has enabled a wide variety of 
chemical transformations.190 By virtue of its environmental friendliness and versatility, 
there also have been efforts to leverage the photochemical reactivity in carbohydrate 
chemistry. 
3.1.1 Mechanisms of the photo-induced glycosylation reactions 
The capability of UV light to cleave the C-S bond is well known,191 and has been 
exploited by Ye and coworkers for glycosidic bond formation.192 In this approach, UV 
light-induced homolytic cleavage of the anomeric C-S bond in thioglycoside donors is 
followed by oxidation of the resulting glycosyl radicals by an external oxidant to afford 
the key glycosyl oxocarbenium ion intermediates for glycosylation reactions (Scheme 
19). Another approach involves the use of naphthol derivatives or aryl thiourea 
derivatives as organo photoacids, whose acidities can be enhanced with light 





Scheme 19. Photoinduced C-S Bond Cleavage of Thioglycosides and Subsequent 
Oxidation. 
A more intriguing approach of broader application resolves around the notion of 
photocatalysis. In this context, the photocatalyst acts as a receiver of light energy and 
transfers it to the substrates. More specifically, the absorption of a photon by a 
photocatalyst molecule promotes the movement of an electron from the HOMO to the 
LUMO of the catalyst, a process called photoexcitation. In competition with relaxation, 
the excited photocatalyst then can be involved in a subsequent single electron transfer 
process by either of two distinct pathways: i) it can be oxidized by donating the 
high-energy electron to an electron acceptor (Scheme 20, Z), or ii) it can be reduced by 
accepting an electron from an electron donor to fill its partially occupied orbital, 
corresponding to oxidative or reductive quenching of the photocatalyst, respectively 
(Scheme 20). 
 
Scheme 20. General Mechanism of the Photocatalytic Glycosylation Reaction. 
In photocatalytic glycosylation the transfer of an electron from an electron-rich 




photocatalyst (reductive quenching), or the oxidized form of photocatalyst resulting 
from the initial oxidative quenching process, gives a radical cation (Scheme 20, B). 
The glycosyl radical cation then undergoes mesolytic cleavage to give a radical species 
and a glycosyl oxocarbenium ion (Scheme 20, C). The oxocarbenium ion C can then 
be trapped by a nucleophilic glycosyl acceptor leading directly to glycosidic product E 
(Scheme 20, Path A), or it can be trapped by another suitable nucleophile in situ to 
give a transient activated glycosyl donor (Scheme 20, D, Path B), which then 
undergoes SN2-type substitution reaction with a glycosyl acceptor. Neighboring group 
participation can also play a role in this process if the glycosyl donor is equipped with a 
participating functionality at a suitable location. Meanwhile, the expelled radical is 
typically considered to undergo degradation by radical−radical pathways such as 
dimerization. Alternatively, the expelled radical may suffer reduction by the radical 
anion resulting from the initial single electron transfer step (RX
·
= Z), thereby rendering 
the process catalytic in the photostimulated oxidant. 
3.1.2 Recent progress in photo-induced glycosylation reactions 
Early in the 1980s, Noyori was able to achieve an UV-induced glycosylation 
reaction with O-phenyl glycosides as donors using a binary photo-sensitizing system 
consisting of the light-absorbing phenanthrene and p-dicyanobenzene (DCNB), which 
is of high reduction potential (Scheme 21a).195 Subsequent work focused on the more 
readily oxidized seleno- or thioglycosides. For example, Crich and Cumpstey reported 
an UV-initiated glycosylation in which selenoglycosides were oxidized by the photo-
excited N-methylquinolinium hexafluorophosphate (NMQ-PF6) through single electron 




and that oxygen was required to reoxidize the reduced NMQ radical. However, these 
methods employed high energy photons at UV wavelengths, which comes with the 
inherent problem of functional group compatibility. Consequently, there is significant 
current interest in applications of photocatalysis using visible light in glycosylation 
reactions. 
 
Scheme 21. UV-Induced Photocatalytic Glycosylation Reactions. 
The photocatalysts employed in visible light photocatalytic glycosylation 
reactions are usually transition metal complexes, whose redox properties can be 
regulated by ligand modification. For example, Bowers and coworkers developed a 
method for O-glycosylation with thioglycosides via the visible light mediated activation 
of Ir-based photocatalyst 92 (Scheme 22a).197 The co-oxidant bromotrichloromethane 
(BrCCl3) and the non-nucleophilic protic solvent hexafluoroisopropanol (HFIP) were 
required for efficient glycosylation. A visible light photocatalytic O-glycosylation of 
alcohols with selenoglycosides employing the Ru-based photocatalyst 95 was reported 
by Ragains and coworkers (Scheme 22b).198 Similarly, additives including the 
co-oxidant tetrabromomethane, organic base 2,6-di-tert-butyl-4-methylpyridine (DTBMP) 




same Ru-based photocatalyst 95 was reported by Ye and coworkers where both 
Umemoto’s reagent 99 and Cu(OTf)2 were necessary for smooth progress of the 
sunlight mediated reaction (Scheme 22c).199 
 
Scheme 22. Visible Light-Induced Photocatalytic Glycosylation Reactions. 
While the employment of visible light was proven to be more advantageous in 
terms of functional group compatibility and handling, these reported methodologies all 
require the employment of stoichiometric amounts of electrophilic species. Apparently, 
the simple photocatalytic mechanism (Scheme 20) is not operative in these cases. The 
need for the extra electrophiles also potentially causes problems in product purification. 
Therefore, a new visible light-induced photocatalytic glycosylaltion method which does 






Considering these problems, the recent work of Knowles on the photocatalytic 
generation of simple alkyl, allyl, and benzyl cations from sterically hindered O-alkyl 
hydroxylamines was considered to be attractive (Scheme 23).200 This method includes 
a reductive quenching process and, with the photocatalytic cycle being closed by re-
oxidation of the reduced iridium catalyst by the expelled nitroxyl radical, the reaction 
proceeded in the absence of any electrophilic additives. 
 
Scheme 23. Photocatalytic Generation of a Cation from a Tempol Ether and Its 
Trapping by a Nucleophile. 
Inspired by Knowles work, the possibility of generating glycosyl oxocarbenium 
ions from relevant Tempol glycosides was envisaged (Scheme 24). If the highly 
destabilizing effect of adjacent C-O bonds on oxocarbenium ions could be overcome, 
subsequent reaction with a suitable glycosyl acceptor would lead to the generation of a 





Scheme 24. Putative Generation of Glycosyl Oxocarbenium Ions from Tempol 
Glycosides. 
3.3 Chemistry 
The synthesis of various Tempol glycosides started from the preparation of 
glycosyl fluorides 104-107 (Scheme 25). Following a method reported by Noyori,201 
treatment of mannose and glucose pentaacetates (108 and 109) with Olah’s reagent in 
toluene at room temperature gave the α-glycosyl fluorides 110 and 111 in 86% and 53% 
yield, respectively. Subsequent protecting group transformation by deacetylation 
followed by benzylation furnished the perbenzylated glycosyl fluorides 104 and 105 in 
good yields. Similarly, the galacto-configured α-glycosyl fluoride 106 was prepared in 
good yield from the known acetate 112202 by treatment with Olah’s reagent. The 
fluoride 107 was accessed by hydrolysis of the known thioglycoside 113203 with 
N-bromosuccinimide (NBS) in aqueous acetone to the corresponding hemiacetal 
followed by treatment with Olah’s reagent. Consistent with the literature,201 all four 
glycosyl fluorides obtained from the reaction with Olah’s reagent were the 





Scheme 25. Preparation of Glycosyl Fluorides. 
Subsequently, the Tempol glycosides 114-117 were prepared from the relevant 
glycosyl fluorides (104-107) following a method developed by Sato and coworkers.204 
Coupling of the manno-configured glycosyl fluoride 104 with the persistent radical 
Tempo in the presence of BF3·OEt2 and tetramethylguanidine (TMG) in acetonitrile 
gave a single α-glycoside 114 (Table 2, entry 1), whereas the coupling reactions of the 
gluco- and galacto-configured glycosyl fluorides 115-117 under the same conditions 
afforded the corresponding Tempol glycosides as mixtures of α- and β-anomers (Table 





Table 2. Synthesis of Tempol Glycosides. 
 
Entry Glycosyl fluorides  Tempol glycosides (% yield)  
1 104 
 
114, α (64)  
2 105  
115, α (38), β (37)  
3 106  
116, α (41), β (30)  
4 107  
117, α (22), β(63)  
 
With the Tempol glycosides in hand, the blue light induced photocatalytic 
glycosylation reactions were attempted. In the event, photolysis of 0.1 M nitromethane 
solutions of the Tempol glycosides 114-117 with blue LEDs through Pyrex at room 
temperature in the presence of powdered 4 Å MS, 5 mol % of iridium photocatalyst 103, 
and the model acceptor alcohols 118-120 led to the formation of the expected 




Table 3. Photoglycosylation of Alcohols with Tempol Glycosides. 
 
Entry Donor Acceptor Time 
Products 
(% yield, α:β-ratio) 
1 114 118 (3 equiv) 36 h 121 (80, 1.3:1) 
2 119 (1.5 equiv) 48 h 122 (62, 1.5:1) 
3 120 (1.5 equiv) 60 h 123 (64, 1:1) 
4 115α 118 (3 equiv) 36 h 124 (96, 1:2.5) 
5 119 (1.5 equiv) 48 h 125 (88, 1:1) 
6 120 (1.5 equiv) 48 h 126 (69, 1.3:1) 
7 115β 118 (5 equiv) 36 h 124 (91, 1.2:1) 
8 119 (1.5 equiv) 48 h 125 (79, 1.3:1) 
9 120 (1.5 equiv) 48 h 126 (63, 1.6:1) 
10 116α 118 (3 equiv) 36 h 127 (95, 1:1.6) 
11 119 (1.5 equiv) 48 h 128 (82, 1.2:1) 
12 120 (1.5 equiv) 48 h 129 (77, 1.6:1) 
13 116β 118 (3 equiv) 36 h 127 (87, 1.6:1) 
14 119 (1.5 equiv) 48 h 128 (75, 1.4:1) 
15 120 (1.5 equiv) 60 h 129 (59, 1.6:1) 
16 117β 118 (3 equiv) 36 h 130 (86, 1.8:1) 
17 119 (1.5 equiv) 72 h 131 (61, 1.4:1) 





Figure 15. Structures of Glycosyl Acceptors and Glycosylation Products. 
Good to excellent yields were obtained in all glycosylation reactions conducted 
in this study with only modest differences in yield observed between the α- and β-
anomers of a particular donor. The stereoselectivity of the glycosylation reactions is 
modest, but it is reproducibly a function of the anomeric configuration of the Tempol 
glycosides, with the reactions involving the more reactive acceptors 118 and 119 
displaying greater difference between two anomers of a given Tempol glycoside. 
3.4 Discussion 
The method of Sato and coworkers204 applied for the preparation of Tempol 
glycosides, with coupling of glycosyl fluorides and the Tempo radical in the presence of 




noted in Sato and coworkers’ synthesis of glucose-linked nitroxide radicals 134 
(Scheme 26), using reaction conditions adapted from Yamaguchi’s glycosidation of 
phenols with 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl fluoride 111. In these conditions, 
TMG was reportedly added to the BF3·OEt2 promoted glycosylation of acidic hydroxy 
groups by glycosyl fluorides to enhance the β-selectivity rendered by neighboring group 
participation of the 2-O-acetate group.205 According to Sato,204 the coupling reaction 
does not proceed via the hydroxylamine Tempol, since the direct glycosylation of the 
hydroxylamine under the same reaction conditions failed to give the glycosylation 
product. The presence of base is also essential for the reaction as no glycosylation 
product was observed in the absence of TMG. Other organic bases including 
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 2,6-di-tert-butyl-4-methylpiridine 
(DTBMP) were also effective in promoting the glycosylation reactions. Nevertheless, 
with only preliminary mechanistic studies available, the mechanism of these reactions 
remains to be clarified. 
 
Scheme 26. Sato’s Synthesis of Glucose-Linked Nitroxide Radical and the 
Concomitant Formation of a Glycosyl Hydroxylamine. 
The blue light-induced glycosylation reaction conditions were directly derived 
from the Knowles work200 on simple cation generation. A preliminary investigation 
showed that, in the absence of molecular sieves, the reactions were hampered by the 




Control reactions conducted in the dark or in the absence of iridium catalyst 103 did not 
progress as revealed by mass spectrometry and TLC. Nevertheless, the success of 
glycosylation in all other cases demonstrated the ability of the photo-excited iridium 
catalyst 103 to oxidize the Tempol glycosides through single electron transfer, and the 
weakness of the anomeric C-O bond in the resulting radical cation. The longer reaction 
times required by these glycosylation reactions, as compared to the shorter reaction 
times with the simpler substrates in Knowles’ systems (12 h) is a manifestation of 
influence of the multiple electron-withdrawing C-O in the carbohydrate systems. These 
C-O bonds both render the substrate more difficult to oxidize and destabilize the 
cationic glycosyl oxocarbenium ions, as observed in many simple systems206,207 and 
emphasized in carbohydrate chemistry by Crich208 and others.209-212  
Overall, a mechanism similar to that illustrated in Scheme 23 is proposed 
(Scheme 27). In this mechanism, the photo-excited iridium (III) catalyst removes one 
electron from the nitrogen lone pair of the Tempol glycoside, resulting in the formation 
of a radical cation and an iridium (II) species. The radical cation then undergoes 
mesolytic cleavage of the weak anomeric C-O bond to generate the stable Tempo 
radical and the key glycosyl oxocarbenium ion. In the presence of protons, the Tempo 
radical oxidizes the iridium (II) species to regenerate the iridium (III) catalyst and a 
molecule of Tempol hydroxylamine via a proton-coupled electron transfer (PCET) 
process.213 The fate of the generated glycosyl oxocarbenium ion was discussed in 
Chapter 1, i.e., it may directly couple with a suitable glycosyl acceptor via a SN1-like 




the reaction media and then undergo reactions with a nucleophile via a SN2-like 
mechanism. 
 
Scheme 27. Proposed Mechanism for the Blue Light Photocatalytic Glycosylation with 
Tempol Glycosides. 
Based on previous work,109 the hexafluorophosphate counter ion is not 
considered to participate in covalent adducts or tight ion pairs with glycosyl 
oxocarbenium ions. However, the stereoselectivity pattern of the glycosylation reactons 
indicates that glycosylation proceeds at least in part by a concerted SN2-like manner. 
Therefore, it is proposed that the departure of the Tempo radical from the oxidatively 
activated donor is coupled with attack by the incoming acceptor. Thus, the acceptor 
can either directly attack the oxidatively activated donor (Scheme 28, Path A) or it can 






Scheme 28. Proposed Mechanisms for the Displacement of the Tempo Radical by the 
Incoming Acceptor. 
3.5 Conclusion 
As in many other fields of organic chemistry, carbohydrate chemistry recently 
has witnessed an unprecedented increase in the implementation of light-driven 
processes, especially visible light-driven catalysis in glycosylation reactions. Compared 
with traditional ways of glycosylation, photocatalytic glycosylation reactions usually run 
under mild, Brønsted-neutral conditions and therefore, have better functional group 
compatibility and create less environmental impact. While most of the reported visible 
light photocatalytic glycosylation methods still require the assistance of external 
electrophilic agents, the glycosylation method reported in this study successfully 
eliminates these problems by utilizing the Tempol glycosides as glycosyl donors. The 
stability and facile preparation are additional advantages of the hydroxyamine 




CHAPTER 4. DESIGN AND SYNTHESIS OF β-(1→3)-D-GLUCAN 
MIMETICS 
4.1 Introduction 
β-(1→3)-D-Glucans, often simply called β-glucans, comprise a group of naturally 
occurring β-D-glucose polysaccharides featuring a linear backbone linked by 
1,3-β-glycosidic bonds (Figure 16). They exist widely in nature, with the cell walls of 
cereals, seaweeds, bacteria, and fungi being the most common sources. Depending on 
the source and the way they are purified, β-glucan molecules can have different lengths 
and different branching structures attached to the linear backbones. Therefore they 
vary in molecular weight and many other physicochemical properties. These 
differences can then have implications in the activities of β-glucans. 
 
Figure 16. General Structure of Branched β-(1→3)-D-Glucans. 
4.1.1 The biological activity of β-glucans 
There is long history of using medicinal herbs for the treatment of diseases, 
including cancer, among many Asian countries, and recently one of the active 
ingredients of these herbal extracts was found to be the β-glucans.214,215 Unlike many 
other herb-derived chemotherapeutic agents such as paclitaxel and vincristine that are 
cytotoxic, β-glucans were found to have no direct cytotoxic effects. In contrast, 
β-glucans function through their immunomodulatory effects and are believed to be non-




β-Glucans are also considered as non-digestible carbohydrates.217 Orally 
administrated β-glucans are detected in the proximal small intestine shortly after 
ingestion, where they are taken up by macrophages through interaction with the 
Dectin-1 receptors.218 The macrophages then degrade the large β-glucans into smaller 
fragments and transport them to the endothelial reticular system. Subsequently, the 
small fragments of β-glucans are released by the macrophages and taken up via the 
complement receptor 3 (CR3) by circulating granulocytes, monocytes and 
macrophages, where they can induce the relevant immune responses.219 
Since β-glucans are conserved structural components in the cell walls of many 
fungal and bacterial pathogens, and they are absent in mammalian cells, the ability to 
rapidly recognize and respond to β-glucans has evolved in the mammalian immune 
systems as a quick way to control infections. The use of β-glucans to stimulate the 
immune responses is also based on this ability. β-Glucans are thought to exert their 
effects via interaction with the Dectin-1 receptors expressed on the plasma membrane 
of cells such as macrophages, neutrophils and dendritic cells that are responsible for 
the innate immune response. Dectin-1 consists of a C-type lectin domain, a short stalk, 
and a cytoplasmic tail containing an immunoreceptor tyrosine-based activation motif 
(ITAM).220 Binding of β-glucans to the lectin domain of Dectin-1, alone or in 
collaboration with other ligand-receptor interactions, triggers the downstream signaling 
pathway and eventually leads to the activation of macrophages, phagocytosis and lysis 
of pathogens, and secretion of proinflamatory cytokines including tumor necrosis factor 
(TNF)-α, interleukin (IL)-12, IL-6, and IL-10.221 It was also reported that β-glucans can 




lymphocytes and monocytes),222 and stimulate the activation and maturation of human 
monocyte-derived dendritic cells.222,223 
Another mechanism of β-glucan functioning is mediated by the complement 
receptor 3 (CR3) and so is called CR3-dependent cellular cytotoxicity (CR3-DCC).224 
CR3, which is found on effector cells such as natural killer (NK) cells, neutrophiles, and 
lymphocytes, is a heterodimeric transmembrane glycoprotein consisting of a CD11b 
subunit, and a CD13 subunit noncovalently bound to each other. Two functional 
domains are identified in the CD11b subunit: the C-terminal lectin domain and the 
N-terminal I-domain, and the cytotoxic function requires the ligation of both of them. 
Therefore, pathogens that possess β-glucans as exposed cell wall components activate 
the complement and are then coated with complement 3b (C3b) fragments of serum 
protein C3. These C3b fragments are then proteolysed by factor I into inactivated 
complement 3b (iC3b) fragments, which serve as ligands of high avidity for the I-
domains on the CD11b subunit.225 On the other hand, the binding of cell wall β-glucans 
to the C-terminal lectin domains promotes the required dual ligation and triggers the 
cytotoxic degranulation and phagocytosis of the iC3b-coated reactor cells.225 
β-Glucans also have implications in cancer therapies as adjuvants. For example, 
leukopenia, a result of the impaired blood forming function, is the major side effect of 
most chemotherapeutic drugs. Studies of the effect of SCG, the β-glucan purified from 
the mushroom Sparassis crispa, on cyclophosphamide-induced leukopenic mice have 
shown the enhanced hematopoietic responses associated with increased cytokine IL-6 
production.226 In another study, β-glucans (PG101, a water-soluble extract from 




cytokines (GM-CSF, IL-1β, IL-6) and decrease the level of radioinduced TNF-α in 
irradiated mice, suggesting their protective effects during radiotherapy.227 Moreover, 
the use of β-glucans as adjuvants in monoclonal antibody (mAb) immunotherapy 
enables the iC3b deposited on the tumor cells through complement activation by mAbs 
to activate CR3 on effector cells and trigger the CR3-dependent tumor cytotoxicity.224 
One of the fundamental problems associated with the research on β-glucans lies 
in their heterogeneity in natural sources. Currently, most studies are conducted with 
natural products isolated from various microbial cell walls, and the isolation methods 
usually involve extensive extraction and washing processes. These isolation methods 
are rather inefficient and give only mixtures of polymers with varying lengths and 
different branching frequencies, depending on both the source of the cell walls and the 
isolation procedures. The intrinsic difference among β-glucans isolated from different 
sources causes variable immune and anti-cancer responses. Even β-glucans of similar 
structures and molecular weights display different biological activities. Therefore, the 
use of natural isolates of heterogeneous properties for biological studies is plagued by 
reproducibility issues.216 The problem is further complicated by the presence of 
contaminants of non-β-glucan origin. For example, Zymosan, which has been 
frequently used in the study of interactions between β-glucans and various cell types, is 
a mixture obtained from baker's yeast (Saccharomyces cerevisiae) consisting of a 
variety of different cell wall particles beyond β-glucans. These potential contaminants, 
lipopolysaccharides (LPS) for instance, may have the ability to initiate an immune 




biological evaluation, it is difficult to rule out the effects of these confounding 
compounds, and to establish a precise structure activity relationship for β-glucans. 
4.1.2 Synthetic β-glucans and mimetics 
The combination of the immunomodulating effects of β-glucans and difficulties in 
the isolation of pure homogeneous glycoforms from heterogeneous natural sources has 
stimulated substantial interest in the chemical synthesis of such polysaccharides. 
Synthetic β-glucans have advantages over natural isolates thanks to their unambiguous 
structures. The synthesis of β-glucans has been attempted by several research groups 
with polysaccharides of different degrees of polymerization being prepared.138,229-239 
Notably, Tanaka and coworkers were able to achieve the synthesis of linear 
hexadecasaccharides (Figure 17, 137) and branched heptadecasaccharides (Figure 
17, 138) by the coupling of thioglycosides with 2,3-diol glycosides.234,235 Automated 
solid-phase synthesis was also described for the preparation of a β-glucan 
dodecasaccharide.233 Many of these synthetic β-glucans have been used for biological 
tests and conformational studies, and were shown to have similar binding and 
immunostimulatory effects as natural β-glucans.230,232,234,235,239 Essentially all of these 
methods employed neighboring group participation to achieve the desired β-selectivity 
by means of an acyl substituent at the 2-O position of glycosyl donors. However, cases 
exist where more α- than β-anomers were obtained, even in the presence of a C-2 
ester capable of neighboring group participation.237,240,241 Therefore, the need for 
control of anomeric stereoselectivity and careful protecting group manipulation is still an 





Figure 17. Structures of Synthetic 16- and 17-Mers of β-Glucans. 
The advance in the chemical synthesis of β-glucans has also enabled the 
rational modification of the parent structure. For example, a series of laminaritetra- or 
pentaoside derivatives with the reducing end connected to a mannose moiety, to a 
4-deoxymannose moiety, and to gluco- and manno-configured glycitols were prepared 
by   tvi ka and coworkers (Figure 18).242,243 It was found that structural modifications 
only on the reducing residue resulted in altered biological activities, such as stimulation 
of phagocytosis, production of IL-2, and modulation of gene expression, as compared 
to the parent linear laminarihepta- and pentaoses. Particularly, the molecules with the 






Figure 18. Structures of β-Glucan Mimetics with Modification on the Reducing 
Residues. 
Similarly, a series of β-glucan-based polysaccharides characterized by the 
presence of one or two thioglycosidic linkages (Figure 19) were synthesized.244 
Biological evaluations have shown that these polyglucans, including the trimer (147 and 
149), display similar stimulating activities towards peritoneal macrophages and 
peritoneal blood neutrophils and monocytes, compared to those of natural laminarin. 
Moreover, the immunostimulating abilities are prolonged in time, which suggests a 
longer survival time of these molecules in vivo, presumably as a result of the presence 
of the more hydrolysis-resistant thioglycosidic bonds. 
 




These synthetic β-glucans and β-glucan-based mimetics provided substrates 
with definite structures for structure activity relationship studies. However, the intrinsic 
difficulties in the efficient and stereocontrolled synthesis of oligosaccharides have not 
been addressed. Considering these problems, Crich and coworkers have adopted a 
medicinal chemistry approach in the design and synthesis of a series of glycan 
mimetics, including oligomeric phostones245,246 and oligomeric hydroxylamines.98,247,248 
These mimetics possess the general structural features of the natural polysaccharides, 
but have modifications at the anomeric linkages to avoid the problems in glycosidic 
bond formation. Particularly, the oligomeric hydroxylamines (Figure 20) were accessed 
by an asymmetric synthesis featuring a ring-closing double reductive amination 
reaction. Interestingly, binding tests revealed that both dimeric 151 and trimeric 152 
were capable of binding to the lectin domains of CR3 and Dectin-1. Moreover, the level 
of phagocytosis induced by the trimeric 152 was more than 50% of that induced by the 
commercial yeast-derived insoluble whole glucan particles (WGP).98 
 
Figure 20. Structures of the Hydroxylamine-Based β-Glucan Mimetics. 
4.2 Design and hypothesis 
The promising results obtained from these synthetic β-glucan mimetics, 
especially these from the thioglycosidic bond-linked mimetics (147-150) and the 
hydroxylamine-based mimetics (151-152) are instructive and have inspired further 




these results, the oligomeric thioether-linked carbasugars (Figure 21, 153) were 
designed. These structures have the β-(1→3)-construction, with the 2-OH groups 
replaced by hydrogen atoms and the endocyclic oxygen atoms replaced by CH2 groups, 
similar to the structural features imbedded in 151 and 152. Meanwhile, similar to 147-
150, the glycosidic oxygen atoms are substituted with sulfur atoms, leading to the 
thioether-linked structures. The influence of 4-OH groups will also be investigated, as 
their absence has shown to increase the biological activities of molecules bearing such 
structure modifications.243 
 
Figure 21. Structures of the Linear β-(1→3)-Glucans and Their Mimetics. 
4.3 Chemistry 
4.3.1 Attempted synthesis via SN2 substitution 
Initially, it was anticipated that the polymeric type structure of A would be 
accessed by condensation of building block B via SN2 substitution (Scheme 29), if the 
competing elimination reaction could be suppressed. An efficient synthesis of poly-
hydroxylated cyclohexyl derivatives was reported by Shing and coworkers in their 




considered to be accessible from cyclic enone C by stereoselective hydrogenation. 
Enone C in turn would be obtained from suitably protected 2-deoxy gluconolatone 
derivatives D following Shing’s strategy for the synthesis gabosine derivatives. 
 
Scheme 29. Retro-Synthetic Analysis for the Oligomeric Thioether-Linked Carbasugars. 
Therefore, adapting the protocol described by Shing and coworkers, the 
treatment of commercially available 2-deoxy-D-glucopyranose 154 with a catalytic 
amount of acetyl chloride in benzyl alcohol at 50 oC gave the benzyl 
2-deoxy-α-D-glycopyranoside as the major product. Subsequent protection of the 4- 
and 6-OH groups with isopropylidene functionality by treatment with 
2,2-dimethoxypropane in DMF in the presence of camphor-10-sulfonic acid (CSA) gave 
the alcohol 155 in 77% yield after two steps. Silylation of the 3-OH group with tert-
butyldimethylsilyl chloride (TBSCl) and imidazole in DMF followed by deprotection of 
the anomeric benzyl ether by hydrogenation with Pd/C in ethyl acetate afforded the 
lactol 156 in 86% yield as a mixture of anomers. Oxidation of the anomeric hydroxy 
group with a catalytic amount of tetrapropylammonium perruthenate (TPAP) and N-
methyl-morpholine N-oxide (NMMO) furnished the lactone 157 in 88% yield. The 
lactone 157 was subsequently treated with the lithium salt of dimethyl 




diastereomer. While direct oxidation of the ketose 158 resulted only in the formation of 
elimination products, a two-step strategy involving sodium borohydride reduction of 158 
and subsequent Swern oxidation of the resulting diol 159 gave the dione 160. Without 
purification, 160 was immediately treated with potassium carbonate and 18-crown-6 in 
toluene to give the enone 161 in 65% overall yield from 158 (Scheme 30). 
 
Scheme 30. Synthesis of Enone 161. 
With the enone 161 in hand, the stereoselective reduction was then attempted 
(Table 4). Exposure of 161 to hydrogenation (1 atm) and Pd/C in THF led to the 
formation of an approximately 1:1.1 mixture of the ketone products 162 and 163, from 
which the individual compounds were isolated in 29 and 32% yield, respectively (Table 
4, entry 1). Attempted reduction with a catalytic amount of Stryker’s reagent250 and a 
stoichiometric amount of phenylsilane was incomplete and only resulted in the isolation 
of the undesired product 163 in 30% yield, with 47% of the starting material recovered 
(Table 4, entry 2). Reduction with copper (I) hydride generated in situ in the presence 




acetylacetonate in the presence of diisobutylaluminum hydride (DIBAL-H) were 
demonstrated to be ineffective in the current system (Table 4, entry 3-4). 
Table 4. 1,4-Conjugate Reduction of Enone 161. 
 
Entry Conditions  162 (% Yield)  163 (% yield) 
1 Pd/C, H2, THF 29  32  
2 (PPh3CuH)6, PhSiH3, toluene  0  30  
3 Cu(I)Cl, NaOtBu, (R)-DTBM-SEGPHOS  
PMHS, toluene 
No reaction 
4 Co(acac)2, DIBAL-H , THF  No reaction 
 
With little success in the 1,4-reduction of enone 161, more attention was paid to 
the 1,2-reduction in order to obtain the allylic alcohol. All such reductions involving L-
Selectride, CeCl3-NaBH4, 9-borabicyclo(3.3.1)nonane (9-BBN), and DIBAL-H led to the 
formation of the pseudo-equatorial-configured allyl alcohol 165 as the predominant 
product, as judged by NMR spectroscopy of the crude reaction mixture (Table 5). 
Among these conditions, the Luche reduction252 (Table 5, entry 2) operated with less 
moisture-sensitive reagents and gave good yield and excellent stereoselectivity, and so 





Table 5. 1,2-Conjugate Reduction of Enone 161. 
 
Entry Conditions  164 : 165  Yield (%) 
1 L-Selectride, THF, -78 oC, 1.5h  0 : 1  67 
2 CeCl3 7H2O, NaBH4, MeOH, -20 
oC, 2h  0 : 1  74 
3 9-BBN, THF, rt, 34h 1 : 4.8  67 
4 DIBAL-H, DCM, 0 oC, 1.5h  1 : 4.3 78 
 
Subsequently, the allyl alcohol 165 was converted to the benzoyl ester 166 in 77% 
yield by a Mitsunobu inversion.253 Treatment of the benzoyl ester 166 with sodium 
methoxide in methanol furnished the allyl alcohol 164 with the desired configuration 
(Scheme 31). 
 
Scheme 31. Synthesis of Allyl Alcohol 164 from Its Epimer 165. 
Next, the pseudo-axial-configured hydroxy gourp in 164 was anticipated to direct 
the hydrogenation of the endocyclic double bond. However, instead of reduction, 
exposure of 164 to one atmosphere of hydrogen in the presence of Crabtree’s 
catalyst254 resulted in migration of the double bond into the heterocyclic ring, giving 169 
in 66% isolated yield (Table 6, entry 1). No reaction was observed in the attempted 




stirred with potassium azodicarboxylate and acetic acid in methanol (Table 6, entry 2 
and 4). Hydrogenation over Pd/C or PtO2 under hydrogen at atmospheric pressure only 
resulted in complex mixtures containing products arising from saturation of the double 
bond, deoxygenation, and loss of the isopropylidene group, as indicated by mass 
spectrometry analysis of the crude reaction mixture. Using Raney nickel as catalyst for 
hydrogenation gave relatively clean reaction mixtures, with the trans- and cis-fused 
bicyclic alcohols 167 and 168 isolated in 41 and 29% yield, respectively (Table 6, entry 
3). 
Table 6. Reduction of the Endocyclic Double Bond in 164. 
 
Eentry Conditions 167 : 168 Yield (%) 
1 Crabtree’s catalyst, H2 (1 atm), DCM  Not observed 169 (66%)  
2 Wilkinson’s catalyst, H2, (40 psi), benzene  No reaction  
3 Raney nickel, H2 (1atm), EtOH  2 : 1  60%  
4 KO2CN=NCO2K, AcOH, MeOH  No reaction  
 
The generally complex reaction profiles and relatively low yields and poor 
selectivities in the reduction of 164 was not anticipated, especially when Shing and 
coworkers’ clean and high yielding hydrogenation of structurally related allyl alcohol 
170 to saturated alcohol 171 was considered (Scheme 32).256 To approach the Shing 





Scheme 32. Shing’s Hydrogenation of Allyl Alcohol 170. 
Treatment of the benzoate ester 166 with a solution of iodine in methanol at 
room temperature facilitated the cleavage of the isopropylidene functionality, with minor 
concomitant cleavage of the silyl ether. The triol 172 and diol 173 were isolated in 26 
and 69% yield, respectively. A Similar transformation was achieved by treatment of 166 
with Amberlyst 15 hydrogen form in methanol. Methoxymethyl ethers were conveniently 
introduced to the diol 173 by reaction with chloromethyl methyl ether in Hunig’s base, 
when the MOM ether 174 was isolated in 87% yield. Transesterification with sodium 
methoxide in methanol afforded the monocyclic allylic alcohol 175 in quantitative yield 
(Scheme 33). 
 
Scheme 33. Synthesis of Monocyclic Allylic Alcohol 175. 
Both the diol 173 and the allylic alcohol 175 were subjected to a hydrogenation 
study. Hydrogenation of the double bond in diol 173 over Pd/C under one atmosphere 
hydrogen proceeded in the desired stereoselective fashion. However, the 
hydrogenation was accompanied by the hydrogenolysis of the primary alcohol, 




protected allylic alcohol 175 was efficiently hydrogenated over Raney nickel in ethanol 
to give the saturated alcohol 177 with the desired configuration in 92% yield (Scheme 
34, b). The NMR spectra of the crude reaction mixture gave no indication of the 
formation of the other diastereomer. 
 
Scheme 34. Hydrogenation of the Monocyclic Allylic Alcohols 173 and 175. 
The successful preparation of the alcohol 177 was then followed by the 
adjustment of functionality at the 3-position. First, the free hydroxy group was protected 
by treatment of 177 with 2-(bromomethyl)naphthalene, sodium hydride, and catalytic 
tetrabutylammonium iodide (TBAI) in DMF. The 2-naphthyl methyl ether 178 was 
obtained in 92% yield. Desilylation of 178 with tetrabutylammonium fluoride (TBAF) 
was followed by oxidation with the Dess-Martin periodinane (DMP) to give a 91% yield 
of the ketone 180, which upon reduction with the bulky borohydride L-Selectride in THF 
at -78 oC afforded the epimeric alcohol 181 in 95% yield. A mesylate was introduced as 
a leaving goup by the reaction with methanesulfonyl chloride in pyridine, resulting in the 
formation of 182 in 84% yield. The subsequent substitution reaction with cesium 
thioacetate was hampered by low reactivity and the formation of elimination products. 
Nevertheless, under microwave irradiation conditions, the reaction time was 




(Scheme 35). The use of mesylate as leaving group in the substitution reaction is 
preferable to that of triflate, which, even though more reactive, gives a higher ratio of 
the elimination product 184.  
 
Scheme 35. Synthesis of the Thioester 183. 
With the thioester 183 in hand as a key intermediate, the two building blocks for 
the coupling reactions could be prepared. Thus, the thioacetate group can be 
deprotected by treatment with sodium methoxide in methanol to give the labile free thiol 
185. Alternatively, the mesylate 186 was accessed in 77% yield by first deprotection 
with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and then mesylation with 
methanesulfonyl chloride in pyridine (Scheme 36). 
 
Scheme 36. Preparation of Coupling Building Blocks from Thioester 183. 
Unfortunately, the attempted coupling reactions between the thiol 185 and the 
mesylate 186 only resulted in complex mixtures, presumably due to the quick formation 




186 with simple sodium ethanethiolate under various conditions leads to the quick 
formation of elimination and deacetylation products, as revealed by mass spectrometry 
analysis. Considering the number of steps required for the preparation of these building 
blocks, analogs with simpler structures were used for optimization of reaction 
conditions. However, even with a simplified structure, all conditions tested afforded the 
elimination products predominantly, as exemplified by the reaction shown in Scheme 
37. 
 
Scheme 37. Reaction of Mesylate 187 with Sodium Ethanethiolate. 
4.3.2 Synthesis of 4-deoxy mimetics 
The formation of major amounts of elimination products under the attempted 
substitution reaction conditions led to the reevaluation of the synthetic route. The strong 
nucleophilicity of thiolates, which is required in the synthesis of the target molecules, 
makes it not only a good nucleophile in SN2 substitution reactions, but also a good 
Michael donor in thiol-Michael addition reactions.257 Therefore, if the addition reaction 
of a thiol to a cyclic enone (Figure 22) could proceed in a stereoselective fashion 
favoring the desired equatorial isomer, the thioether linkages required in the target 
molecules would be constructed without the problem of elimination. 
 




Enones with structures similar to those represented by 190 have been 
synthesized. The thiol structures 191 could also be potentially derived from 190. 
Therefore, a new synthetic route began with the preparation of enones 190. 
Following a protocol reported by Mori and coworkers,258 the commercially 
available (S)-(−)-3-cyclohexene-1-carboxylic acid 192 was converted to the enone 196 
in four known steps with high yields. Protection of the free hydroxy group as a MOM 
ether gave enone 197 in 94% yield (Scheme 38). 
 
Scheme 38. Synthesis of Enone 197. 
While the introduction of a 4-OH group by α-oxygenation of 197 can be done at 
this stage, the synthesis of the 4-deoxy series of β-glucan mimetics directly from 197 
was attempted first. Stirring of 197 with sodium ethanethiolate in methanol at room 
temperature resulted in the formation of the equatorial isomer 198 and the axial isomer 
199 in 56 and 31% isolated yield, respectively. Subjecting the isolated axial isomer 199 
to the same conditions also led to the isolation of its epimer 198 in 64% yield. 
Fortunately, the isolation of the desired equatorial isomer as the major product under 
these conditions demonstrated the feasibility of implemented thiol-Michael addition 
method. Subsequent transformation of the ketone functionality to an equatorial 
thioester group was accomplished (Scheme 39). Again, microwaves were employed to 





Scheme 39. Synthesis of Thioether 198 and Thioester 202. 
The thioacetate 202 was then treated with sodium methoxide in methanol to give 
the corresponding thiol. Without purification, the crude thiol was reacted with the enone 
197 in the presence of the strong organic base DBU using 2,2,2-trifluoroethanol (TFE) 
as solvent to give the desired equatorial thioether 203 in 55% yield and the axial 
thioether 204 in 33% yield. Reduction of the ketone functionality with sodium 
borohydride in methanol followed by deprotection of the MOM ethers by treatment with 
catalytic HCl in methanol at 60 oC afforded the dimeric product 206 (Scheme 40). 
 
Scheme 40. Synthesis of Dimeric β-Glucan Mimetic. 
By iterative application of the same strategy, the trimer 213 (Scheme 41) and 





Scheme 41. Synthesis of Trimeric β-Glucan Mimetic. 
 




4.3.3 Synthesis of “natural” type mimetics 
The feasibility of the thiol-Michael addition in the construction of the thioether 
linkage was established by the successful synthesis of the 4-deoxy series of β-glucan 
mimetics. Therefore, the key to the synthesis of the “natural” type mimetics bearing 
hydroxy groups at the 4-position lies in the α’-oxygenation of the intermediate enone 
197. Investigation in this direction began with preparation of a TBS ether protected 
enone 221 from the alcohol 196 (Scheme 43). 
 
Scheme 43. Synthesis of the TBS Ether-Protected Enone 221. 
The Rubottom oxidation259 of the enones 197 and 221 was attempted first 
(Scheme 44). While the TBS enol ethers were obtained successfully by treatment of 
the relevant enone with tert-butyldimethylsilyl trifluoromethanesulfonate and 
triethylamine in DCM, the subsequent oxidation with mCPBA led to a 1:1.6 mixture of 
isomers, favoring the undesired cis-product in the case of 197, as judged by NMR 
spectroscopy of the crude reaction mixture (Scheme 44, a). Similarly, a mixture of 
epimers resulted from the TBS-protected enone 221, with over oxidation products 





Scheme 44. Rubottom Oxidation of the Enones 197 and 221. 
The conditions for the catalytic stereoselective α-aminoxylation of ketones by 
nitrosobenzene in the presence of L-proline reported by Cordova and coworkers261 
were attemped (Scheme 45). The reaction was incomplete after overnight stirring at 
room temperature (35% starting material was recovered), and together with the 
alkoxylamine 226 of undesired configuration, a byproduct structurally similar to bridged 
227 was also observed by NMR spectroscopy, consistent with earlier observations of 
Yamamoto and coworkers in the tandem O-nitroso aldol/Michael reactions.262 
 
Scheme 45. α’-Aminoxylation of the Enone 197. 
An incomplete reaction resulted from oxidation of the lithium enolate of 197 with 
the Vedejs reagent263 in THF at -20 oC (Scheme 46). In addition, NMR spectroscopic 






Scheme 46. Oxidation of the Lithium Enolate with Vedejs Reagent. 
Similarly, α’-acetoxylation reactions with either manganese(III) acetate in 
benzene at refluxing or lead(IV) acetate in refluxing toluene gave poor stereoselectivity. 
To complicate matters even more, subsequent deacetylation reactions under various 
conditions were marred by the addition of the solvent (methanol) to the enone and the 
aromatization of the cyclic structures (Scheme 47). 
 
Scheme 47. α’-Acetoxylation Reactions and Subsequent Deacetylation. 
The situation was only improved when the sulfonyloxaziridines (233-236) were 
used as oxidants (Table 7). Therefore, treatment of the lithium enolates of 197 and 221 
with the benzaldehyde-derived oxaziridine 233 led to the formation of the desired 
trans-alcohols trans-229 and trans-238 in low yields. Byproducts from the reaction of 
the enolates with the sulfonamide generated in situ were either observed by mass 
spectrometry or isolated as a mixture of isomers (Table 7, entry 1 and 3). Oxidation 
using the camphorsulfonic acid-derived chiral oxaziridine 234 gave the desired 
trans-products 229 and 238 as single isomers, in 48 and 49% yield, respectively (Table 
7, entry 2 and 4). When the TBS protected enone 221 was treated with LDA and the 
methyl oxaziridine 235 in THF at -78 oC, almost equal amount of trans- and cis-isomers 




entry 5). In contrast, the sterically more hindered oxaziridine 236 was less reactive and 
required higher temperature for the reaction to proceed. Even though the reaction was 
incomplete, NMR spectroscopic analysis of the crude reaction mixture revealed trans-
238 as a single isomer, with 64% isolated yield after chromatographic purification 





Table 7. α’-Hydroxylation with Oxaziridines. 
 
Entry Substrate Oxaziridine Conditions Products (% yield) 
1 197 233 THF, -78 oC trans-229 (20), 237 (by MS) 
2 197 234 THF, -78 oC to 
rt 
trans-229 (48) 
3 221 233 THF, -78 oC trans-238 (33), cis-238 (18), 239 
(32) 
4 221 234 THF, -78 oC to 
rt 
trans-238 (49) 
5 221 235 THF, -78 oC trans-238 (38), cis-238 (31) 




With the α’-hydroxylated compounds 229 and 238 in hand, the free hydroxy 
groups were next protected as MOM and TBS ethers, respectively. The subsequent 
transformation to the thioesters 250 and 251 was accomplished by following the 
method described in the preparation of the 4-deoxy series of β-glucan mimetics. All the 
reactions went smoothly to give comparable yields, except that the reduction of the 




migration of one of the TBS groups to the newly formed hydroxy group, and 
consequently gave only 17% of the desired axial alcohol 247 (Scheme 48). Currently, 
the optimization of this step and the coupling reactions leading to the oligomeric 
structures are being conducted by group members in the Crich laboratory. 
 
Scheme 48. Synthesis of the Thioester 250 and 251. 
4.4 Biological evaluation 
The 4-deoxy series of β-glucan mimetics 206, 213, and 220 were screened to 
evaluate their biological activities. Specifically, in order to study the binding affinity to 
the common β-glucan receptors CR3 and Dectin-1, their ability to inhibit the staining of 
human neutrophils by fluorescein ligated anti-CR3 antibodies and that of mouse 
macrophages by anti-Dectin-1 antibodies were investigated (Table 8). At 0.1 µg·mL-1 
concentration, all three compounds displayed significant inhibitory effect towards the 
staining of both receptors by the respective antibodies. The tetramer 220 was the most 
effective among the three compounds in both tests, and caused 45% inhibition in the 
binding of anti-CR3 antibody to the CR3 receptors on human neutrophils, and more 
than 50% inhibition for that of anti-Dectin-1 antibody to the Dectin-1 receptors on 
mouse macrophages (Table 8, entry 4). Inducing a 40% and nearly 49% decrease in 




anti-Dectin-1, respectively, the dimer 206 appeares to be more effective in this 
inhibition assay than the trimer 213, which caused a 33% and 41% decrease in the 
respective experiments. Nevertheless, these results suggest the capacity of these 
thioether-linked oligomeric cabasugars to bind to the lectin domains of both CR3 and 
Dectin-1, even at the dimer level. 








1 206 (0.30) 2 40.5 ± 3.6 48.9 ± 4.1 
2 213 (0.21) 3 33.2 ± 2.8 41.6 ± 3.6 
3 220 (0.16) 4 45.3 ± 3.9 54.7 ± 3.8 
  
Solutions (10 µg·mL-1) of compounds 206, 213, and 220 were also screened for 
their ability to stimulate phagocytosis of synthetic polymeric 2-hydroxyethyl 
methacrylate microspheres by human macrophage-like RAW 264 cells and that of 
neutral red dye by mouse macrophages. Commercially available Glucan #300 (natural 
extracts of yeast cell walls, primarily β-glucans) was used as comparison standard 
(Table 9, entry 4) and phosphate-buffered saline (PBS) was used in control experiment 
(Table 9, entry 5). Although less effective than the natural extracts of much higher 
degree of polymerization, the mimetics under current study displayed considerable 
stimulating effect on macrophages, as indicated by their significant differences from the 
PBS control. While the tetramer 220 was found to be more effective than the trimer 213 
in stimulating both phagocytosis and pinocytosis, the pattern seems not to hold with the 




are considered. Alternatively, it might also be a manifestation of the topological 
property of the β-glucan receptors on the surface of the macrophages. Overall, the 
phagocytosis-stimulating effect displayed by these relatively short β-glucan mimetics in 
these in vitro assays suggests their potential immunomodulating effect in vivo, just as 
that of their natural counterparts. 








1 206 (30) 2 17.7 ± 1.6 20.81 ± 2.87 
2 213 (21) 3 12.3 ± 1.5 9.12 ± 2.01 
3 220 (16) 4 18.3 ± 0.9 16.17 ± 2.98 
4 Glucan #300 - 37.5 ±  2.5 38.9 ± 2.81 
5 PBS - 2.1 ± 0.2 1.77 ± 0.11 
 
4.5 Discussion 
Adapting Shing’s method of preparing gabosin derivatives, the key intermediate 
177 was successfully prepared. However, the high stereoselectivity and excellent 
chemical yield of the reduction of monocyclic 175 (Scheme 49, b), along with that of 
170 (Scheme 49, c), as reported by Shing and coworkers,256 contrasts with the modest 
selectivity and yield obtained with the bicyclic 164 under the same reaction conditions 
(Scheme 49, a). The clear difference in stereoselectivity between these two systems 
ruled out the directing effect of hydroxy group as the sole stereochemical determination 
factor. A careful analysis of the coupling constants by NMR spectroscopy revealed the 




164 adopts the half-chair conformation A, which is enforced by the trans-fused bicyclic 
system. The same conformation was largely retained upon cleavage of the acetonide, 
as shown by the structure of 173. However, after the installation of the MOM protecting 
groups, the structure undergoes a ring flip to adopt the half-chair conformation B. The 
reason for this conformational transformation is presumably to minimize the 1,2A strain 
between the allylic MOM ether on the ring and the methoxymethoxymethyl substituent. 
Removal of the benzoyl group has little influence on this half-chair conformation, as the 
allyl alcohol 175 was shown to take the same conformation B. The 
methoxymethoxymethyl substituent is thought to adopt a perpendicular conformation to 
the alkene, so as to minimize the 1,3A interaction with the olefinic hydrogen and the 
dipolar repulsion with the MOM ether on the ring. Therefore, the combined hydroxy 
group directing effect and the steric effect exerted by the pseudo-axially oriented TBS 
and MOM ethers are responsible for the high stereoselectivity observed in the 





Scheme 49. Comparison of the Hydrogenation Reactions for the Mono- and Bicyclic 
Systems.  
 
Figure 23. Conformations and Diagnostic Coupling Constants in Hz for Compounds 
164, and 173-175. 
The thiol-Michael addition reactions were the key steps in the preparation of the 
thioether-linked oligomeric structures. The use of strong bases such as DBU and 




crucial to the generation of the β-(1,3)-like configuration (Figure 24). The use of weaker 
base such as triethylamine only resulted in the predominant formation of the 
axial-thioether as kinetic product. 
 
Figure 24. Energy Profiles for the Reaction of Enone 197 with Thiolates. 
The ability of the oligomeric thioether-linked carbasugars 206, 213, and 220 to 
bind to the β-glucan receptors CR3 and Dectin-1, and to stimulate the phagocytosis 
activity of macrophages supports the use of glycomimetics as natural β-glucan 
surrogates. The binding of these short β-glucan mimetics, as compared to that of 
natural264 and synthetic229 β-glucans of the same length emphasizes the structural 
advantages of these mimetics. Indeed, these compounds even show slightly better 
biological activities than the hydroxylamine-based β-glucan mimetics 151 and 152.98 




comparable length β-glucans can be attributed to the increased hydrophobicity of the 
α-face as a result of the absence of both the 2α- and 4α-hydroxy groups (carbohydrate 
numbering). The increased hydrophobicity in turn enhances the hydrophobic interaction 
between these molecules and the aromatic side chains of Trp 221 and His223 in the 
binding pocket (Figure 25).265 It has been suggested that the replacement of the 
glycosidic oxygen by sulfur leads to enhanced resistance to acidic and enzymatic 
hydrolysis and increased interactions with proteins, and on the other hand, this 
replacement has little influence on the conformation of the oligosaccharides.266 In fact, 
not only in carbohydrates, sulfur containing functionalities have been incorporated into 
a wide range of small molecule pharmaceuticals.267 
 
Figure 25. The Hydrophobic Binding Pocket Revealed by X-Ray Crystallographic 
Studies. 
4.6 Conclusion 
While the synthesis of natural polysaccharides still requires high levels of 
expertise in controlling the regio- and stereo-selectivity of glycosylation reactions, the 
synthesis of glycomemetics as surrogates is facilitated by a much larger reservoir of 
chemical tools. The synthesis of the β-glucan mimetics in this study, despite the 




chemistry. While SN2 substitution in constructing the thioether linkages was impeded by 
concomitant elimination, a thiol-Michael addition reaction was employed to achieve the 
synthesis of the 4-deoxy series of β-glucan mimetics. The synthesis of the 4-hydroxy 
series of β-glucan mimetics was complicated by the inefficiency of α’-oxidation of the 
relevant enones, with the oxidation of enolate with sulfonyloxaziridine being the best 
conditions found so far. Biological assays of the synthesized β-glucan mimetics 
revealed their ability to bind to common β-glucan receptors, and to stimulate 
macrophages in vitro. Overall, beyond the development of a new class of active β-
glucan mimetics, the results presented in this study demonstrate the value of β-glucan 
mimetics in simplifying the chemical synthesis as well as in modulating the biological 





CHAPTER 5. CONCLUSIONS 
A series of 2-O-phenacyl and 2-O-alkoxycarbonylmethyl ether protected 
mannopyranosyl donors were prepared and used in glycosylation reactions. The 
isolation of tricyclic products in two cases demonstrates the stereoelectronic feasibility 
of participation by the designed systems through six-membered cyclic intermediates. 
The high β-selectivity in all other cases argues against effective stereodirecting 
participation by these groups. DFT calculations suggest that the cyclization of the 
2-O-alkoxycarbonylmethyl functionality onto the anomeric carbon of a glycosyl 
oxocarbenium ion is more energetically favourable than the putative participation by a 
3-O-ester group. It is therefore suggested that, without conformational predisposition, 
the participation by non-vicinal esters through the formation of six- or larger membered 
intermediates is unlikely to be a serious contributing factor in glycosylation. 
An improved blue-light photocatalytic method for the formation of glycosidic 
bonds has been developed. This method employs stable and easily accessible Tempol 
glycosides as glycosyl donors, with as little as 5 mol% of an Ir-based photocatalyst, and 
allows the effective glycosylation of both carbohydrate and non-carbohydrate acceptors 
at room temperature. Compared with existing photocatalytic glycosylation methods, this 
method neither requires nor generates any strongly eletrophilic species. The 
stereoselectivities of these reactions are modest but are nevertheless a function of the 
anomeric configurations of the donors, suggesting the involvement of a partially 
concerted mechanism. 
To study the immunostimulating activities of natural β-glucans and to avoid the 




were designed as mimetics. The equatorial thioether linkages were successfully 
constructed by thiol-Michael addition reactions between a thiol and a cyclic enone 
under thermodynamic control. Dimeric, trimeric, and tetrameric mimetics of the 4-deoxy 
series were synthesized in this manner and subjected to biological studies. The ability 
of these mimetics to inhibit the staining of human neutrophils and mouse macrophages 
by anti-CR3 antibodies and anti-Dectin-1 antibodies, respectively, revealed the 
significant affinity of these mimetics for the common β-glucan receptors CR3 and 
Dectin-1. Moreover, the ability of these short mimetics to stimulate phagocytosis was 
also demonstrated. The biological activities of these relatively short glycomimetics 
reinforce the idea of enhancing the interaction between the β-glucan-based ligands and 
the target receptors by increasing the hydropobicity of the α-faces of the ligand 
molecules. The facile synthesis and low degree of polymerization needed for biological 
activity shows the advantages of glycomimetics as valuable complements to 





CHAPTER 6. EXPERIMENTAL SECTION 
General Information: 
All reactions were performed using oven-dried glassware under an atmosphere 
of argon. All reagents and solvents were purchased from commercial suppliers and 
were used without further purification unless otherwise specified. Chromatographic 
purifications were performed on silica gel (230-400 mesh) columns (20-50 g of silica gel 
per gram of crude compound). Reactions were monitored by analytical thin-layer 
chromatography on pre-coated glass backed plates (w/UV 254) and visualized by UV 
irradiation (254 nm) or by staining with 25% H2SO4 in EtOH or ceric ammonium 
molybdate (CAM) solution. Specific rotations were measured on an automatic 
polarimeter with a path length of 100 mm in the solvent specified. Concentrations are 
given in g/100 mL. High resolution mass spectra (HRMS) were recorded with an 
electrospray ionization (ESI) source coupled to a time-of-flight (TOF) mass analyzer or 
with an electron impact (EI) source coupled to a TOF mass analyzer. 1H, 13C, 19F, 
spectra were recorded on a 400, 500 or 600 MHz spectrometer. NMR solvents were 
used without purification. Chemical shifts are given in ppm (δ) and coupling constants 
(J) are given in Hz. Multiplicities are given as singlet (s), broad singlet (br s), doublet (d), 
triplet (t), doublet of doublets (dd), triplet of doublets (td), multiplet (m), apparent quartet 
(app q), apparent pentet (app p), etc. 
1-(3-Bromoprop-1-en-2-yl)-2,4-bis(trifluoromethyl)benzene (43). 
A solution of 1-[2,4-bis(trifluoromethyl)phenyl]ethanone (50 mg, 0.20 mmol) in 
diethyl ether (0.5 mL) was added dropwise into a stirred solution of methylmagnesium 




min, the reaction was quenched by adding 3 N HCl (1 mL) slowly. The resulting mixture 
was extracted with diethyl ether, the combined organic layers was washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure. Chromatographic 
purification (10% ethyl acetate/hexanes) afforded 2-[2',4'-
bis(trifluoromethyl)phenyl]propan-2-ol as a colorless oil (42 mg, 79%): 1H NMR (400 
MHz, CDCl3) δ 8.03 – 8.00 (m, 1H), 7.83 – 7.71 (m, 2H), 1.71 (s, 6H). 
13C NMR (101 
MHz, CDCl3) δ 152.3, 129.4 (q, J = 33.5 Hz), 129.0, 128.3, 127.9 (q, J = 31.9 Hz), 
125.3 – 124.9 (m), 124.0 (q, J = 273.5 Hz), 123.4 (q, J = 272.0 Hz), 73.6, 32.3. 19F 
NMR (376 MHz, CDCl3) δ -54.66, -63.01. To a solution of 2-[2',4'-
bis(trifluoromethyl)phenyl]propan-2-ol (42 mg, 0.15 mmol) in benzene (1.5 mL) was 
added p-toluenesulfonic acid monohydrate (2.9 mg, 0.015 mmol) at rt. The mixture was 
then refluxed for 12 h before cooling to rt and concentration under reduced pressure. 
Chromatographic purification (hexanes) afforded 2-[2',4'-
bis(trifluoromethyl)phenyl]propene as a colorless oil (30 mg, 76%): 1H NMR (400 MHz, 
CDCl3) δ 7.90 (s, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 5.32 – 5.28 (m, 
1H), 4.93 (s, 1H), 2.09 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 147.1, 142.1, 130.8, 
129.5 (q, J = 33.2 Hz), 128.6 (q, J = 31.0 Hz), 128.2 (d, J = 3.9 Hz), 123.4 (q, J = 274.6 
Hz, 2*CF3), 123.5 – 123.1 (m), 117.0, 24.8. 
19F NMR (376 MHz, CDCl3) δ -58.77, -
62.86. HRMS (EI-TOF) m/z: Calcd. for C11H8F6 ([M]
+．): 254.0530; found: 254.0543. A 
solution of 2-[2',4'-bis(trifluoromethyl)phenyl]propene (84 mg, 0.33 mmol), N-
bromosuccinimide (64 mg, 0.36 mmol) and azobisisobutyronitrile (5.4 mg, 0.03 mmol) 
in benzene (1.5 mL) was refluxed at 85 oC under argon for 2 h. After cooling to rt, the 




purification (hexanes) afforded the title compound as a colorless oil (43, 93 mg, 84%): 
1H NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.59 (d, J = 8.0 Hz, 
1H), 5.73 (s, 1H), 5.24 (s, 1H), 4.24 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 142.0, 
132.9 , 132.8 , 130.6 (q, J = 33.6 Hz), 129.1 (q, J = 30.9 Hz), 128.2 (d, J = 4.0 Hz), 
123.6 – 123.2 (m), 123.30 (q, J = 274.0 Hz), 123.25 (q, J = 272.2 Hz), 122.1, 35.5 (d, J 
= 2.8 Hz). 19F NMR (376 MHz, CDCl3) δ -58.62, -62.97. HRMS (EI-TOF) m/z: Calcd. for 
C11H7F6Br ([M]
+．): 331.9635; found: 331.9630 (1%), Calcd. for C11H7F6 ([M - Br
．
]+): 
253.0452; found: 253.0447 (100%). 
Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-(2-phenylprop-2-en-1-yl)-1-thio-α-D-
mannopyranoside (44). 
To a stirred solution of phenyl 3-O-benzyl-4,6-O-benzylidene-1-thio-α-D-
mannopyranoside 40 (500 mg, 1.1 mmol) in THF (1.5 mL) at 0 oC was added sodium 
hydride (58 mg, 60% suspension in mineral oil, 1.4 mmol). After stirring at 0 oC for 30 
min, a solution of 3-bromoprop-1-en-2-yl-benzene 41 (284 mg, 1.4 mmol) in THF (0.4 
mL) was added dropwise. The resulting mixture was stirred at rt for 48 h. After 
completion, ethyl acetate was added, and the reaction mixture was washed with brine 3 
times, dried over Na2SO4 and concentrated under reduced pressure. Chromatographic 
purification (6% ethyl acetate/hexanes) afforded the title compound as a colorless oil 
(44, 588 mg, 94%): [α]D
21 +124.2 (c 3.12, CH2Cl2). 
1H NMR (600 MHz, CDCl3) δ 7.59 – 
7.21 (m, 20H), 5.62 (s, 1H), 5.54 (s, 1H), 5.36 (d,  J = 1.2 Hz, 2H), 5.32 (d, J = 1.2 Hz, 
2H), 4.84 (d, J = 12.1 Hz, 1H), 4.72 – 4.63 (m, 2H), 4.57 (d, J = 13.0 Hz, 2H), 4.30 – 
4.22 (m, 2H), 4.19 (dd, J = 10.2, 3.9 Hz, 1H), 4.09 (dd, J = 3.2, 1.4 Hz, 1H), 3.96 (dd, J 




138.39, 137.6, 133.7, 131.9, 131.7, 129.1, 128.9, 128.6, 128.40, 128.37, 128.3, 128.2, 
127.9, 127.73, 127.66, 127.6, 126.8, 126.3, 126.1, 115.6, 101.5, 101.4, 87.3, 79.2, 77.6, 
76.4, 73.2, 68.5, 65.4. HRMS (ESI-TOF) m/z: Calcd. for C35H34O5SNa ([M + Na]
+): 
589.2025; found: 589.2025. 
Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-phenacyl-1-thio-α-D-mannopyranoside 
(47) and Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-phenacyl-1-thio-α-D-
mannopyranoside S-oxide (50). 
O3 was bubbled into a stirred solution of 44 (268 mg, 0.47 mmol) in DCM (10 mL) 
at -78 oC for 10 min until the appearance of a deep blue color. Ar was then bubbled 
through the solution for 15 min, before triphenylphosphine (373 mg, 1.42 mmol) was 
added and the reaction mixture was allowed to warm to rt. After stirring at rt for a 
further 3 h, the mixture was concentrated. Chromatographic purification (14% ethyl 
acetate/hexanes) afforded the desired ketone product as a colorless oil (47, 161 mg, 
60%) [α]D
21 +102.2 (c 0.7, CH2Cl2). 
1H NMR (600 MHz, CDCl3) δ 7.86 – 7.82 (m, 2H), 
7.59 – 7.55 (m, 1H), 7.53 – 7.25 (m, 17H), 5.99 (d, J = 1.4 Hz, 1H), 5.64 (s, 1H), 5.14 – 
5.04 (m, 2H), 4.92 (d, J = 12.0 Hz, 1H), 4.70 (d, J = 11.9 Hz, 1H), 4.36 – 4.29 (m, 2H), 
4.23 (dd, J = 10.3, 3.8 Hz, 1H), 4.08 (dd, J = 3.0, 1.4 Hz, 1H), 4.00 (dd, J = 9.6, 2.9 Hz, 
1H), 3.91 – 3.87 (m, 1H). 13C NMR (151 MHz, CDCl3) δ 196.5, 138.2, 137.5, 134.7, 
133.59, 133.55, 131.5, 129.1, 128.9, 128.7, 128.4, 128.2, 127.81, 127.77, 127.7, 127.5, 
126.1, 101.5, 87.9, 80.1, 79.4, 74.9, 73.7, 68.5, 65.3. HRMS (ESI-TOF) m/z: Calcd. for 
C34H32O6SNa ([M + Na]
+): 591.1817; found: 591.1790. Further elution (20% ethyl 
acetate/hexanes) gave the sulfoxide as a colorless oil (50, 51 mg, 18%): [α]D
21 -26.4 (c 
1.48, CHCl3). 




Hz, 2H), 7.57 – 7.47 (m, 6H), 7.43 – 7.34 (m, 7H), 7.33 – 7.26 (m, 3H), 5.63 (s, 1H), 
5.10 (d, J = 1.3 Hz, 1H), 5.08 (d, J = 17.4 Hz, 1H), 4.96 (d, J = 11.8 Hz, 1H), 4.88 (d, J 
= 17.1 Hz, 1H), 4.75 (d, J = 11.8 Hz, 1H), 4.38 – 4.32 (m, 2H), 4.31 (s, 1H), 4.26 (dd, J 
= 10.4, 4.9 Hz, 1H), 4.18 (td, J = 9.5, 4.8 Hz, 1H), 3.79 (t, J = 10.2 Hz, 1H). 13C NMR 
(151 MHz, CDCl3) δ 195.6, 141.4, 138.2, 137.2, 134.5, 133.5, 131.6, 129.4, 129.0, 
128.6, 128.4, 128.3, 127.9, 127.8, 127.7, 126.1, 124.5, 101.7, 98.2, 78.3, 77.1, 75.8, 
75.2, 74.0, 69.9, 68.3. HRMS (ESI-TOF) m/z: Calcd. for C34H32O7SNa ([M + Na]
+): 
607.1766; found: 607.1765. 
Compound 50 was also prepared by mCPBA oxidation of 47: To a stirred 
solution of 47 (104 mg, 0.18 mmol) in DCM (2 mL) at -78 oC under an argon 
atmosphere was added a solution of mCPBA (77%, 40.9 mg, 0.18 mmol) in DCM (1 mL) 
dropwise. After stirring at this temperature for 3 h, saturated NaHCO3 solution (1 mL) 
was added and the mixture was then allowed to warm to rt. DCM (10 mL) was added 
and the separated organic layer was washed with saturated NaHCO3 solution once, 
brine 3 times, dried over Na2SO4 and concentrated under reduced pressure. 
Chromatographic purification (20% ethyl acetate/hexanes) afforded 50 (64.2 mg, 60%) 
which was identical to the above sample. 
Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-[2-(4’-trifluoromethyl)phenylprop-2-en-
1-yl])-1-thio-α-D-mannopyranoside (45). 
To a stirred solution of 3-O-benzyl-4,6-O-benzylidene-1-thio-α-D-
mannopyranoside 40 (100 mg, 0.22 mmol) in THF (0.5 mL) at 0 oC was added sodium 
hydride (13.3 mg, 60% suspension in mineral oil, 0.33 mmol). After stirring at 0 oC for 




0.33 mmol) in THF (1.5 mL) was added dropwise. The resulting mixture was stirred at rt 
for 48 h. After the completion of reaction, ethyl acetate was added, then it was washed 
with brine 3 times, dried over Na2SO4 and concentrated under reduced pressure. 
Chromatographic purification (6% ethyl acetate/hexanes) afforded the title compound 
as a colorless oil (45, 109 mg, 78%): [α]D
21 +94.6 (c 0.95, CHCl3). 
1H NMR (500 MHz, 
CDCl3) δ 7.61 (d, J = 8.1 Hz, 2H), 7.57 – 7.48 (m, 4H), 7.44 – 7.28 (m, 13H), 5.65 (s, 
1H), 5.64 (s, 1H), 5.48 (s, 1H), 5.36 (d, J = 1.3 Hz, 1H), 4.91 (d, J = 11.9 Hz, 1H), 4.70 
(d, J = 11.9 Hz, 1H), 4.66 (d, J = 12.5 Hz, 1H), 4.58 (d, J = 12.6 Hz, 1H), 4.34 – 4.25 (m, 
2H), 4.23 (dd, J = 10.3, 4.5 Hz, 1H), 4.11 (dd, J = 3.3, 1.4 Hz, 1H), 4.02 (dd, J = 9.3, 
3.2 Hz, 1H), 3.87 (t, J = 9.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 143.0, 142.0, 138.3, 
137.5, 133.6, 131.7, 129.8 (q, J = 32.3 Hz), 129.2, 128.9, 128.4, 128.2, 127.79, 127.76 
(2 carbons), 126.7, 126.1, 125.3 (q, J = 3.9 Hz), 124.2 (q, J = 272.0 Hz), 117.8, 101.5, 
87.2, 79.3, 78.0, 76.4, 73.5, 73.2, 68.5, 65.4. 19F NMR (376 MHz, CDCl3) δ -62.51. 
HRMS (ESI-TOF) m/z: Calcd. for C36H33F3O5SNa ([M + Na]
+): 657.1898; found: 
657.1901. 
Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-(4’-trifluoromethylphenacyl)-1-thio-α-D-
mannopyranoside (48) and Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-(4’-
trifluoromethylphenacyl)-1-thio-α-D-mannopyranoside S-oxide (51). 
O3 was bubbled into a stirred solution of 453 (100 mg, 0.16 mmol) in DCM (4 mL) 
and methanol (1 mL) at -78 oC for 5 min until the appearance of a deep blue color. Ar 
was then bubbled through the solution for 15 min, before triphenylphosphine (124 mg, 
0.47 mmol) was added and the reaction mixture was allowed to warm to rt. After stirring 




ethyl acetate/hexanes) afforded the desired ketone product as a colorless oil (48, 78 
mg, 77%): [α]D
21 +72.7 (c 1.245, CHCl3). 
1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 8.1 
Hz, 2H), 7.68 (d, J = 8.2 Hz, 2H), 7.56 – 7.46 (m, 4H), 7.44 – 7.28 (m, 11H), 5.91 (d, J 
= 1.4 Hz, 1H), 5.64 (s, 1H), 5.10 – 5.00 (m, 2H), 4.94 (d, J = 11.7 Hz, 1H), 4.70 (d, J = 
11.8 Hz, 1H), 4.36 (td, J = 9.6, 4.7 Hz, 1H), 4.30 (t, J = 9.5 Hz, 1H), 4.26 (dd, J = 10.3, 
4.7 Hz, 1H), 4.10 (dd, J = 3.0, 1.5 Hz, 1H), 4.04 (dd, J = 9.5, 3.0 Hz, 1H), 3.89 (t, J = 
10.1 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 195.7, 138.1, 137.5, 137.4, 134.7 (q, J = 
32.7 Hz), 133.5, 131.6, 129.2, 129.0, 128.5, 128.4, 128.2, 127.9, 127.8, 127.7, 126.1, 
125.7 (q, J = 3.9 Hz), 123.5 (q, J = 272.7 Hz), 101.6, 87.8, 80.4, 79.5, 77.0, 75.2, 74.0, 
68.5, 65.3. 19F NMR (376 MHz, CDCl3) δ -63.19. HRMS (ESI-TOF) m/z: Calcd. for 
C35H31F3O6SNa ([M + Na]
+): 659.1691; found: 659.1662. Further elution (20% ethyl 
acetate/hexanes) gave the sulfoxide as a colorless oil (51, 19 mg, 18%): [α]D
21 -10.4 (c 
0.94, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 7.85 – 7.81 (m, 2H), 7.63 (dd, J = 7.6, 1.8 
Hz, 4H), 7.57 – 7.52 (m, 3H), 7.49 (dd, J = 7.7, 1.9 Hz, 2H), 7.41 – 7.33 (m, 5H), 7.32 – 
7.26 (m, 3H), 5.62 (s, 1H), 5.03 (d, J = 16.9 Hz, 1H), 4.97 (s, 1H), 4.96 (d, J = 11.8 Hz, 
1H), 4.84 (d, J = 16.9 Hz, 1H), 4.72 (d, J = 11.6 Hz, 1H), 4.33 (m, 3H), 4.25 (dd, J = 
10.4, 4.9 Hz, 1H), 4.15 (td, J = 9.5, 4.9 Hz, 1H), 3.77 (t, J = 10.2 Hz, 1H).  13C NMR 
(151 MHz, CDCl3) δ 194.9, 141.5, 138.1, 137.2, 137.1, 134.7 (q, J = 32.8 Hz), 131.7, 
129.4, 129.1, 128.4, 128.27, 128.26, 128.0, 127.9, 126.0, 125.6 (q, J = 3.7 Hz), 124.5, 
123.4 (q, J = 272.7 Hz), 101.7, 98.1, 78.4, 77.1, 75.9, 75.5, 74.3, 69.9, 68.2. 19F NMR 
(376 MHz, CDCl3) δ -63.21. HRMS (ESI-TOF) m/z: Calcd. for C35H31F3O7SNa ([M + 




Compound 51 was also prepared by mCPBA oxidation of 48: To a stirred 
solution of 48 (37 mg, 0.06 mmol) in DCM (0.8 mL) at -78 oC under argon atmosphere 
was added a solution of mCPBA (77%, 13.1 mg, 0.06 mmol) in DCM (0.4 mL) dropwise. 
After stirring at this temperature for 4 h, saturated NaHCO3 solution (1 mL) was added 
and the mixture was then allowed to warm to rt. DCM (10 mL) was added and the 
separated organic layer was washed with saturated NaHCO3 solution once, brine 3 
times, dried over Na2SO4 and concentrated under reduced pressure. Chromatographic 
purification (20% ethyl acetate/hexanes) afforded 51 (31.6 mg, 83%) which was 
identical to the above sample. 
Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-[2-(2’,4’-bis-trifluoromethyl)phenylprop-
2-en-1-yl])-1-thio-α-D-mannopyranoside (46). 
To a solution of 3-O-benzyl-4,6-O-benzylidene-1-thio-α-D-mannopyranoside 40 
(100 mg, 0.22 mmol) and tetrabutylammonium iodide (4.1 mg, 0.01 mmol) in DMF (0.8 
mL) was added sodium hydride (13.4 mg, 60% suspension in mineral oil, 0.33 mmol) at 
0 oC. After stirring at this temperature for 30 min, a solution of 1-(3-bromoprop-1-en-2-
yl)-2,4-bis(trifluoromethyl)benzene (97 mg, 0.29 mmol) in DMF (0.7 mL) was added 
dropwise. After that, the reaction mixture was stirred at rt for 6 h before it was diluted 
with ethyl acetate, washed with brine 3 times, dried over Na2SO4 and concentrated 
under reduced pressure. Chromatographic purification (6% ethyl acetate/hexanes) 
afforded the title compound as a colorless oil (46, 140 mg, 89%): [α]D
21 +80.5 (c 1.225, 
CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 7.93 (d, J = 1.7 Hz, 1H), 7.61 – 7.53 (m, 3H), 
7.53 – 7.29 (m, 14H), 5.72 (d, J = 1.5 Hz, 1H), 5.68 (s, 1H), 5.51 (d, J = 1.3 Hz, 1H), 




J = 9.7, 5.1 Hz, 1H), 4.29 (t, J = 10.0 Hz, 1H), 4.28 (dd, J = 10.2, 5.0 Hz, 1H), 4.10 (dd, 
J = 3.1, 1.4 Hz, 1H), 4.05 (dd, J = 9.7, 3.1 Hz, 1H), 3.90 (t, J = 10.1 Hz, 1H). 13C NMR 
(126 MHz, CDCl3) δ 143.0, 142.0, 138.2, 137.5, 133.6, 132.3, 131.8, 130.0 (q, J = 33.4 
Hz), 129.3 (q, J = 30.7 Hz), 129.2, 129.0, 128.4, 128.3, 128.0 (d, J = 3.6 Hz), 127.89, 
127.85, 127.8, 126.1, 123.43 (q, J = 274.1 Hz), 123.37 (q, J = 272.4 Hz), 123.4 – 123.0 
(m), 118.8, 101.6, 87.0, 79.4, 79.3, 76.3, 74.0, 73.6, 68.6, 65.4. 19F NMR (376 MHz, 
CDCl3) δ -58.22, -62.81. HRMS (ESI-TOF) m/z: Calcd. for C37H32F6O5SNa ([M + Na]
+): 
725.1772; found: 725.1763. 
Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-(2’,4’-bis-trifluoromethylphenacyl)-1-
thio-α-D-mannopyranoside (49) and Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-
(2’,4’-bis-trifluoromethylphenacyl)-1-thio-α-D-mannopyranoside S-oxide (52). 
O3 was bubbled into a stirred solution of 46 (124 mg, 0.18 mmol) in DCM (4 mL) 
and methanol (1 mL) at -78 oC for 15 min until the appearance of a deep blue color. Ar 
was then bubbled through the solution for 15 min, before triphenylphosphine (139 mg, 
0.53 mmol) was added and the reaction mixture was allowed to warm to rt. After stirring 
at rt for a further 1 h, the mixture was concentrated. Chromatographic purification (14% 
ethyl acetate/hexanes) afforded the desired ketone product as a colorless oil (49, 25 
mg, 20%): [α]D
21 +108.1 (c 0.67, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.95 (s, 1H), 
7.76 – 7.71 (m, 1H), 7.54 – 7.27 (m, 16H), 5.71 (d, J = 1.5 Hz, 1H), 5.60 (s, 1H), 4.92 (d, 
J = 11.7 Hz, 1H), 4.83 (s, 2H), 4.69 (d, J = 11.7 Hz, 1H), 4.31 (td, J = 9.7, 4.8 Hz, 1H), 
4.23 (dd, J = 10.6, 5.1 Hz, 1H), 4.18 (t, J = 9.7 Hz, 1H), 4.09 (dd, J = 3.0, 1.5 Hz, 1H), 
4.02 (dd, J = 9.8, 2.9 Hz, 1H), 3.83 (t, J = 10.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 




128.60 (q, J = 32.9 Hz), 128.5, 128.4, 128.2, 127.92, 127.90, 127.8, 126.0, 124.0 – 
123.8 (m), 122.8 (q, J = 272.5 Hz), 122.7 (q, J = 274.5 Hz), 101.6, 88.0, 80.4, 79.6, 
77.0, 76.7, 74.1, 68.5, 65.3. 19F NMR (376 MHz, CDCl3) δ -58.27, -63.17. HRMS (ESI-
TOF) m/z: Calcd. for C36H30F6O6SNa ([M + Na]
+): 727.1565; found: 727.1570. As well 
as sulfoxide product Further elution (20% ethyl acetate/hexanes) gave the sulfoxide as 
a colorless oil (52, 69 mg, 54%): [α]D
21 -36.4 (c 0.963, CHCl3). 
1H NMR (500 MHz, 
CDCl3) δ 7.93 (d, J = 1.6 Hz, 1H), 7.73 (dd, J = 8.0, 1.6 Hz, 1H), 7.65 – 7.47 (m, 7H), 
7.45 – 7.23 (m, 9H), 5.61 (s, 1H), 4.97 (d, J = 11.6 Hz, 1H), 4.84 (d, J = 17.0 Hz, 1H), 
4.82 (s, 1H), 4.74 (d, J = 11.5 Hz, 1H), 4.67 (d, J = 18.4 Hz, 1H), 4.38 (dd, J = 9.7, 3.2 
Hz, 1H), 4.34 (dd, J = 3.3, 1.4 Hz, 1H), 4.27 (dd, J = 9.8, 4.2 Hz, 1H), 4.24 (t, J = 9.0 Hz, 
1H), 4.18 (td, J = 9.5, 4.7 Hz, 1H), 3.75 (t, J = 10.0 Hz, 1H). 13C NMR (126 MHz, CDCl3) 
δ 199.8, 141.2, 140.2, 138.1, 137.1, 132.7 (q, J = 33.9 Hz), 131.8, 129.5, 129.1, 128.63 
(d, J = 3.8 Hz), 128.57 (q, J = 33.4 Hz), 128.5, 128.33, 128.30, 128.1, 128.0, 126.0, 
124.4, 124.0 – 123.7 (m), 122.7 (q, J = 264.5 Hz), 122.6 (q, J = 274.2 Hz), 101.7, 98.2, 
78.5, 77.6, 77.1, 75.6, 74.4, 69.9, 68.2. 19F NMR (376 MHz, CDCl3) δ -58.32, -63.16. 
HRMS (ESI-TOF) m/z: Calcd. for C36H30F6O7SNa ([M + Na]
+): 743.1514; found: 
743.1486. 
Compound 52 was also prepared by mCPBA oxidation of 49: To a stirred 
solution of 49 (46 mg, 0.07 mmol) in DCM (1 mL) at -78 oC under argon atmosphere 
was added a solution of mCPBA (77%, 14.6 mg, 0.07 mmol) in DCM (0.5 mL) dropwise. 
After stirring at this temperature for 4 h, saturated NaHCO3 solution (1 mL) was added 
and the mixture was then allowed to warm to rt. DCM (10 mL) was added and the 




times, dried over Na2SO4 and concentrated under reduced pressure. Chromatographic 
purification (20% ethyl acetate/hexanes) afforded 52 (39 mg, 83%) which was identical 
to the above sample. 
Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-(methoxycarbonylmethyl)-1-thio-α-D-
mannopyranoside (53). 
To a stirred solution of 3-O-benzyl-4,6-O-benzylidene-1-thio-α-D-
mannopyranoside 40 (100 mg, 0.22 mmol) in THF (0.8 mL) at 0 oC was added sodium 
hydride (13.3 mg, 60% suspension in mineral oil, 0.33 mmol). After stirring at 0 oC for 
25 min, a solution of methyl bromoacetate (51 mg, 0.33 mmol) in THF (0.2 mL) was 
added dropwise. The resulting mixture was stirred at rt for 5 h. After the completion of 
reaction, ethyl acetate was added, then it was washed with brine 3 times, dried over 
Na2SO4 and concentrated under reduced pressure. Chromatographic purification (14% 
ethyl acetate/hexanes) afforded the title compound as a colorless oil (53, 89 mg, 78%): 
[α]D
21 +167.7 (c 1, CHCl3). 
1H NMR (500 MHz, CDCl3) δ 7.53 (dd, J = 7.7, 1.9 Hz, 2H), 
7.50 – 7.46 (m, 2H), 7.35 (m, 11H), 5.86 (d, J = 1.5 Hz, 1H), 5.67 (s, 1H), 4.94 (d, J = 
12.0 Hz, 1H), 4.75 (d, J = 12.0 Hz, 1H), 4.49 – 4.38 (m, 2H), 4.36 – 4.29 (m, 2H), 4.25 
(dd, J = 10.3, 3.8 Hz, 1H), 4.09 (dd, J = 3.0, 1.5 Hz, 1H), 4.01 (dd, J = 9.6, 3.0 Hz, 1H), 
3.91 (t, J = 9.9 Hz, 1H), 3.72 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 171.0, 138.2, 137.5, 
133.6, 131.6, 129.2, 128.9, 128.5, 128.2, 127.8, 127.7, 127.6, 126.1, 101.5, 88.0, 80.4, 
79.4, 77.31, 77.25, 77.1, 76.8, 76.7, 73.7, 69.4, 68.5, 65.3, 51.9. HRMS (ESI-TOF) m/z: 
Calcd. for C29H30O7SNa ([M + Na]








To a stirred solution of 3-O-benzyl-4,6-O-benzylidene-1-thio-α-D-
mannopyranoside 40 (100 mg, 0.22 mmol) in THF (1.0 mL) at 0 oC was added sodium 
hydride (13.3 mg, 60% suspension in mineral oil, 0.33 mmol). After stirring at 0 oC for 
20 min, a solution of tert-butyl bromoacetate (65.0 mg, 0.33 mmol) in THF (0.4 mL) was 
added dropwise. The resulting mixture was stirred at rt for 5 h. After the completion of 
reaction, ethyl acetate was added, and the reaction mixture was washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure. Chromatographic 
purification (8% ethyl acetate/hexanes) afforded the title compound as a colorless oil 
(54, 75 mg, 60%): [α]D
21 +140.3 (c 1.21, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 7.52 – 
7.49 (m, 2H), 7.47 – 7.43 (m, 2H), 7.41 – 7.33 (m, 7H), 7.32 – 7.23 (m, 4H), 5.86 (d, J = 
1.4 Hz, 1H), 5.64 (s, 1H), 4.92 (d, J = 12.0 Hz, 1H), 4.73 (d, J = 12.1 Hz, 1H), 4.33 – 
4.25 (m, 4H), 4.24 – 4.21 (m, 1H), 4.03 (dd, J = 3.0, 1.5 Hz, 1H), 3.99 – 3.97 (m, 1H), 
3.92 – 3.87 (m, 1H), 1.43 (s, 9H). 13C NMR (151 MHz, CDCl3) δ 169.7, 138.3, 137.5, 
133.7, 131.3, 129.1, 128.9, 128.4, 128.2, 127.72, 127.67, 127.5, 126.0, 101.5, 87.9, 
81.8, 80.1, 79.4, 76.7, 73.6, 70.2, 68.5, 65.2, 28.1. HRMS (ESI-TOF) m/z: Calcd. for 
C32H36O7SNa ([M + Na]
+): 587.2079; found: 587.2083. 
Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-(methoxycarbonylmethyl)-1-thio-α-D-
mannopyranoside S-oxide (55)  
To a stirred solution of 53 (104 mg, 0.20 mmol) in DCM (2 mL) at -78 oC under 
argon atmosphere was added a solution of mCPBA (77%, 44.4 mg, 0.20 mmol) in DCM 




mL) was added and the mixture was then allowed to warm to rt. DCM (10 mL) was 
added and the separated organic layer was washed with saturated NaHCO3 solution 
once, brine 3 times, dried over Na2SO4 and concentrated under reduced pressure. 
Chromatographic purification (33% ethyl acetate/hexanes) afforded the sulfoxide 
product as a colorless oil (55, 70.2 mg, 66%). [α]D
21 -4.8 (c 0.15, CHCl3). 
1H NMR (500 
MHz, CDCl3) δ 7.67 – 7.60 (m, 2H), 7.57 (dt, J = 4.7, 2.9 Hz, 3H), 7.54 – 7.48 (m, 2H), 
7.45 – 7.30 (m, 8H), 5.65 (s, 1H), 4.97 (s, 1H), 4.96 (d, J = 10.7 Hz, 1H), 4.78 (d, J = 
11.9 Hz, 1H), 4.40 (d, J = 16.9 Hz, 1H), 4.38 – 4.31 (m, 3H), 4.28 (d, J = 16.9 Hz, 1H), 
4.27 (dd, J = 10.3, 4.9 Hz, 2H), 4.15 (td, J = 8.6, 7.5, 4.6 Hz, 1H), 3.80 (t, J = 10.2 Hz, 
1H), 3.62 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.6, 141.7, 138.1, 137.2, 131.7, 
129.4, 129.0, 128.5, 128.3, 127.84, 127.81, 126.0, 124.5, 101.7, 98.2, 78.3, 76.7, 75.4, 
74.0, 70.1, 69.9, 68.2, 51.8. HRMS (ESI-TOF) m/z: Calcd. for C29H30O8SNa ([M + Na]
+): 
561.1559; found: 561.1550.  The sulfone product (20% ethyl acetate/hexanes) was 
also isolated as a colorless oil (35.4 mg, 32%): [α]D
21 +81.5 (c 0.15, CHCl3). 
1H NMR 
(500 MHz, CDCl3) δ 7.97 – 7.90 (m, 2H), 7.75 – 7.68 (m, 1H), 7.61 (t, J = 7.9 Hz, 2H), 
7.54 – 7.47 (m, 2H), 7.43 – 7.29 (m, 8H), 5.62 (s, 1H), 5.33 (s, 1H), 4.97 (d, J = 11.7 Hz, 
1H), 4.77 (d, J = 11.7 Hz, 1H), 4.63 – 4.53 (m, 2H), 4.48 (d, J = 17.1 Hz, 1H), 4.44 (dd, 
J = 10.1, 3.4 Hz, 1H), 4.39 (d, J = 17.1 Hz, 1H), 4.27 (t, J = 9.8 Hz, 1H), 4.15 (dd, J = 
10.3, 4.9 Hz, 1H), 3.73 (s, 3H), 3.69 (t, J = 10.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
170.9, 138.1, 137.3, 136.5, 134.4, 129.3, 129.0, 128.9, 128.5, 128.3, 127.88, 127.86, 
126.1, 101.7, 93.6, 78.1 77.0, 74.8, 74.3, 70.6, 68.5, 68.4, 52.0. HRMS (ESI-TOF) m/z: 
Calcd. for C29H30O9SNa ([M + Na]





mannopyranoside S-oxide (56). 
To a stirred solution of 54 (47 mg, 0.08 mmol) in DCM (1 mL) at -78 oC under 
argon atmosphere was added a solution of mCPBA (77%, 18.5 mg, 0.08 mmol) in DCM 
(0.5 mL) dropwise. After stirring at this temperature for 3 h, saturated NaHCO3 solution 
(1 mL) was added and the mixture was then allowed to warm to rt. DCM (10 mL) was 
added and the separated organic layer was washed with saturated aqueous NaHCO3, 
brine, dried over Na2SO4 and concentrated under reduced pressure. Chromatographic 
purification (17% ethyl acetate/hexanes) afforded the sulfoxide product as a colorless 
oil (56, 38.0 mg, 79%). [α]D
21 -9.0 (c 1.26, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.65 – 
7.58 (m, 2H), 7.57 – 7.46 (m, 5H), 7.44 – 7.28 (m, 8H), 5.64 (s, 1H), 5.00 (d, J = 1.3 Hz, 
1H), 4.94 (d, J = 12.0 Hz, 1H), 4.78 (d, J = 12.0 Hz, 1H), 4.38 – 4.28 (m, 3H), 4.27 (d, J 
= 16.9 Hz, 1H), 4.25 (dd, J = 10.2, 4.9 Hz, 1H), 4.20 – 4.13 (m, 1H), 4.12 (d, J = 16.9 
Hz, 1H), 3.79 (t, J = 10.1 Hz, 1H), 1.40 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 169.3, 
141.5, 138.2, 137.2, 131.5, 129.3, 129.0, 128.4, 128.2, 127.8, 127.7, 126.0, 124.5, 
101.6, 98.1, 81.8, 78.3, 76.7, 75.4, 73.8, 70.8, 69.8, 68.2, 28.1. HRMS (ESI-TOF) m/z: 
Calcd. for C32H36O8SNa ([M + Na]
+): 603.2029; found: 603.2015. 
General procedure I: glycosylation with thioglycosides 
A mixture of glycosyl donor (1 equiv), diphenylsulfoxide or 1-benzenesulfinyl 
piperidine (1.1 equiv), tri-tert-butylpyrimidine (2 equiv) and activated 3 Å molecular 
sieves (2 g per mmol of donor) was stirred in dry DCM (13.3 mL per 1 mmol of donor) 
for 1 h at rt before it was cooled to -78 oC, then trifluoromethanesulfonic anhydride (1.1 




acceptor (1.5 equiv) in dry DCM (4.4 mL per 1 mmol of acceptor) was added dropwise. 
The resulting mixture was then stirred at -78 oC for 3 h before quenching with sat. 
NaHCO3 solution at the same temperature. After warming to rt, the mixture was filtered 
and the filtrate was extracted with DCM 3 times, the combined organic layers was 
washed with sat. NaHCO3 solution, brine, dried over Na2SO4 and concentrated under 
reduced pressure. Chromatographic purification afforded the product. 
General procedure II: glycosylation with sulfoxides 
A mixture of glycosyl donor (1 equiv), tri-tert-butylpyrimidine (2 equiv) and 
activated 3 Å molecular sieves (2 g per mmol of donor) was stirred in dry DCM (13 mL 
per 1 mmol of donor) for 1 h at rt before it was cooled to -78 oC, then 
trifluoromethanesulfonic anhydride (1.1 equiv) was added. After stirring at the same 
temperature for 10 min, a solution of acceptor (1.5 equiv) in dry DCM (4.4 mL per 1 
mmol of acceptor) was added dropwise. The resulting mixture was then stirred at -78 
oC for 3 h before quenching with sat. NaHCO3 solution. After warming to rt, the mixture 
was filtered and the filtrate was extracted with DCM 3 times, the combined organic 
layer was washed with sat. NaHCO3 solution and brine, dried over Na2SO4 and 




61β was obtained from 52 by following general procedure II, 10% ethyl 
acetate/hexanes,  colorless oil (34.3 mg, 50%): [α]D
21 -31.0 (c 0.545, CHCl3). 
1H NMR 




7.27 (m, 8H), 5.53 (s, 1H), 5.01 – 4.84 (m, 2H), 4.83 – 4.71 (m, 3H), 4.25 (dd, J = 10.4, 
4.8 Hz, 1H), 3.98 (t, J = 9.6 Hz, 1H), 3.87 (d, J = 3.1 Hz, 1H), 3.81 (t, J = 10.3 Hz, 1H), 
3.64 (dd, J = 9.9, 3.1 Hz, 1H), 3.30 (td, J = 9.7, 4.8 Hz, 1H), 2.22 – 2.10 (m, 3H), 1.84 – 
1.68 (m, 6H), 1.68 – 1.53 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 200.4, 140.8, 138.3, 
137.5, 132.3 (q, J = 33.8 Hz), 129.4, 128.9, 128.6 (q, J = 33.8 Hz), 128.32, 128.26, 
128.20, 127.8, 127.6, 126.0, 123.9 – 123.5 (m), 122.94 (q, J = 271.6 Hz), 122.87 (q, J = 
274.2 Hz), 101.4, 94.8, 80.0, 78.4, 77.6, 77.4, 75.8, 72.6, 68.8, 67.2, 42.3, 36.1, 30.6. 
19F NMR (376 MHz, CDCl3) δ -58.19, -63.12. HRMS (ESI-TOF) m/z: Calcd. for 
C40H40F6O7Na ([M + Na]
+): 769.2576; found: 769.2543. 
1-Adamantanyl 3-O-benzyl-4,6-O-benzylidene-2-O-(methoxycarbonylmethyl)-α-D-
mannopyranoside (62α). 
62α was obtained from 53 by following general procedure I using DPSO as 
activation agent, 14% ethyl acetate/hexanes, colorless oil (5.2 mg, 16%): [α]D
21 +60.4 
(c 0.26, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 7.49 (dd, J = 7.7, 1.6 Hz, 2H), 7.38 – 7.26 
(m, 8H), 5.62 (s, 1H), 5.50 (d, J = 1.8 Hz, 1H), 4.90 (d, J = 11.9 Hz, 1H), 4.68 (d, J = 
11.9 Hz, 1H), 4.41 (s, 2H), 4.21 (dd, J = 10.5, 5.1 Hz, 1H), 4.18 (t, J = 9.6 Hz, 1H), 4.03 
(dd, J = 9.8, 3.2 Hz, 1H), 4.01 (td, J = 9.8, 4.8 Hz, 1H), 3.82 (t, J = 10.3 Hz, 1H), 3.71 (s, 
3H), 3.68 – 3.66 (m, 1H), 2.13 (q, J = 3.3 Hz, 3H), 1.86 – 1.74 (m, 6H), 1.61 (q, J = 12.5 
Hz, 6H). 13C NMR (151 MHz, CDCl3) δ 171.4, 138.7, 137.8, 128.7, 128.3, 128.1, 
127.48, 127.47, 126.0, 101.3, 93.5, 80.3, 79.9, 77.0, 74.9, 73.8, 69.4, 68.9, 63.6, 51.7, 
42.4, 36.2, 36.1, 30.7, 30.6. HRMS (ESI-TOF) m/z: Calcd. for C33H40O8Na ([M + Na]
+): 






62β was obtained from 53 by following general procedure I using DPSO as 
activation agent, 20% ethyl acetate/hexanes, colorless oil (20.6 mg, 63%): [α]D
21 -33.8 
(c 1.03, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 7.50 – 7.46 (m, 2H), 7.46 – 7.25 (m, 8H), 
5.58 (s, 1H), 4.86 – 4.78 (m, 2H), 4.76 (d, J = 0.9 Hz, 1H), 4.58 – 4.50 (m, 2H), 4.24 (dd, 
J = 10.4, 4.8 Hz, 1H), 4.18 (t, J = 9.6 Hz, 1H), 3.92 – 3.87 (m, 2H), 3.70 (s, 3H), 3.62 
(dd, J = 9.9, 3.1 Hz, 1H), 3.30 (td, J = 9.7, 4.8 Hz, 1H), 2.14 (p, J = 3.3 Hz, 3H), 1.84 – 
1.71 (m, 6H), 1.66 – 1.55 (m, 6H). 13C NMR (151 MHz, CDCl3) δ 170.9, 138.5, 137.7, 
128.8, 128.24, 128.15, 127.6, 127.4, 126.0, 101.4, 94.8, 79.2, 78.1, 77.5, 75.5, 72.2, 
70.0, 68.8, 67.4, 51.6, 42.3, 36.1, 30.6. HRMS (ESI-TOF) m/z: Calcd. for C33H40O8Na 
([M + Na]+): 587.2621; found: 587.2597. 
1,2-O-(2-Benzenesulfenyl-1-phenyl-1,2-ethenediyl)-3-O-benzyl-4,6-O-benzylidene 
β-D-mannopyranose (63). 
63 was obtained from 47 by following general procedure I using DPSO as 
activation agent, 8% ethyl acetate/hexanes, colorless oil (7.8 mg, 33%): [α]D
21 -83.8 (c 
0.185, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 7.57 – 7.53 (m, 2H), 7.49 – 7.45 (m, 2H), 
7.39 – 7.33 (m, 5H), 7.32 – 7.25 (m, 10H), 7.21 – 7.16 (m, 1H), 5.55 (s, 1H), 5.33 (d, J 
= 0.8 Hz, 1H), 4.76 (d, J = 12.3 Hz, 1H), 4.69 (d, J = 12.3 Hz, 1H), 4.43 (dd, J = 10.4, 
4.8 Hz, 1H), 4.35 (d, J = 2.8 Hz, 1H), 4.17 (t, J = 9.5 Hz, 1H), 3.90 (t, J = 10.3 Hz, 1H), 
3.81 (dd, J = 9.6, 2.9 Hz, 1H), 3.54 (td, J = 9.7, 4.9 Hz, 1H). 13C NMR (151 MHz, CDCl3) 
δ 140.1, 137.7, 137.2, 135.7, 132.9, 128.99, 128.96, 128.7, 128.6, 128.4, 128.2, 127.74, 




67.8. HRMS (ESI-TOF) m/z: Calcd. for C34H30O6SNa ([M + Na]




64β was obtained from 52 by following general procedure II, 17% ethyl 
acetate/hexanes, colorless oil (19.3 mg, 57%): [α]D
21 -73.4 (c 0.535, MeOH). 1H NMR 
(600 MHz, CDCl3) δ 7.93 (s, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.49 
– 7.44 (m, 2H), 7.40 – 7.26 (m, 8H), 5.50 (s, 1H), 4.96 (d, J = 0.8 Hz, 1H), 4.83 (s, 1H), 
4.81 – 4.75 (m, 2H), 4.78 (d, J = 12.2 Hz, 1H), 4.70 (d, J = 12.1 Hz, 1H), 4.24 (dd, J = 
10.4, 4.8 Hz, 1H), 4.11 (dd, J = 7.4, 5.5 Hz, 1H), 4.07 (d, J = 5.5 Hz, 1H), 3.97 (d, J = 
3.0 Hz, 1H), 3.88 (t, J = 9.6 Hz, 1H), 3.80 (t, J = 10.3 Hz, 1H), 3.65 (dd, J = 9.8, 3.0 Hz, 
1H), 3.58 (dd, J = 10.0, 7.4 Hz, 1H), 3.55 – 3.48 (m, 1H), 3.36 (s, 3H), 3.26 (td, J = 9.8, 
4.9 Hz, 1H), 1.47 (s, 3H), 1.32 (s, 3H), 1.17 (d, J = 6.1 Hz, 3H). 13C NMR (151 MHz, 
CDCl3) δ 200.5, 140.9, 138.1, 137.3, 132.3 (q, J = 33.8 Hz), 129.1, 128.9, 128.7 (q, J = 
33.4 Hz), 128.4, 128.20, 128.18, 127.8, 127.7, 126.0, 123.7 – 123.5 (m), 122.9 (q, J = 
272.9 Hz), 122.8 (q, J = 273.9 Hz), 109.4, 101.4, 99.7, 97.8, 78.81, 78.79, 78.21, 78.17, 
77.7, 77.3, 76.1, 72.9, 68.6, 67.4, 63.9, 54.8, 27.8, 26.4, 17.4. 19F NMR (376 MHz, 
CDCl3) δ -58.27, -63.10. HRMS (ESI-TOF) m/z: Calcd. for C40H42F6O11Na ([M + Na]
+): 
835.2529; found: 835.2495. 
Methyl 4-O-[4,6-O-benzylidene-2-O-(methoxycarbonylmethyl)-3-O-benzyl-β-D-
mannopyranosyl]-(1→4)-2,3-O-isopropylidene-α-L-rhamanopyranoside (65β). 
65β was obtained from 53 by following general procedure I (50.1 mg, 83%) and 





21 -60.7 (c 1.045, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 7.50 – 7.46 (m, 
2H), 7.41 – 7.25 (m, 8H), 5.60 (s, 1H), 4.98 (s, 1H), 4.84 (s, 1H), 4.84 – 4.78 (m, 2H), 
4.48 – 4.39 (m, 2H), 4.25 (dd, J = 10.4, 4.8 Hz, 1H), 4.18 (t, J = 9.6 Hz, 1H), 4.14 (dd, J 
= 7.0, 5.5 Hz, 1H), 4.07 (d, J = 5.5 Hz, 1H), 4.03 (d, J = 3.0 Hz, 1H), 3.94 (t, J = 10.3 
Hz, 1H), 3.70 (s, 3H), 3.67 – 3.58 (m, 3H), 3.36 (s, 3H), 3.30 (td, J = 9.8, 4.9 Hz, 1H), 
1.48 (s, 3H), 1.31 (s, 3H), 1.30 (d, J = 5.8 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 170.7, 
138.4, 137.5, 128.8, 128.3, 128.2, 127.6, 127.5, 126.0, 109.4, 101.4, 99.8, 97.8, 78.3, 
78.2, 77.9, 77.8, 77.5, 76.1, 72.3, 69.8, 68.5, 67.7, 64.0, 54.8, 51.7, 27.8, 26.4, 17.6. 
HRMS (ESI-TOF) m/z: Calcd. for C33H42O12Na ([M + Na]
+): 653.2574; found: 653.2559. 
Methyl 4-O-[4,6-O-benzylidene-2-O-(t-butoxycarbonylmethyl)-3-O-benzyl-β-D-
mannopyranosyl]-(1→4)-2,3-O-isopropylidene-α-L-rhamanopyranoside (66β). 
To a stirred solution of 69 (15.3 mg, 0.027 mmol) in THF (0.4 mL) at 0 oC was 
added sodium hydride (1.7 mg, 60% suspension in mineral oil, 0.04 mmol). After 
stirring at 0 oC for 25 min, a solution of tert-butyl bromoacetate (8.0 mg, 0.04 mmol) in 
THF (0.2 mL) was added dropwise. The resulting mixture was stirred at rt for 3 h. After 
the completion of reaction, ethyl acetate was added, and the reaction mixture was 
washed with brine, dried over Na2SO4 and concentrated under reduced pressure. 
Chromatographic purification (17% ethyl acetate/hexanes) afforded the title compound 
as a colorless oil (66β, 11.6 mg, 63%): [α]D
21 -56.6 (c 0.35, CHCl3). 
1H NMR (400 MHz, 
CDCl3) δ 7.52 – 7.47 (m, 2H), 7.45 – 7.23 (m, 8H), 5.61 (s, 1H), 4.97 (s, 1H), 4.86 (s, 
1H), 4.83 (s, 2H), 4.35 – 4.26 (m, 2H), 4.28 – 4.18 (m, 2H), 4.16 (dd, J = 7.1, 5.4 Hz, 
1H), 4.08 (dd, J = 5.5, 0.7 Hz, 1H), 4.06 (d, J = 3.0 Hz, 1H), 3.94 (t, J = 10.3 Hz, 1H), 




9H), 1.33 (s, 3H), 1.31 (d, J = 5.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.2, 138.6, 
137.6, 128.8, 128.3, 128.2, 127.6, 127.4, 126.0, 109.4, 101.3, 100.0, 97.8, 81.1, 78.30, 
78.25, 77.8, 77.6, 77.5, 76.1, 72.1, 70.0, 68.6, 67.7, 64.1, 54.9, 28.1, 27.8, 26.4, 17.6. 
HRMS (ESI-TOF) m/z: Calcd. for C36H48O12Na ([M + Na]
+): 695.3043; found: 695.3026. 




67α was obtained from 53 by following general procedure I, 20% ethyl 
acetate/hexanes, colorless oil (23.9 mg, 24%): [α]D
21 +26.7 (c 0.375, CHCl3). 
1H NMR 
(600 MHz, CDCl3) δ 7.50 – 7.44 (m, 2H), 7.40 – 7.21 (m, 23H), 5.60 (s, 1H), 5.38 (d, J 
= 1.8 Hz, 1H), 5.06 (d, J = 11.4 Hz, 1H), 4.78 (d, J = 12.0 Hz, 1H), 4.69 (d, J = 12.1 Hz, 
1H), 4.63 – 4.57 (m, 4H), 4.56 (d, J = 12.1 Hz, 1H), 4.50 (d, J = 11.9 Hz, 1H), 4.23 (t, J 
= 9.3 Hz, 1H), 4.13 (d, J = 16.6 Hz, 1H), 4.09 (dd, J = 9.2, 3.6 Hz, 1H), 3.92 – 3.77 (m, 
6H), 3.73 (t, J = 2.4 Hz, 1H), 3.70 (m, 3H), 3.57 (s, 3H), 3.55 (dd, J = 9.1, 3.4 Hz, 1H), 
3.38 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 170.6, 138.7, 138.4, 137.9, 137.8, 137.6, 
128.8, 128.5, 128.4, 128.3 (2 carbons), 128.14, 128.13, 128.0, 127.7, 127.59, 127.56, 
127.55, 127.45, 126.9, 126.0, 102.2, 101.4, 97.8, 81.2, 80.0, 79.3, 79.2, 77.9, 76.2, 
75.2, 73.6, 73.5, 73.2, 69.7, 69.3, 68.8, 68.7, 64.9, 55.3, 51.6. HRMS (ESI-TOF) m/z: 
Calcd. for C51H56O13Na ([M + Na]








67β was obtained from 53 by following general procedure I (35.6 mg, 42%) and 
from 55 by following general procedure II (30.3 mg, 59%), 25% ethyl acetate/hexanes, 
colorless oil: [α]D
21 -14.7 (c 0.32, CHCl3). 
1H NMR (500 MHz, CDCl3) δ 7.51 – 7.47 (m, 
2H), 7.47 – 7.42 (m, 2H), 7.42 – 7.23 (m, 20H), 7.19 (ddd, J = 8.8, 6.0, 3.1 Hz, 1H), 
5.53 (s, 1H), 5.01 (d, J = 10.6 Hz, 1H), 4.85 – 4.76 (m, 3H), 4.72 – 4.63 (m, 3H), 4.62 (d, 
J = 3.7 Hz, 1H), 4.46 – 4.31 (m, 4H), 4.11 (t, J = 9.6 Hz, 1H), 4.03 (dd, J = 10.4, 4.8 Hz, 
1H), 3.92 (t, J = 9.2 Hz, 1H), 3.87 (t, J = 9.1 Hz, 1H), 3.75 (d, J = 3.0 Hz, 1H), 3.74 – 
3.60 (m, 6H), 3.58 – 3.50 (m, 2H), 3.40 (s, 3H), 3.33 (dd, J = 9.9, 3.0 Hz, 1H), 3.03 (td, 
J = 9.7, 4.8 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.5, 139.3, 138.5, 138.3, 137.6, 
137.5, 128.9, 128.6, 128.4, 128.3, 128.2, 128.14, 128.12, 128.07, 128.05, 127.82, 
127.76, 127.6, 127.4, 127.3, 126.1, 101.33, 101.26, 98.4, 80.2, 79.1, 78.3, 78.1, 77.8, 
77.3, 75.3, 73.63, 73.60, 72.5, 69.9, 69.5, 68.5, 68.4, 67.4, 55.4, 51.6. HRMS (ESI-TOF) 
m/z: Calcd. for C51H56O13Na ([M + Na]
+): 899.3619; found: 899.3586. 
1,2-O-(1-Oxo-ethanediyl)-3-O-benzyl-4,6-O-benzylidene β-D-mannopyranose (68). 
68 was obtained from 56 by following general procedure II (18.1 mg, 70%), 20% 
ethyl acetate/hexanes, colorless oil: [α]D
21 -24.8 (c 0.31, CHCl3). 
1H NMR (400 MHz, 
CDCl3) δ 7.49 (m, 2H), 7.44 – 7.28 (m, 8H), 5.62 (s, 1H), 5.28 (s, 1H), 4.92 (d, J = 12.4 
Hz, 1H), 4.76 (d, J = 12.4 Hz, 1H), 4.60 (d, J = 17.8 Hz, 1H), 4.37 (dd, J = 10.5, 4.9 Hz, 
1H), 4.30 (d, J = 17.8 Hz, 1H), 4.16 (t, J = 9.6 Hz, 1H), 3.98 (d, J = 3.2 Hz, 1H), 3.90 (t, 
J = 10.3 Hz, 1H), 3.80 (dd, J = 9.7, 3.2 Hz, 1H), 3.44 (td, J = 9.7, 4.9 Hz, 1H). 13C NMR 




101.7, 96.2, 77.6, 75.1, 73.4, 71.4, 68.1, 67.6, 65.3. HRMS (ESI-TOF) m/z: Calcd. for 
C22H22O7Na ([M + Na]
+): 421.1263; found: 421.1280. 
Reductive removal of phenacyl-type protecting groups using SmI2. 
Methyl 4-O-[4,6-O-benzylidene-3-O-benzyl-β-D-mannopyranosyl]-(1→4)-2,3-O-
isopropylidene-α-L-rhamanopyranoside (69). 
A solution of SmI2 in THF (0.1 M in THF, 0.66 mL, 0.07 mmol) was added to a 
round bottom flask containing 64β (10.7 mg, 0.01 mmol) at 0 oC under argon 
atmosphere. The reaction mixture was stirred at 0 oC for 10 min before it was 
quenched by adding saturated NaHCO3 solution (1 mL) at 0 
oC. The resulting mixture 
was diluted with ethyl acetate (20 mL) and washed with brine 3 times, dried over 
Na2SO4 and concentrated under reduced pressure. Chromatographic purification (33% 
ethyl acetate/hexanes) afforded the title compound as a colorless oil (64, 5.5 mg, 75%), 
whose spectral data were identical with the literature.268 [α]D
21 -40.7 (c 0.3, CHCl3). 
1H 
NMR (400 MHz, CDCl3) δ 7.50 (dd, J = 7.6, 2.1 Hz, 2H), 7.42 – 7.27 (m, 8H), 5.61 (s, 
1H), 5.02 (d, J = 1.1 Hz, 1H), 4.86 (s, 1H), 4.85 (d, J = 12.4 Hz, 1H), 4.79 (d, J = 12.4 
Hz, 1H), 4.29 (dd, J = 10.5, 4.9 Hz, 1H), 4.22 – 4.11 (m, 3H), 4.10 (t, J = 5.5 Hz, 1H), 
3.90 (t, J = 10.3 Hz, 1H), 3.73 – 3.62 (m, 3H), 3.36 (s, 3H), 3.33 (dt, J = 9.8, 4.9 Hz, 
1H), 1.51 (s, 3H), 1.33 (s, 3H), 1.30 (d, J = 5.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
137.9, 137.4, 128.9, 128.4, 128.2, 127.8 (2 carbons), 126.0, 109.4, 101.5, 98.7, 97.8, 
78.5, 78.23, 78.20, 76.8, 76.1, 72.4, 70.0, 68.6, 67.0, 63.9, 54.8, 27.8, 26.4, 17.5. 
HRMS (ESI-TOF) m/z: Calcd. for C30H38O10Na ([M + Na]





Oxidative removal of the methoxycarbonylmethyl protecting group using (1S)-(+)-
(10-camphorsulfonyl)oxaziridine. 
THF (0.3 mL) was added to a solution of KHMDS in toluene (0.5 M, 0.17 mL, 
0.09 mmol) at -78 oC under argon. To the resulting mixture was added a solution of 65β 
(34.4 mg, 0.06 mmol) in THF (0.45 mL) dropwise over 15 min. After stirring at the same 
temperature for 30 min, (1S)-(+)-(10-camphorsulfonyl)-oxaziridine (39.3 mg, 0.17 mmol) 
was added in one portion and the reaction mixture was stirred at -78 oC for another 1 h 
before it was quenched with saturated NaHCO3 solution (1 mL). After warming to rt, the 
mixture was diluted with ethyl acetate (20 mL) and washed with brine 3 times, dried 
over Na2SO4 and concentrated under reduced pressure. Chromatographic purification 
(33% ethyl acetate/hexanes) afforded the title compound as a colorless oil (69, 19.6 mg, 
64%). 
2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl fluoride (110) 
To a suspension of D-(+)-mannose (800 mg, 4.44 mmol) in ethyl acetate (30 mL) 
was added pyridine (2.5 mL, 31.08 mmol) and acetic anhydride (2.94 mL, 31.08 mmol). 
After stirring for 3 h at rt, the reaction mixture was diluted with ethyl acetate and 
washed successively with 1 N HCl solution, saturated NaHCO3 solution, brine, dried 
over anhydrous Na2SO4 and concentrated under reduced pressure to dryness. The 
crude product obtained (1.75 g) was dissolved in toluene (8 mL) and added to a 70% 
hydrogen fluoride – pyridine complex (2 mL) in a 20 mL polyethylene vessel pre-cooled 
to 0 oC in an ice-water bath. The reaction mixture was allowed to warm to rt and stirred 
for 24 h. After diluting with ethyl acetate, the mixture was washed successively with 10% 




pressure to dryness. Chromatographic purification (25% ethyl acetate/hexanes) 
afforded the title compound as a colorless oil (110, 1.34 g, 86%). [α]D
21 +20.3 (c 1.72, 
CHCl3). 
1H NMR (400 MHz, CDCl3) δ 5.56 (dd, J = 48.4, 1.9 Hz, 1H), 5.40 – 5.37 (m, 
1H), 5.35 – 5.31 (m, 2H), 4.28 (dd, J = 12.7, 5.3 Hz, 1H), 4.19 – 4.09 (m, 2H), 2.16 (s, 
3H), 2.10 (s, 3H), 2.05 (s, 3H), 1.99 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.5, 169.7, 
169.6, 169.5, 104.7 (d, J = 223.7 Hz), 70.8 (d, J = 3.0 Hz), 68.1 (d, J = 1.8 Hz), 67.6 (d, 
J = 39.5 Hz), 65.0, 61.8, 20.7 (2 carbons), 20.62, 20.55. 19F NMR (376 MHz, CDCl3) δ -
138.39 (d, J = 47.9 Hz). HRMS (ESI-TOF) m/z: Calcd. for C14H19O9FNa ([M + Na]
+): 
373.0911; found: 373.0906. 
2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl fluoride (111) 
To a 70% hydrogen fluoride – pyridine complex (2 mL) stirring in a 20 mL 
polyethylene vessel cooled to 0 oC in an ice-water bath was added a solution of β-D-
(+)-glucose pentaacetate (1.00 g, 2.56 mmol) in toluene (10 mL). The reaction mixture 
was allowed to warm to rt and stirred for 32 h. After diluting with ethyl acetate, the 
mixture was washed successively with 10% KF solution and brine, dried over 
anhydrous Na2SO4 and concentrated under reduced pressure to dryness. 
Chromatographic purification (25% ethyl acetate/hexanes) afforded the title compound 
as a white solid (111, 474 mg, 53%). [α]D
21 +86.8 (c 0.30, CHCl3). 
1H NMR (400 MHz, 
CDCl3) δ 5.73 (dd, J = 52.8, 2.8 Hz, 1H), 5.47 (t, J = 9.9 Hz, 1H), 5.13 (t, J = 9.9 Hz, 
1H), 4.93 (ddd, J = 24.2, 10.2, 2.8 Hz, 1H), 4.27 (dd, J = 12.3, 3.9 Hz, 1H), 4.20 – 4.10 
(m, 2H), 2.09 – 2.07 (m, 6H), 2.02 (s, 3H), 2.01 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
170.5, 169.93, 169.89, 169.4, 103.7 (d, J = 229.4 Hz), 70.2 (d, J = 24.5 Hz), 69.7 (d, J 




149.78 (dd, J = 52.8, 24.2 Hz). HRMS (ESI-TOF) m/z: Calcd. for C14H19O9FNa ([M + 
Na]+): 373.0911; found: 373.0903. 
2,3,4,6-Tetra-O-benzyl-α-D-mannopyranosyl fluoride (104) 
2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl fluoride 110 (1.27 g, 3.63 mmol) 
was dissolved in methanol (5 mL) and stirred at rt. Sodium methoxide (97.9 mg, 1.81 
mmol) was added and the reaction mixture was stirred at rt for 3 h before it was 
neutralized with Amberlyst 15 hydrogen form. The resin was filtered off and the filtrate 
was concentrated under reduced pressure to dryness to give crude product as a 
colorless oil (752.2 mg). The crude product was then dissolved in DMF (6 mL) and 
stirred in an ice-water bath. Sodium hydride (725.1 mg, 60% suspension in mineral oil, 
18.13 mmol) was added and the heterogeneous mixture was stirred for 20 min before 
benzyl bromide (2.16 mL, 18.13 mmol) was added. The reaction mixture was allowed 
to warm to rt and stirred for 14 h. After diluting with ethyl acetate, the mixture was 
washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced 
pressure to dryness. Chromatographic purification (7% ethyl acetate/hexanes) afforded 
the title compound as a colorless oil (104, 1.23 g, 63%). The spectral data are 
consistent with the literature.269 [α]D
21 +22.3 (c 0.86, CHCl3). 
1H NMR (400 MHz, CDCl3) 
δ 7.41 – 7.27 (m, 18H), 7.21 – 7.16 (m, 2H), 5.62 (dd, J = 50.6, 1.7 Hz, 1H), 4.90 (d, J 
= 10.8 Hz, 1H), 4.82 (d, J = 12.3 Hz, 1H), 4.74 – 4.63 (m, 4H), 4.58 – 4.53 (m, 2H), 
4.10 (dd, J = 10.0, 8.9 Hz, 1H), 3.97 – 3.87 (m, 3H), 3.80 (dd, J = 11.0, 4.5 Hz, 1H), 
3.73 (dd, J = 11.0, 2.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 138.19, 138.15, 138.1, 
137.8, 128.5 (2 carbons), 128.4, 128.3, 128.0, 127.89, 127.87 (2 carbons), 127.8, 




73.5 (d, J = 34.8 Hz), 73.4, 73.2, 72.6, 68.6. 19F NMR (376 MHz, CDCl3) δ -138.03 (d, J 
= 50.5 Hz). HRMS (ESI-TOF) m/z: Calcd. for C34H35O5FNa ([M + Na]
+): 565.2366; 
found: 565.2371. 
2,3,4,6-Tetra-O-benzyl-α-D-glucopyranosyl fluoride (105) 
2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl fluoride 111 (386.3 mg, 1.10 mmol) 
was dissolved in methanol (6 mL) and stirred at rt. Sodium methoxide (29.8 mg, 0.55 
mmol) was added and the reaction mixture was stirred at rt for 1 h before it was 
neutralized with Amberlyst 15 hydrogen form. The resin was filtered off and the filtrate 
was concentrated under reduced pressure to dryness to give crude product as a 
colorless oil (242.9 mg). The crude product was then dissolved in DMF (5 mL) and 
stirred in an ice-water bath. Sodium hydride (220.6 mg, 60% suspension in mineral oil, 
5.51 mmol) was added and the heterogeneous mixture was stirred for 25 min before 
benzyl bromide (0.65 mL, 5.51 mmol) was added. The reaction mixture was allowed to 
warm to rt and stirred for 22 h. After diluting with ethyl acetate, the mixture was washed 
with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to 
dryness. Chromatographic purification (9% ethyl acetate/hexanes) afforded the title 
compound as a white solid (105, 565.1 mg, 94%). The spectral data are consistent with 
the literature.269 [α]D
21 +4.2 (c 1.69, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.26 
(m, 18H), 7.19 – 7.14 (m, 2H), 5.57 (dd, J = 53.2, 2.7 Hz, 1H), 4.98 (d, J = 10.9 Hz, 1H), 
4.90 – 4.84 (m, 2H), 4.82 (d, J = 11.9 Hz, 1H), 4.72 (d, J = 11.9 Hz, 1H), 4.62 (d, J = 
12.1 Hz, 1H), 4.53 (d, J = 10.8 Hz, 1H), 4.49 (d, J = 12.1 Hz, 1H), 4.04 – 3.93 (m, 2H), 
3.80 – 3.73 (m, 2H), 3.68 (dd, J = 10.9, 2.1 Hz, 1H), 3.59 (ddd, J = 25.6, 9.6, 2.7 Hz, 




128.43, 128.41, 128.1, 128.03, 127.96 (2 carbons), 127.9, 127.8 (2 carbons), 127.7, 
105.6 (d, J = 226.7 Hz), 81.5, 79.3 (d, J = 24.8 Hz), 76.6, 75.8, 75.2, 73.6, 73.5, 72.7 (d, 
J = 4.0 Hz), 67.8. 19F NMR (376 MHz, CDCl3) δ -149.53 (dd, J = 53.3, 25.7 Hz). HRMS 
(ESI-TOF) m/z: Calcd. for C34H35O5FNa ([M + Na]
+): 565.2366; found: 565.2365. 
2,3,4,6-Tetra-O-benzyl-α-D-galactopyranosyl fluoride (106) 
2,3,4,6-Tetra-O-benzyl-D-galactopyranosyl acetate 112 (373.0 mg, 0.64 mmol) 
was dissolved in toluene (3 mL) and added to a 70% hydrogen fluoride – pyridine 
complex (0.9 mL) in a 20 mL polyethylene vessel pre-cooled to 0 oC in an ice-water 
bath. The reaction mixture was allowed to warm to rt and stirred for 4 h. After diluting 
with ethyl acetate, the mixture was washed successively with 10% KF solution and 
brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to 
dryness. Chromatographic purification (8% ethyl acetate/hexanes) afforded the title 
compound as a colorless oil (106, 217.5 mg, 63%). The spectral data are consistent 
with the literature.269 [α]D
21 +1.8 (c 0.76, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.42 – 
7.24 (m, 20H), 5.60 (dd, J = 53.7, 2.7 Hz, 1H), 4.95 (d, J = 11.3 Hz, 1H), 4.88 – 4.70 (m, 
4H), 4.58 (d, J = 11.3 Hz, 1H), 4.49 (d, J = 11.9 Hz, 1H), 4.42 (d, J = 11.9 Hz, 1H), 4.14 
– 3.99 (m, 3H), 3.95 (dd, J = 10.0, 2.7 Hz, 1H), 3.57 – 3.53 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ 138.34, 138.32, 138.0, 137.7, 128.4 (3 carbons), 128.3, 128.2, 128.0, 
127.9, 127.83, 127.82, 127.71, 127.66, 127.5, 106.2 (d, J = 226.1 Hz), 78.4, 75.7 (d, J 
= 23.8 Hz), 74.8, 74.3, 73.8, 73.5, 73.1, 71.7 (d, J = 3.1 Hz), 68.2. 19F NMR (376 MHz, 
CDCl3) δ -150.21 (dd, J = 53.8, 25.1 Hz).HRMS (ESI-TOF) m/z: Calcd. for 
C34H35O5FNa ([M + Na]





2-Azido-2-deoxy-3,4,6-tri-O-benzyl-α-D-glucopyranosyl fluoride (107) 
To a solution of phenyl 2-azido-2-deoxy-3,4,6-tri-O-benzyl β-D-
thioglucopyranoside 113 (515.6 mg, 0.91 mmol) in acetone (10 mL) was added water 
(0.5 mL) and N-bromosuccinimide (484.9 mg, 2.72 mmol). After stirring at rt for 40 min, 
the reaction mixture was quenched by adding sodium bicarbonate. Then the mixture 
was concentrated under reduced pressure to dryness and the residue was partitioned 
between ethyl acetate and water. The separated organic layer was then washed 
successively with saturated NaHCO3 solution and brine, dried over anhydrous Na2SO4 
and concentrated under reduced pressure to dryness. Chromatographic purification (25% 
ethyl acetate/hexanes) afforded the hydrolyzed product as a white solid (411.5 mg, 
95%).  The hydrolyzed product obtained (395.0 mg, 0.83 mmol) was dissolved in 
toluene (7 mL) and added to a 70% hydrogen fluoride – pyridine complex (1.6 mL) in a 
20 mL polyethylene vessel pre-cooled to 0 oC in an ice-water bath. The reaction 
mixture was allowed to warm to rt and stirred for 46 h. After diluting with ethyl acetate, 
the mixture was washed successively with saturated NaHCO3 solution and brine, dried 
over anhydrous Na2SO4 and concentrated under reduced pressure to dryness. 
Chromatographic purification (6% ethyl acetate/hexanes) afforded the title compound 
as a colorless oil (107, 227.7 mg, 57%). [α]D
21 +30.3 (c 1.33, CHCl3). 
1H NMR (400 
MHz, CDCl3) δ 7.40 – 7.26 (m, 13H), 7.20 – 7.15 (m, 2H), 5.67 (dd, J = 52.8, 2.6 Hz, 
1H), 4.93 – 4.86 (m, 2H), 4.83 (d, J = 10.9 Hz, 1H), 4.62 (d, J = 12.1 Hz, 1H), 4.57 (d, J 
= 10.9 Hz, 1H), 4.51 (d, J = 12.1 Hz, 1H), 4.01 – 3.93 (m, 2H), 3.83 (t, J = 9.5 Hz, 1H), 
3.79 (dd, J = 11.1, 3.3 Hz, 1H), 3.69 (dd, J = 11.0, 1.9 Hz, 1H), 3.49 (ddd, J = 25.8, 




128.46, 128.1, 128.0, 127.92, 127.90, 127.86, 127.7, 106.1 (d, J = 226.8 Hz), 79.8, 
77.2, 75.7, 75.2, 73.6, 73.2 (d, J = 3.8 Hz), 67.6, 63.4 (d, J = 24.8 Hz). 19F NMR (376 
MHz, CDCl3) δ -145.97 (dd, J = 52.8, 25.4 Hz). HRMS (ESI-TOF) m/z: Calcd. for 
C27H28O4N3FNa ([M + Na]
+): 500.1962; found: 500.1960. 
Preparation of Tempol Glycosides 114-117 
Tempol glycosides were prepared from the corresponding glycopyranosyl 
fluorides according to the method of Sato and coworkers.270  
General procedure: To a solution of glycopyranosyl fluoride (1 equiv) and Tempo 
radical (1.3 equiv) in acetonitrile (0.25 mL per mmol of glycopyranosyl fluoride) stirring 
at rt was added 1,1,3,3-tetramethylguanidine (3 equiv) and boron trifluoride diethyl 
etherate (≥46.5 BF3, 4 equiv). After completion (4-5 h, as indicated by TLC and mass 
spectrometry), the reaction mixture was diluted with ethyl acetate and washed 
successively with saturated NaHCO3 solution and brine, dried over anhydrous Na2SO4 
and concentrated under reduced pressure to dryness. Chromatographic purification 
afforded the corresponding Tempol glycosides. 
1-(2,3,4,6-Tetra-O-benzyl-α-D-mannopyranosyloxy)-2,2,6,6-tetramethylpiperidine 
(114) 
Prepared from 104 (599.8 mg). Chromatographic purification (7% ethyl 
acetate/hexanes) afforded the title compound as a colorless oil (477.2 mg, 64%). [α]D
21 
+36.8 (c 1.97, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.22 (m, 20H), 5.18 (d, J = 
2.0 Hz, 1H), 4.95 (d, J = 10.6 Hz, 1H), 4.79 – 4.70 (m, 3H), 4.70 – 4.62 (m, 2H), 4.59 (d, 
J = 10.7 Hz, 1H), 4.53 (d, J = 12.1 Hz, 1H), 4.16 (t, J = 9.6 Hz, 1H), 3.95 (t, J = 2.5 Hz, 




1.36 (m, 5H), 1.34 – 1.19 (m, 4H), 1.04 (s, 3H), 0.94 (s, 3H), 0.86 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 138.63, 138.59, 138.57, 138.4, 128.40, 128.35, 128.3, 128.20, 
128.16, 127.94, 127.86, 127.7, 127.6 (2 carbons), 127.5, 127.3, 103.5, 78.0, 75.3, 75.0, 
73.9, 73.4, 72.7, 72.4, 71.7, 69.3, 60.3, 59.4, 40.5, 40.1, 33.7, 33.4, 20.7, 20.1, 17.0. 
HRMS (ESI-TOF) m/z: Calcd. for C43H53O6NNa ([M + Na]
+): 702.3771; found: 702.3773. 
1-(2,3,4,6-Tetra-O-benzyl-α-D-glucopyranosyloxy)-2,2,6,6-tetramethylpiperidine 
(115α) 
Prepared from 105 (545.1 mg). Chromatographic purification (6% ethyl 
acetate/hexanes) afforded the title compound as a white solid (258.8 mg, 38%). [α]D
21 
+63.1 (c 0.68, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.24 (m, 18H), 7.20 – 7.15 
(m, 2H), 5.40 (d, J = 3.8 Hz, 1H), 4.96 (d, J = 10.9 Hz, 1H), 4.91 – 4.84 (m, 2H), 4.84 – 
4.75 (m, 2H), 4.69 (d, J = 12.2 Hz, 1H), 4.54 (d, J = 10.7 Hz, 1H), 4.47 (d, J = 12.2 Hz, 
1H), 4.02 – 3.93 (m, 2H), 3.84 (dd, J = 10.6, 2.8 Hz, 1H), 3.79 (t, J = 9.5, 1H), 3.68 – 
3.61 (m, 2H), 1.49 (br s, 5H), 1.39 – 1.07 (m, 13H). 13C NMR (101 MHz, CDCl3) δ 138.7, 
138.4, 138.3, 138.2, 128.4, 128.3 (2 carbons), 128.1, 128.0, 127.9 (2 carbons), 127.7, 
127.59, 127.56, 127.5, 127.3, 102.6, 82.1, 81.4, 78.1, 75.5, 75.2, 74.1, 73.6, 71.3, 68.4, 
61.3, 59.4, 41.3, 41.2, 33.8, 32.4, 21.0, 20.2, 17.0. HRMS (ESI-TOF) m/z: Calcd. for 
C43H54O6N ([M + H]
+): 680.3951; found: 680.3943. 
1-(2,3,4,6-Tetra-O-benzyl-β-D-glucopyranosyloxy)-2,2,6,6-tetramethylpiperidine 
(115β) 
Prepared from 105 (545.1 mg). Chromatographic purification (7% ethyl 
acetate/hexanes) afforded the title compound as a white solid (251.8 mg, 37%). [α]D
21 -
7.2 (c 1.04, CHCl3). 




11.0 Hz, 1H), 4.91 (d, J = 11.1 Hz, 1H), 4.86 – 4.76 (m, 4H), 4.66 – 4.53 (m, 3H), 3.79 
– 3.71 (m, 3H), 3.68 (t, J = 8.9 Hz, 1H), 3.47 (t, J = 8.6 Hz, 1H), 3.42 (ddd, J = 9.5, 3.4, 
2.0 Hz, 1H), 1.71 – 1.25 (m, 12H), 1.20 (s, 3H), 1.17 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 138.8, 138.5, 138.38, 138.36, 128.4, 128.31, 128.29, 128.2, 128.0, 127.8, 
127.69, 127.68, 127.6, 127.5, 127.4 (2 carbons), 105.8, 85.7, 82.4, 78.0, 75.7, 75.4, 
74.9, 74.5, 73.6, 68.7, 61.3, 59.4, 40.6, 40.3, 34.9, 32.8, 20.9, 20.8, 17.2. HRMS (ESI-
TOF) m/z: Calcd. for C43H54O6N ([M + H]
+): 680.3951; found: 680.3962. 
1-(2,3,4,6-Tetra-O-benzyl-α-D-galactopyranosyloxy)-2,2,6,6-tetramethylpiperidine 
(116α) 
Prepared from 106 (55.1 mg). Chromatographic purification (6% ethyl 
acetate/hexanes) afforded the title compound as a colorless oil (28.3 mg, 41%). [α]D
21 
+76.6 (c 0.74, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.22 (m, 20H), 5.34 (d, J = 
4.0 Hz, 1H), 4.98 (d, J = 11.4 Hz, 1H), 4.88 (d, J = 11.6 Hz, 1H), 4.81 – 4.72 (m, 3H), 
4.61 (d, J = 11.4 Hz, 1H), 4.50 – 4.41 (m, 2H), 4.17 (dd, J = 10.5, 4.0 Hz, 1H), 4.15 – 
4.07 (m, 2H), 3.96 (dd, J = 10.5, 2.6 Hz, 1H), 3.69 (t, J = 8.9 Hz, 1H), 3.49 (dd, J = 8.9, 
4.8 Hz, 1H), 1.48 (br s, 5H), 1.38 – 1.05 (m, 13H). 13C NMR (101 MHz, CDCl3) δ 139.0, 
138.73, 138.65, 138.1, 128.4, 128.3, 128.2, 128.0, 127.9, 127.8, 127.74, 127.69, 127.4 
(2 carbons), 127.3, 127.2, 102.9, 79.1, 77.1, 75.0, 74.7, 74.3, 73.5, 72.6, 69.59, 68.0, 
61.4, 59.3, 41.2 (2 carbons), 33.6, 32.5, 20.9, 20.1, 17.0. HRMS (ESI-TOF) m/z: Calcd. 
for C43H53O6NNa ([M + Na]








Prepared from 106 (55.1 mg). Chromatographic purification (9% ethyl 
acetate/hexanes) afforded the title compound as a colorless oil (20.5 mg, 30%). [α]D
21 -
5.5 (c 0.73, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.26 (m, 20H), 5.01 – 4.93 (m, 
2H), 4.83 (d, J = 10.8 Hz, 1H), 4.76 (d, J = 8.1 Hz, 1H), 4.71 (s, 2H), 4.65 (d, J = 11.8 
Hz, 1H), 4.43 (s, 2H), 3.95 (d, J = 3.0 Hz, 1H), 3.80 (dd, J = 9.8, 8.1 Hz, 1H), 3.68 – 
3.54 (m, 4H), 1.69 – 1.38 (m, 5H), 1.38 – 1.27 (m, 4H), 1.24 (s, 3H), 1.20 (s, 3H), 1.13 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 139.0, 138.7, 138.6, 138.0, 128.4, 128.3, 128.2, 
128.14, 128.11, 128.0, 127.9, 127.7, 127.4 (3 carbons), 127.3, 105.9, 83.5, 79.4, 75.5, 
74.6, 73.8, 73.5, 73.0, 72.8, 68.5, 61.3, 59.4, 40.7, 40.4, 34.6, 32.8, 20.8, 20.7, 17.2. 
HRMS (ESI-TOF) m/z: Calcd. for C43H54O6N ([M + H]
+): 680.3951; found: 680.3922. 
1-(2-Azido-2-deoxy-3,4,6-tri-O-benzyl-α-D-glucopyranosyloxy)-2,2,6,6-
tetramethylpiperidine (117α) 
Prepared from 107 (175.6 mg). Chromatographic purification (6% ethyl 
acetate/hexanes) afforded the title compound as a white solid (57.2 mg, 22%). [α]D
21 
+40.1 (c 0.78, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.23 (m, 13H), 7.21 – 7.15 
(m, 2H), 5.36 (d, J = 4.2 Hz, 1H), 4.96 – 4.87 (m, 2H), 4.81 (d, J = 10.7 Hz, 1H), 4.67 (d, 
J = 12.1 Hz, 1H), 4.57 (d, J = 10.7 Hz, 1H), 4.46 (d, J = 12.1 Hz, 1H), 3.91 (dt, J = 10.0, 
2.3 Hz, 1H), 3.89 – 3.79 (m, 3H), 3.63 – 3.57 (m, 2H), 1.54 – 1.05 (m, 18H). 13C NMR 
(101 MHz, CDCl3) δ 138.0 (2 carbons), 137.9, 128.4 (2 carbons), 128.3, 128.1, 127.9, 
127.8 (3 carbons), 127.6, 101.9, 80.8, 78.3, 75.5, 75.0, 73.6, 71.7, 68.0, 64.6, 41.3 (2 




visible due to line broadening caused by conformational exchange. HRMS (ESI-TOF) 
m/z: Calcd. for C36H46O5N4Na ([M + Na]
+): 637.3366; found: 637.3353. 
1-(2-Azido-2-deoxy-3,4,6-tri-O-benzyl-β-D-glucopyranosyloxy)-2,2,6,6-
tetramethylpiperidine (117β) 
 Prepared from 107 (175.6 mg). Chromatographic purification (8% ethyl 
acetate/hexanes) afforded the title compound as a white solid (166.2 mg, 63%). [α]D
21 -
56.3 (c 1.50, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.20 (m, 15H), 4.95 – 4.83 (m, 
2H), 4.81 (d, J = 11.0 Hz, 1H), 4.64 (d, J = 10.9 Hz, 1H), 4.62 – 4.51 (m, 3H), 3.77 – 
3.67 (m, 3H), 3.47 (dd, J = 9.9, 8.4 Hz, 1H), 3.44 – 3.35 (m, 2H), 1.70 – 1.43 (m, 5H), 
1.40 – 1.22 (m, 10H), 1.14 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 138.2, 138.14, 138.12, 
128.44, 128.42, 128.3, 127.9 (3 carbons), 127.8, 127.7, 127.6, 104.0, 84.0, 77.7, 75.6, 
74.9, 74.7, 73.6, 68.5, 67.0, 61.2, 59.7, 40.6, 40.3, 34.6, 33.2, 20.7, 20.3, 17.2. HRMS 
(ESI-TOF) m/z: Calcd. for C36H46O5N4Na ([M + Na]
+): 637.3366; found: 637.3356. 
Preparation of Iridium Cataylst 103 
Iridium catalyst 103 was prepared according to the method of Knowles and 
coworkers.271 The spectral data are consistent with the literature.272  
General Procedure for Blue Light Promoted Glycosylation 
An oven-dried 17x60 mm glass vial was charged with a magnetic stirring bar, 
Tempol glycoside (1 equiv), glycosyl acceptor (1.5 equiv for carbohydrate-derived 
acceptors or 3 equiv for cyclohexanol), photocatalyst 103 (0.05 equiv) and activated 4 
Å molecular sieves (240 mg/mL of nitromethane). Then the vial was evacuated and 
backfilled with Ar three times followed by addition of nitromethane (10 mL/mmol of 




light. Progress of reaction was monitored by TLC and mass spectrometry. After 
completion, the mixture was filtered through a pad of Celite and the filtrate was 
concentrated under reduced pressure to dryness. The annomeric ratio of the products 
was determined by integration of the 1H NMR spectrum of the crude product mixture. 
Pure glycosylation products were obtained after chromatographic purification. 
Cyclohexyl 2,3,4,6-tetra-O-benzyl-D-mannopyranoside (121α and 121β)273  
121α and 121β were obtained from the reaction of 114 (30.0 mg, 0.04 mmol) 
and cyclohexanol 118 (13.3 mg, 0.13 mmol) following the general procedure for 
glycosylation (8% ethyl acetate/hexanes). Combined yield: 22.0 mg, 80%. α:β = 1.3:1. 
121α: colorless oil. [α]D
21 +48.7 (c 0.12, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.41 – 7.21 (m, 18H), 7.16 (dd, J = 7.3, 2.1 Hz, 2H), 4.99 (d, J = 1.9 Hz, 1H), 4.87 (d, J 
= 10.7 Hz, 1H), 4.75 (d, J = 12.5 Hz, 1H), 4.70 (d, J = 12.5 Hz, 1H), 4.66 (d, J = 12.2 
Hz, 1H), 4.64 – 4.60 (m, 2H), 4.52 (d, J = 12.1 Hz, 1H), 4.49 (d, J = 10.6 Hz, 1H), 3.97 
(t, J = 9.5 Hz, 1H), 3.92 (dd, J = 9.4, 3.0 Hz, 1H), 3.87 – 3.82 (m, 1H), 3.78 (dd, J = 
10.7, 5.1 Hz, 1H), 3.74 – 3.69 (m, 2H), 3.60 – 3.53 (m, 1H), 1.85 – 1.70 (m, 2H), 1.69 – 
1.59 (m, 2H), 1.51 – 1.43 (m, 1H), 1.36 – 1.11 (m, 5H). 13C NMR (151 MHz, CDCl3) δ 
138.6, 138.50, 138.47 (2 carbons), 128.29 (2 carbons), 128.26, 128.2, 128.1, 127.8, 
127.7, 127.62, 127.56, 127.49, 127.45, 127.4, 95.7, 80.3, 75.3, 75.18, 75.16, 74.7, 73.2, 
72.5, 72.1, 71.7, 69.4, 33.2, 31.3, 25.6, 24.0, 23.8. HRMS (ESI-TOF) m/z: Calcd. for 
C40H46O6Na ([M + Na]
+): 645.3192; found: 645.3198. 
121β: colorless oil. [α]D
21 -60.0 (c 0.10, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.48 (d, J = 7.2 Hz, 2H), 7.35 – 7.25 (m, 16H), 7.21 – 7.17 (m, 2H), 5.01 (d, J = 12.7 Hz, 




2H), 4.42 (d, J = 11.8 Hz, 1H), 3.87 – 3.79 (m, 3H), 3.74 – 3.68 (m, 2H), 3.49 (dd, J = 
9.4, 3.0 Hz, 1H), 3.44 (ddd, J = 8.7, 6.7, 1.8 Hz, 1H), 1.97 (d, J = 11.8 Hz, 1H), 1.83 – 
1.66 (m, 3H), 1.56 – 1.46 (m, 1H), 1.40 – 1.21 (m, 5H).  13C NMR (151 MHz, CDCl3) δ 
138.9, 138.6, 138.4, 138.2, 128.5, 128.3 (2 carbons), 128.2, 128.03, 128.00, 127.7, 
127.6, 127.51, 127.49, 127.4, 127.3, 99.5, 82.6, 76.6, 75.9, 75.1, 75.0, 74.0, 73.6, 73.4, 
71.3, 69.9, 33.5, 31.6, 25.7, 23.8, 23.7. HRMS (ESI-TOF) m/z: Calcd. for C40H46O6Na 
([M + Na]+): 645.3192; found: 645.3194. 
Methyl 2,3,4-tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-D-mannopyranosyl)-β-D-
galactopyranoside (122α and 122β) 
122α and 122β were obtained from the reaction of 114 (30.0 mg, 0.04 mmol) 
and methyl 2,3,4-tri-O-benzyl-β-D-galactopyranoside 119 (30.7 mg, 0.07 mmol) 
following the general procedure for glycosylation (14% ethyl acetate/hexanes). 
Combined yield: 26.9 mg, 62%. α:β = 1.5:1. 
122α: colorless oil. [α]D
21 +15.6 (c 0.57, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.37 – 7.19 (m, 33H), 7.17 – 7.14 (m, 2H), 4.90 – 4.84 (m, 3H), 4.77 (d, J = 11.9 Hz, 
1H), 4.75 (d, J = 1.8 Hz, 1H), 4.72 (d, J = 11.0 Hz, 1H), 4.71 – 4.58 (m, 6H), 4.53 – 
4.48 (m, 3H), 4.18 (d, J = 7.6 Hz, 1H), 3.98 (t, J = 9.4 Hz, 1H), 3.79 (dd, J = 6.4, 3.1 Hz, 
1H), 3.78 – 3.73 (m, 3H), 3.72 – 3.68 (m, 3H), 3.60 (t, J = 2.5 Hz, 1H), 3.51 (dd, J = 9.6, 
7.5 Hz, 1H), 3.49 – 3.45 (m, 4H), 3.43 (t, J = 6.6 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 
138.8, 138.6, 138.52, 138.45 (2 carbons), 138.28, 138.27, 128.34, 128.31, 128.30, 
128.28 (3 carbons), 128.2, 128.14, 128.08, 128.05, 127.9, 127.8, 127.7, 127.58, 127.56 
(2 carbons), 127.54, 127.52, 127.45 (3 carbons), 104.9, 98.1, 82.1, 79.8, 79.6, 75.06, 




57.0. HRMS (ESI-TOF) m/z: Calcd. for C62H66O11Na ([M + Na]
+): 1009.4503; found: 
1009.4498. 
122β: colorless oil. [α]D
21 -20.6 (c 0.35, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.43 – 7.39 (m, 2H), 7.37 – 7.15 (m, 33H), 4.92 (d, J = 12.4 Hz, 1H), 4.90 – 4.86 (m, 
3H), 4.83 (d, J = 12.4 Hz, 1H), 4.76 – 4.70 (m, 2H), 4.67 – 4.63 (m, 2H), 4.59 (d, J = 
12.0 Hz, 1H), 4.52 (d, J = 10.8 Hz, 1H), 4.51 – 4.44 (m, 3H), 4.38 (d, J = 0.8 Hz, 1H), 
4.23 (d, J = 7.7 Hz, 1H), 3.91 (t, J = 9.5 Hz, 1H), 3.88 – 3.84 (m, 2H), 3.78 (dd, J = 9.7, 
7.6 Hz, 1H), 3.76 – 3.71 (m, 4H), 3.53 – 3.50 (m, 1H), 3.49 – 3.44 (m, 5H), 3.39 (ddd, J 
= 9.7, 4.6, 2.6 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 138.8, 138.7, 138.42, 138.40, 
138.36, 138.3, 138.1, 128.34, 128.31, 128.29, 128.25 (3 carbons), 128.23, 128.17, 
128.13, 128.05 (2 carbons), 128.0, 127.8, 127.60, 127.57 (3 carbons), 127.54, 127.48, 
127.43, 127.35, 105.0, 102.0, 82.1, 81.9, 79.5, 75.7, 75.13, 75.07, 74.8, 74.4, 74.2, 
73.80, 73.78, 73.4, 73.0, 71.5, 69.5, 69.3, 56.9, 50.9. HRMS (ESI-TOF) m/z: Calcd. for 
C62H66O11Na ([M + Na]
+): 1009.4503; found: 1009.4501. 
Methyl 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl-D-mannopyranosyl)-α-D-
glucopyranoside (123α and 123β)273  
123α and 123β were obtained from the reaction of 114 (30.0 mg, 0.04 mmol) 
and methyl 2,3,6-tri-O-benzyl-α-D-glucopyranoside 120 (30.7 mg, 0.07 mmol) following 
the general procedure for glycosylation (17% ethyl acetate/hexanes). Combined yield: 
27.9 mg, 64%. α:β = 1:1. 
123α: colorless oil. [α]D
21 +16.4 (c 0.37, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.38 – 7.16 (m, 33H), 7.16 – 7.11 (m, 2H), 5.29 (d, J = 1.9 Hz, 1H), 5.08 (d, J = 11.6 Hz, 




= 10.9 Hz, 1H), 4.42 (dd, J = 12.0, 3.3 Hz, 2H), 4.30 (d, J = 12.1 Hz, 1H), 4.20 (d, J = 
12.1 Hz, 1H), 3.96 (t, J = 9.5 Hz, 1H), 3.85 (dd, J = 9.2, 2.9 Hz, 1H), 3.84 – 3.80 (m, 
1H), 3.78 (ddd, J = 9.7, 4.9, 1.7 Hz, 1H), 3.74 – 3.68 (m, 5H), 3.65 (dd, J = 10.8, 4.8 Hz, 
1H), 3.56 (dd, J = 10.8, 1.8 Hz, 1H), 3.53 (dd, J = 9.6, 3.5 Hz, 1H), 3.38 (s, 3H). 13C 
NMR (151 MHz, CDCl3) δ 138.8, 138.64, 138.55, 138.5, 138.4, 138.3, 137.8, 128.42, 
128.35, 128.3, 128.24, 128.21 (2 carbons), 128.20, 128.1, 128.0, 127.94, 127.93, 127.7, 
127.59 (2 carbons), 127.58, 127.5, 127.37, 127.35, 127.09, 127.06, 126.7, 100.5, 97.7, 
81.5, 80.0, 79.7, 77.7, 76.2, 74.99, 74.95, 74.8, 73.3, 73.2, 73.1, 73.0, 72.2, 72.0, 69.8, 
69.4 (2 carbons), 55.2. HRMS (ESI-TOF) m/z: Calcd. for C62H66O11Na ([M + Na]
+): 
1009.4503; found: 1009.4508. 
123β: colorless oil. [α]D
21 -17.6 (c 0.29, CHCl3).
 1H NMR (600 MHz, CDCl3) δ 
7.41 – 7.37 (m, 2H), 7.36 – 7.15 (m, 33H), 5.14 (d, J = 11.3 Hz, 1H), 4.84 (d, J = 10.9 
Hz, 1H), 4.83 – 4.79 (m, 2H), 4.78 – 4.72 (m, 2H), 4.59 (d, J = 12.2 Hz, 1H), 4.57 (s, 
1H), 4.56 (d, J = 9.5 Hz, 1H), 4.52 (d, J = 10.8 Hz, 1H), 4.49 – 4.44 (m, 2H), 4.43 (d, J 
= 12.1 Hz, 1H), 4.41 (s, 1H), 4.39 – 4.33 (m, 2H), 3.93 – 3.89 (m, 2H), 3.87 (t, J = 9.5 
Hz, 1H), 3.74 – 3.70 (m, 1H), 3.69 (d, J = 2.9 Hz, 1H), 3.67 (dd, J = 11.3, 1.8 Hz, 1H), 
3.58 – 3.55 (m, 2H), 3.54 (dd, J = 11.3, 5.4 Hz, 1H), 3.47 – 3.44 (m, 1H), 3.37 (s, 3H), 
3.30 – 3.25 (m, 2H). 13C NMR (151 MHz, CDCl3) δ 139.6, 138.9, 138.8, 138.5, 138.32, 
138.29, 137.7, 128.5, 128.33 (2 carbons), 128.25, 128.13, 128.08, 128.04, 127.96, 
127.91, 127.89, 127.81, 127.78, 127.74, 127.68, 127.57, 127.56, 127.51, 127.45, 127.3, 
127.1, 127.0, 100.8, 98.4, 82.6, 80.3, 79.1, 77.1, 76.2, 75.2, 75.03, 74.97, 74.8, 74.1, 
73.6, 73.5, 73.4, 71.6, 69.7, 69.5, 68.7, 55.3. HRMS (ESI-TOF) m/z: Calcd. for 
C62H66O11Na ([M + Na]




Cyclohexyl 2,3,4,6-tetra-O-benzyl-D-glucopyranoside (124α and 124β)274  
124α and 124β were obtained from the reaction of 115α (30.0 mg, 0.04 mmol) 
and cyclohexanol 118 (13.3 mg, 0.13 mmol) following the general procedure for 
glycosylation (7% ethyl acetate/hexanes). Combined yield: 26.4 mg, 96%. α:β = 1:2.5. 
124α and 124β were also obtained from the reaction of 115β (30.0 mg, 0.04 mmol) and 
cyclohexanol 118 (22.1 mg, 0.22 mmol) following the general procedure for 
glycosylation (7% ethyl acetate/hexanes). Combined yield: 25.0 mg, 91%. α:β = 1.2:1. 
124α: colorless oil. [α]D
21 +44.1 (c 0.37, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 
7.38 – 7.23 (m, 18H), 7.19 – 7.10 (m, 2H), 5.00 (d, J = 10.8 Hz, 1H), 4.95 (d, J = 3.7 Hz, 
1H), 4.85 – 4.78 (m, 2H), 4.75 (d, J = 12.0 Hz, 1H), 4.66 (d, J = 12.0 Hz, 1H), 4.62 (d, J 
= 12.1 Hz, 1H), 4.49 – 4.43 (m, 2H), 4.00 (t, J = 9.3 Hz, 1H), 3.88 (ddd, J = 10.1, 3.7, 
2.0 Hz, 1H), 3.74 (dd, J = 10.6, 3.8 Hz, 1H), 3.67 – 3.60 (m, 2H), 3.59 – 3.51 (m, 2H), 
1.94 – 1.69 (m, 4H), 1.61 – 1.10 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 139.0, 138.3, 
138.2, 138.0, 128.4 (3 carbons), 128.3, 128.1, 128.0, 127.91, 127.87, 127.8, 127.7, 
127.6, 127.5, 94.7, 82.1, 80.0, 77.9, 75.6, 75.3, 75.1, 73.4, 72.9, 70.0, 68.6, 33.3, 31.4, 
25.6, 24.5, 24.2. HRMS (ESI-TOF) m/z: Calcd. for C40H46O6Na ([M + Na]
+): 645.3192; 
found: 645.3193. 
124β: white solid. [α]D
21 +12.3 (c 0.37, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 
7.41 – 7.23 (m, 18H), 7.21 – 7.11 (m, 2H), 5.00 (d, J = 10.9 Hz, 1H), 4.92 (d, J = 10.9 
Hz, 1H), 4.82 (d, J = 10.8 Hz, 1H), 4.78 (d, J = 11.0 Hz, 1H), 4.71 (d, J = 10.9 Hz, 1H), 
4.64 – 4.52 (m, 3H), 4.51 (d, J = 7.9 Hz, 1H), 3.79 – 3.68 (m, 2H), 3.68 – 3.60 (m, 2H), 
3.55 (t, J = 9.2 Hz, 1H), 3.49 – 3.41 (m, 2H), 2.07 – 1.89 (m, 2H), 1.83 – 1.70 (m, 2H), 




128.34 (2 carbons), 128.31, 128.2, 128.0, 127.9, 127.73, 127.66, 127.62, 127.55, 127.5, 
102.0, 84.8, 82.3, 78.0, 77.8, 75.7, 75.0, 74.84, 74.80, 73.4, 69.2, 33.8, 32.0, 25.6, 24.1, 
24.0. HRMS (ESI-TOF) m/z: Calcd. for C40H46O6Na ([M + Na]
+): 645.3192; found: 
645.3187. 
Methyl 2,3,4-tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-β-D-
galactopyranoside (125α and 125β) 
125α and 125β were obtained from the reaction of 115α (30.0 mg, 0.04 mmol) 
and methyl 2,3,4-tri-O-benzyl-β-D-galactopyranoside 119 (30.7 mg, 0.07 mmol) 
following the general procedure for glycosylation (14% ethyl acetate/hexanes). 
Combined yield: 38.2 mg, 88%. α:β = 1:1. 125α and 125β were also obtained from the 
reaction of 115β (30.0 mg, 0.04 mmol) and methyl 2,3,4-tri-O-benzyl-β-D-
galactopyranoside 119 (30.7 mg, 0.07 mmol) following the general procedure for 
glycosylation (14% ethyl acetate/hexanes). Combined yield: 34.6 mg, 79%. α:β = 1.3:1. 
125α: colorless oil. [α]D
21 +24.3 (c 0.35, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.37 – 7.22 (m, 33H), 7.11 (dd, J = 7.2, 2.0 Hz, 2H), 4.96 (d, J = 10.9 Hz, 1H), 4.93 (d, 
J = 11.7 Hz, 1H), 4.88 (d, J = 10.9 Hz, 1H), 4.84 – 4.79 (m, 2H), 4.77 – 4.70 (m, 4H), 
4.67 (d, J = 11.9 Hz, 1H), 4.64 – 4.57 (m, 3H), 4.48 – 4.43 (m, 2H), 4.25 (d, J = 7.8 Hz, 
1H), 3.96 (t, J = 9.3 Hz, 1H), 3.85 – 3.76 (m, 4H), 3.72 (dd, J = 10.6, 3.3 Hz, 1H), 3.68 
(t, J = 9.5 Hz, 1H), 3.64 (dd, J = 10.7, 1.9 Hz, 1H), 3.58 (t, J = 6.1 Hz, 1H), 3.54 (dd, J = 
9.7, 3.5 Hz, 1H), 3.53 – 3.47 (m, 5H). 13C NMR (151 MHz, CDCl3) δ 138.80, 138.75, 
138.6, 138.5, 138.4, 138.1, 137.9, 128.40, 128.36, 128.34, 128.32, 128.29, 128.2, 
128.14, 128.09, 128.00, 127.96, 127.83 (3 carbons), 127.81, 127.7, 127.59, 127.56, 




74.9, 74.3, 73.9, 73.5, 73.3, 73.11, 73.10, 70.2, 68.3, 67.0, 57.0. HRMS (ESI-TOF) m/z: 
Calcd. for C62H66O11Na ([M + Na]
+): 1009.4503; found: 1009.4485. 
125β: colorless oil. [α]D
21 +3.2 (c 0.25, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.37 – 7.21 (m, 33H), 7.17 – 7.11 (m, 2H), 4.92 (d, J = 11.6 Hz, 1H), 4.90 – 4.84 (m, 
3H), 4.80 (d, J = 10.8 Hz, 1H), 4.76 (d, J = 10.9 Hz, 1H), 4.73 (d, J = 11.0 Hz, 1H), 4.72 
– 4.66 (m, 3H), 4.63 (d, J = 11.9 Hz, 1H), 4.57 (d, J = 12.1 Hz, 1H), 4.51 (d, J = 10.8 Hz, 
1H), 4.47 (d, J = 12.2 Hz, 1H), 4.44 (d, J = 7.8 Hz, 1H), 4.21 (d, J = 7.6 Hz, 1H), 3.86 
(dd, J = 10.7, 5.1 Hz, 1H), 3.82 (dd, J = 10.8, 6.7 Hz, 1H), 3.80 – 3.76 (m, 2H), 3.72 – 
3.65 (m, 2H), 3.65 – 3.58 (m, 2H), 3.51 (t, J = 5.9 Hz, 1H), 3.48 – 3.43 (m, 4H), 3.43 – 
3.37 (m, 2H). 13C NMR (151 MHz, CDCl3) δ 138.8, 138.6 (2 carbons), 138.5 (2 
carbons), 138.11, 138.06, 128.4 (2 carbons), 128.32 (3 carbons), 128.31 (2 carbons), 
128.22, 128.15, 128.0, 127.9, 127.84 (2 carbons), 127.76, 127.7, 127.59, 127.56 (2 
carbons), 127.53, 127.50, 127.46, 104.9, 103.6, 84.6, 82.2, 82.0, 79.5, 77.7, 75.7, 75.1, 
75.0, 74.7, 74.5, 74.3, 73.9, 73.6, 73.5, 73.1, 68.71, 68.65, 57.0. HRMS (ESI-TOF) m/z: 
Calcd. for C62H66O11Na ([M + Na]
+): 1009.4503; found: 1009.4490. 
Methyl 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-α-D-
glucopyranoside (126α and 126β)275  
126α and 126β were obtained from the reaction of 115α (30.0 mg, 0.04 mmol) 
and methyl 2,3,6-tri-O-benzyl-α-D-glucopyranoside 120 (30.7 mg, 0.07 mmol) following 
the general procedure for glycosylation (17% ethyl acetate/hexanes). Combined yield: 
30.0 mg, 69%. α:β = 1.3:1. 126α and 126β were also obtained from the reaction of 




(30.7 mg, 0.07 mmol) following the general procedure for glycosylation (17% ethyl 
acetate/hexanes). Combined yield: 27.6 mg, 63%. α:β = 1.6:1. 
126α: colorless oil. [α]D
21 +45.3 (c 0.29, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.32 – 7.18 (m, 33H), 7.11 – 7.07 (m, 2H), 5.69 (d, J = 3.6 Hz, 1H), 5.02 (d, J = 11.6 Hz, 
1H), 4.87 (d, J = 10.8 Hz, 1H), 4.83 – 4.74 (m, 3H), 4.69 (d, J = 12.1 Hz, 1H), 4.61 – 
4.46 (m, 7H), 4.41 (d, J = 10.8 Hz, 1H), 4.27 (d, J = 12.1 Hz, 1H), 4.08 (t, J = 9.0 Hz, 
1H), 4.04 (t, J = 9.0 Hz, 1H), 3.90 (t, J = 9.3 Hz, 1H), 3.87 – 3.79 (m, 2H), 3.70 (dt, J = 
10.2, 2.4 Hz, 1H), 3.67 – 3.61 (m, 2H), 3.59 (dd, J = 9.3, 3.6 Hz, 1H), 3.51 – 3.45 (m, 
2H), 3.40 – 3.34 (m, 4H). 13C NMR (151 MHz, CDCl3) δ 138.9, 138.7, 138.5, 138.2, 
138.0 (2 carbons), 137.9, 128.4, 128.29, 128.27 (3 carbons), 128.23, 128.19 (3 
carbons), 128.0, 127.9, 127.80, 127.78, 127.7, 127.6, 127.53, 127.47, 127.3, 127.2, 
127.1, 126.7, 97.8, 96.6, 82.03, 82.00, 80.2, 79.5, 77.6, 75.5, 74.9, 74.4, 73.43, 73.35, 
73.2, 73.1, 72.3, 71.0, 69.5, 69.0, 68.2, 55.1. HRMS (ESI-TOF) m/z: Calcd. for 
C62H70O11N ([M + NH4]
+): 1004.4949; found: 1004.4940. 
126β: colorless oil. [α]D
21 +19.1 (c 0.12, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.43 – 7.38 (m, 2H), 7.33 – 7.15 (m, 33H), 5.08 (d, J = 11.3 Hz, 1H), 4.85 (d, J = 10.9 
Hz, 1H), 4.81 – 4.71 (m, 6H), 4.61 – 4.52 (m, 4H), 4.42 (d, J = 12.1 Hz, 1H), 4.39 – 
4.34 (m, 3H), 3.95 (t, J = 9.5 Hz, 1H), 3.86 – 3.80 (m, 2H), 3.70 (dd, J = 11.1, 1.9 Hz, 
1H), 3.61 – 3.56 (m, 2H), 3.53 (dd, J = 11.0, 4.7 Hz, 1H), 3.49 – 3.43 (m, 3H), 3.38 – 
3.33 (m, 4H), 3.28 (ddd, J = 10.0, 4.7, 1.9 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 139.6, 
138.6 (2 carbons), 138.5, 138.4, 138.3, 137.8, 128.4, 128.33, 128.32, 128.30, 128.2 (2 
carbons), 128.1, 128.0 (2 carbons), 127.9, 127.8, 127.74, 127.72 (2 carbons), 127.60, 




76.6, 75.6, 75.4, 75.2, 74.9, 74.8, 73.6, 73.33, 73.31, 69.9, 69.0, 67.8, 55.3. HRMS 
(ESI-TOF) m/z: Calcd. for C62H70O11N ([M + NH4]
+): 1004.4949; found: 1004.4981. 
Cyclohexyl 2,3,4,6-tetra-O-benzyl-D-galactopyranoside (127α and 127β)276  
127α and 127β were obtained from the reaction of 116α (20.0 mg, 0.03 mmol) 
and cyclohexanol 118 (8.8 mg, 0.09 mmol) following the general procedure for 
glycosylation (7% ethyl acetate/hexanes). Combined yield: 17.4 mg, 95%. α:β = 1:1.6. 
127α and 127β were also obtained from the reaction of 116β (20.0 mg, 0.03 mmol) and 
cyclohexanol 118 (8.8 mg, 0.09 mmol) following the general procedure for glycosylation 
(7% ethyl acetate/hexanes). Combined yield: 16.0 mg, 87%. α:β = 1.6:1. 
127α: colorless oil. [α]D
21 +45.8 (c 0.37, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.41 – 7.22 (m, 20H), 5.00 (d, J = 3.7 Hz, 1H), 4.94 (d, J = 11.5 Hz, 1H), 4.85 (d, J = 
11.6 Hz, 1H), 4.78 (d, J = 11.9 Hz, 1H), 4.73 (d, J = 11.6 Hz, 1H), 4.67 (d, J = 11.9 Hz, 
1H), 4.57 (d, J = 11.5 Hz, 1H), 4.47 (d, J = 11.7 Hz, 1H), 4.40 (d, J = 11.8 Hz, 1H), 4.05 
(t, J = 6.5 Hz, 1H), 4.02 (dd, J = 9.9, 3.7 Hz, 1H), 3.99 – 3.94 (m, 2H), 3.57 – 3.50 (m, 
3H), 1.93 – 1.83 (m, 2H), 1.79 – 1.69 (m, 2H), 1.56 – 1.50 (m, 1H), 1.48 – 1.40 (m, 1H), 
1.39 – 1.31 (m, 1H), 1.27 – 1.14 (m, 3H). 13C NMR (151 MHz, CDCl3) δ 139.0, 138.8 (2 
carbons), 138.1, 128.32, 128.27, 128.24, 128.20, 128.16, 127.9, 127.61, 127.60, 
127.49, 127.47, 127.40, 127.35, 95.5, 79.2, 76.6, 75.4, 75.2, 74.7, 73.4, 73.1, 73.0, 
69.2, 69.1, 33.4, 31.6, 25.6, 24.5, 24.3. HRMS (ESI-TOF) m/z: Calcd. for C40H46O6Na 
([M + Na]+): 645.3192; found: 645.3181. 
127β: colorless oil. [α]D
21 -5.2 (c 0.27, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 7.40 
– 7.22 (m, 20H), 4.96 (d, J = 10.8 Hz, 1H), 4.92 (d, J = 11.7 Hz, 1H), 4.77 – 4.72 (m, 




– 4.39 (m, 2H), 3.86 (d, J = 3.0 Hz, 1H), 3.79 (dd, J = 9.7, 7.7 Hz, 1H), 3.67 (tt, J = 9.0, 
3.9 Hz, 1H), 3.60 – 3.54 (m, 2H), 3.53 – 3.47 (m, 2H), 2.00 – 1.87 (m, 2H), 1.78 – 1.69 
(m, 2H), 1.54 – 1.36 (m, 2H), 1.31 – 1.17 (m, 4H). 13C NMR (151 MHz, CDCl3) δ 138.8, 
138.7, 138.6, 138.0, 128.4 (3 carbons), 128.3, 128.22, 128.19, 128.1, 127.8, 127.7, 
127.50, 127.47, 127.45, 102.1, 82.4, 79.6, 77.5, 75.2, 74.4, 73.6, 73.5, 73.4, 73.1, 69.1, 
33.7, 31.9, 25.7, 24.1, 24.0. HRMS (ESI-TOF) m/z: Calcd. for C40H46O6Na ([M + Na]
+): 
645.3192; found: 645.3184. 
Methyl 2,3,4-tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-D-galactopyranosyl)-β-D-
galactopyranoside (128α and 128β)277 
128α and 128β were obtained from the reaction of 116α (20.0 mg, 0.03 mmol) 
and methyl 2,3,4-tri-O-benzyl-β-D-galactopyranoside 119 (20.5 mg, 0.04 mmol) 
following the general procedure for glycosylation (17% ethyl acetate/hexanes). 
Combined yield: 23.9 mg, 82%. α:β = 1.2:1. 128α and 128β were also obtained from 
the reaction of 116β (18.0 mg, 0.03 mmol) and methyl 2,3,4-tri-O-benzyl-β-D-
galactopyranoside 119 (18.4 mg, 0.04 mmol) following the general procedure for 
glycosylation (17% ethyl acetate/hexanes). Combined yield: 19.6 mg, 75%. α:β = 1.4:1. 
128α: white solid. [α]D
21 +27.1 (c 0.92, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.39 – 7.19 (m, 35H), 4.93 (d, J = 11.4 Hz, 1H), 4.90 (d, J = 11.6 Hz, 1H), 4.88 (d, J = 
10.9 Hz, 1H), 4.82 – 4.78 (m, 2H), 4.77 (d, J = 3.7 Hz, 1H), 4.76 – 4.71 (m, 3H), 4.65 (d, 
J = 11.9 Hz, 1H), 4.62 (d, J = 11.9 Hz, 1H), 4.59 (d, J = 11.6 Hz, 1H), 4.56 (d, J = 11.4 
Hz, 1H), 4.46 (d, J = 11.6 Hz, 1H), 4.37 (d, J = 11.6 Hz, 1H), 4.22 (d, J = 7.7 Hz, 1H), 
4.02 (dd, J = 10.0, 3.7 Hz, 1H), 3.99 – 3.95 (m, 1H), 3.95 – 3.88 (m, 2H), 3.82 (d, J = 




CDCl3) δ 138.9, 138.7 (3 carbons), 138.6, 138.5, 137.9, 128.41, 128.35, 128.3 (2 
carbons), 128.24, 128.22, 128.14 (3 carbons), 128.10, 128.0, 127.9, 127.8, 127.7, 
127.62, 127.55, 127.52 (2 carbons), 127.50 (2 carbons), 127.4, 104.9, 98.3, 82.0, 79.6, 
79.0, 76.3, 75.1, 74.80, 74.76, 74.4, 73.9, 73.54, 73.49, 73.0 (2 carbons), 72.8, 69.4, 
68.8, 67.3, 56.9. HRMS (ESI-TOF) m/z: Calcd. for C62H66O11Na ([M + Na]
+): 1009.4503; 
found: 1009.4476. 
128β: white solid. [α]D
21 -4.6 (c 0.50, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 7.38 
– 7.21 (m, 34H), 7.20 – 7.16 (m, 1H), 4.93 (d, J = 11.6 Hz, 1H), 4.90 (d, J = 11.9 Hz, 
1H), 4.88 (d, J = 11.3 Hz, 1H), 4.84 (d, J = 11.2 Hz, 1H), 4.76 – 4.65 (m, 6H), 4.63 – 
4.58 (m, 2H), 4.43 – 4.37 (m, 3H), 4.21 (d, J = 7.7 Hz, 1H), 3.91 (d, J = 2.9 Hz, 1H), 
3.85 (dd, J = 10.7, 5.4 Hz, 1H), 3.81 – 3.74 (m, 4H), 3.58 (t, J = 10.3 Hz, 1H), 3.53 – 
3.47 (m, 4H), 3.46 – 3.42 (m, 4H). 13C NMR (151 MHz, CDCl3) δ 138.8 (2 carbons), 
138.7, 138.5 (2 carbons), 138.4, 137.8, 128.4, 128.31 (2 carbons), 128.29 (2 carbons), 
128.22, 128.20, 128.14, 128.11, 128.05, 127.9, 127.83, 127.80, 127.52 (2 carbons), 
127.50 (3 carbons), 127.48, 127.4 (2 carbons), 104.9, 103.8, 82.1 (2 carbons), 79.53, 
79.46, 75.0, 74.9, 74.6, 74.3, 73.8, 73.5 (2 carbons), 73.4, 73.1, 73.0, 72.9, 68.4, 68.3, 
57.0. HRMS (ESI-TOF) m/z: Calcd. for C62H66O11Na ([M + Na]
+): 1009.4503; found: 
1009.4465. 
Methyl 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl-D-galactopyranosyl)-α-D-
glucopyranoside (129α and 129β)275  
129α and 129β were obtained from the reaction of 116α (20.0 mg, 0.03 mmol) 
and methyl 2,3,6-tri-O-benzyl-α-D-glucopyranoside 120 (20.5 mg, 0.04 mmol) following 




22.3, 77%. α:β = 1.6:1. 129α and 129β were also obtained from the reaction of 116β 
(20.0 mg, 0.03 mmol) and methyl 2,3,6-tri-O-benzyl-α-D-glucopyranoside 120 (20.5 mg, 
0.04 mmol) following the general procedure for glycosylation (14% ethyl 
acetate/hexanes). Combined yield: 17.1 mg, 59%. α:β = 1.6:1. 
129α: colorless oil. [α]D
21 +35.2 (c 0.55, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.34 – 7.14 (m, 35H), 5.76 (d, J = 3.9 Hz, 1H), 4.97 (d, J = 11.5 Hz, 1H), 4.87 (d, J = 
11.4 Hz, 1H), 4.81 (d, J = 11.5 Hz, 1H), 4.72 – 4.62 (m, 4H), 4.60 (d, J = 12.3 Hz, 1H), 
4.57 (d, J = 3.5 Hz, 1H), 4.56 – 4.51 (m, 3H), 4.42 (d, J = 12.3 Hz, 1H), 4.30 (d, J = 
11.6 Hz, 1H), 4.23 (d, J = 11.6 Hz, 1H), 4.07 (t, J = 9.1 Hz, 1H), 4.03 – 3.92 (m, 3H), 
3.88 – 3.83 (m, 2H), 3.82 (dd, J = 10.3, 2.7 Hz, 1H), 3.70 (dd, J = 10.7, 4.7 Hz, 1H), 
3.65 (dd, J = 10.7, 2.3 Hz, 1H), 3.55 (dd, J = 9.5, 3.5 Hz, 1H), 3.48 (t, J = 8.2 Hz, 1H), 
3.43 (dd, J = 8.8, 5.5 Hz, 1H), 3.38 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 139.0, 138.61, 
138.59, 138.4, 138.3, 138.0 (2 carbons), 128.4, 128.33, 128.29, 128.26, 128.21, 128.19 
(3 carbons), 128.1, 127.9 (2 carbons), 127.8, 127.7, 127.6, 127.5, 127.43, 127.35 (2 
carbons), 127.3, 127.0, 126.7, 97.7, 97.5, 82.0, 80.2, 79.2, 75.6, 74.8, 74.6, 74.3, 73.8, 
73.41, 73.37, 73.0, 72.7 (2 carbons), 69.9, 69.5, 69.4, 68.7, 55.1. HRMS (ESI-TOF) m/z: 
Calcd. for C62H70O11N ([M + NH4]
+): 1004.4949; found: 1004.4926. 
129β: colorless oil. [α]D
21 +6.1 (c 0.17, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.38 – 7.34 (m, 2H), 7.34 – 7.10 (m, 33H), 5.03 (d, J = 10.6 Hz, 1H), 4.96 (d, J = 11.4 
Hz, 1H), 4.83 – 4.78 (m, 2H), 4.75 (d, J = 11.3 Hz, 1H), 4.71 (d, J = 10.7 Hz, 1H), 4.70 
– 4.65 (m, 2H), 4.62 (d, J = 12.2 Hz, 1H), 4.55 (s, 1H), 4.54 – 4.50 (m, 2H), 4.35 (d, J = 
11.8 Hz, 1H), 4.32 (d, J = 12.1 Hz, 1H), 4.29 (d, J = 7.7 Hz, 1H), 4.23 (d, J = 11.8 Hz, 




J = 10.0, 3.4, 2.0 Hz, 1H), 3.52 (t, J = 8.7 Hz, 1H), 3.50 – 3.44 (m, 2H), 3.38 – 3.33 (m, 
4H), 3.33 – 3.28 (m, 2H). 13C NMR (151 MHz, CDCl3) δ 139.4, 139.1, 138.9, 138.6, 
138.5, 138.2, 138.1, 128.34, 128.31 (2 carbons), 128.25, 128.2, 128.13 (2 carbons), 
128.10, 128.0, 127.9, 127.8 (3 carbons), 127.7, 127.6, 127.50, 127.46, 127.4, 127.32, 
127.30, 127.0, 102.8, 98.4, 82.5, 80.3, 80.0, 78.9, 76.6, 75.5, 75.2, 74.7, 73.7, 73.6, 
73.4, 73.1, 73.0, 72.5, 70.0, 68.2, 68.0, 55.3. HRMS (ESI-TOF) m/z: Calcd. for 
C62H70O11N ([M + NH4]
+): 1004.4949; found: 1004.4905. 
Cyclohexyl 2-azido-2-deoxy-3,4,6-tri-O-benzyl-D-glucopyranoside (130α and 130β) 
130α and 130β were obtained from the reaction of 117β (20.0 mg, 0.03 mmol) 
and cyclohexanol 118 (9.8 mg, 0.10 mmol) following the general procedure for 
glycosylation (7% ethyl acetate/hexanes). Combined yield: 15.6 mg, 86%. α:β = 1.8:1. 
130α: colorless oil. [α]D
21 +78.4 (c 0.19, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.39 – 7.24 (m, 13H), 7.16 – 7.12 (m, 2H), 5.06 (d, J = 3.6 Hz, 1H), 4.90 – 4.84 (m, 2H), 
4.79 (d, J = 10.7 Hz, 1H), 4.63 (d, J = 12.1 Hz, 1H), 4.51 – 4.46 (m, 2H), 4.02 (dd, J = 
10.3, 8.8 Hz, 1H), 3.92 (dt, J = 10.1, 2.8 Hz, 1H), 3.76 (dd, J = 10.7, 3.7 Hz, 1H), 3.70 
(dd, J = 10.1, 8.8 Hz, 1H), 3.64 (dd, J = 10.7, 2.0 Hz, 1H), 3.60 (dt, J = 9.1, 4.0 Hz, 1H), 
3.27 (dd, J = 10.3, 3.6 Hz, 1H), 1.94 – 1.82 (m, 2H), 1.78 – 1.69 (m, 2H), 1.53 – 1.48 
(m, 1H), 1.46 – 1.34 (m, 2H), 1.32 – 1.17 (m, 3H). 13C NMR (151 MHz, CDCl3) δ 138.1, 
137.9, 137.8, 128.42 (2 carbons), 128.35, 128.0, 127.9, 127.84, 127.80, 127.78, 127.7, 
96.2, 80.0, 78.4, 76.3, 75.2, 75.1, 73.5, 70.6, 68.3, 63.2, 33.3, 31.4, 25.5, 24.1, 23.8. 
HRMS (ESI-TOF) m/z: Calcd. for C33H39O5N3Na ([M + Na]





130β: colorless oil. [α]D
21 -10.0 (c 0.18, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.38 – 7.24 (m, 13H), 7.19 – 7.15 (m, 2H), 4.87 (d, J = 10.8 Hz, 1H), 4.81 – 4.75 (m, 
2H), 4.59 (d, J = 12.2 Hz, 1H), 4.56 – 4.52 (m, 2H), 4.37 (d, J = 7.5 Hz, 1H), 3.73 – 
3.67 (m, 2H), 3.65 (dd, J = 10.9, 5.0 Hz, 1H), 3.56 (t, J = 9.1 Hz, 1H), 3.43 – 3.35 (m, 
3H), 1.99 – 1.88 (m, 2H), 1.79 – 1.72 (m, 2H), 1.54 – 1.39 (m, 3H), 1.32 – 1.22 (m, 3H). 
13C NMR (151 MHz, CDCl3) δ 138.1, 138.0, 137.9, 128.41, 128.40, 128.3, 128.0, 127.9, 
127.8 (2 carbons), 127.7, 127.6, 100.5, 83.2, 78.0, 77.8, 75.4, 75.03, 74.97, 73.4, 68.8, 
66.4, 33.5, 31.7, 25.5, 24.0, 23.8. HRMS (ESI-TOF) m/z: Calcd. for C33H39O5N3Na ([M 
+ Na]+): 580.2787; found: 580.2783. 
Methyl 2,3,4-tri-O-benzyl-6-O-(2-azido-2-deoxy-3,4,6-tri-O-benzyl-D-
glucopyranosyl)-β-D-galactopyranoside (131α and 131β) 
131α and 131β were obtained from the reaction of 117β (30.0 mg, 0.05 mmol) 
and methyl 2,3,4-tri-O-benzyl-β-D-galactopyranoside 119 (34.0 mg, 0.07 mmol) 
following the general procedure for glycosylation (14% ethyl acetate/hexanes). 
Combined yield: 27.5 mg, 61%. α:β = 1.4:1. 
131α: colorless oil. [α]D
21 +50.2 (c 0.21, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 
7.41 – 7.20 (m, 28H), 7.12 (dd, J = 7.3, 2.1 Hz, 2H), 4.99 (d, J = 11.6 Hz, 1H), 4.89 (d, 
J = 11.0 Hz, 1H), 4.84 (s, 2H), 4.80 – 4.71 (m, 4H), 4.70 (d, J = 3.5 Hz, 1H), 4.65 (d, J = 
11.7 Hz, 1H), 4.62 (d, J = 12.0 Hz, 1H), 4.49 (d, J = 10.9 Hz, 1H), 4.46 (d, J = 12.0 Hz, 
1H), 4.25 (d, J = 7.7 Hz, 1H), 3.93 (dd, J = 10.2, 8.7 Hz, 1H), 3.88 (d, J = 2.8 Hz, 1H), 
3.83 – 3.76 (m, 3H), 3.76 – 3.70 (m, 2H), 3.65 (dd, J = 10.8, 2.1 Hz, 1H), 3.54 – 3.48 
(m, 5H), 3.46 (dd, J = 9.4, 6.5 Hz, 1H), 3.30 (dd, J = 10.3, 3.5 Hz, 1H). 13C NMR (151 




carbons), 128.2 (3 carbons), 128.1, 128.0, 127.92, 127.86, 127.8, 127.7, 127.59, 
127.57 (2 carbons), 127.55, 127.5, 105.0, 97.8, 82.0, 80.0, 79.5, 78.1, 75.3, 75.1, 74.9, 
74.3, 73.5, 73.4, 73.1, 72.9, 70.6, 68.1, 66.7, 63.2, 57.0. HRMS (ESI-TOF) m/z: Calcd. 
for C55H63O10N4 ([M + NH4]
+): 939.4544; found: 939.4539. 
131β: colorless oil. [α]D
21 -6.7 (c 0.14, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 7.42 
– 7.19 (m, 28H), 7.13 (dd, J = 7.2, 2.3 Hz, 2H), 4.95 – 4.88 (m, 2H), 4.84 (d, J = 10.8 
Hz, 1H), 4.80 – 4.72 (m, 4H), 4.72 – 4.65 (m, 2H), 4.57 (d, J = 12.1 Hz, 1H), 4.52 (d, J 
= 10.8 Hz, 1H), 4.46 (d, J = 12.1 Hz, 1H), 4.40 (d, J = 7.7 Hz, 1H), 4.30 (d, J = 7.7 Hz, 
1H), 3.87 – 3.81 (m, 2H), 3.81 – 3.77 (m, 2H), 3.70 (dd, J = 10.9, 3.9 Hz, 1H), 3.67 – 
3.62 (m, 2H), 3.59 (t, J = 6.0 Hz, 1H), 3.56 (s, 3H), 3.51 (dd, J = 9.8, 3.0 Hz, 1H), 3.40 
– 3.31 (m, 3H). 13C NMR (151 MHz, CDCl3) δ 138.8, 138.39, 138.36, 137.94, 137.89, 
137.85, 128.40 (4 carbons), 128.35 (2 carbons), 128.22, 128.16, 128.02, 127.97, 127.9, 
127.82, 127.81, 127.79, 127.7, 127.6 (2 carbons), 127.5, 105.0, 102.4, 82.9, 81.9, 79.6, 
77.5, 75.5, 75.1, 75.0, 74.8, 74.3, 74.1, 73.5, 73.4, 73.1, 69.0, 68.3, 66.2, 57.0. HRMS 
(ESI-TOF) m/z: Calcd. for C55H63O10N4 ([M + NH4]
+): 939.4544; found: 939.4542. 
Methyl 2,3,6-tri-O-benzyl-4-O-(2-azido-2-deoxy-3,4,6-tri-O-benzyl-D-
glucopyranosyl)-α-D-glucopyranoside (132α and 132β)278  
132α and 132β were obtained from the reaction of 117β (30.0 mg, 0.05 mmol) 
and methyl 2,3,6-tri-O-benzyl-α-D-glucopyranoside 120 (34.0 mg, 0.07 mmol) following 
the general procedure for glycosylation (14% ethyl acetate/hexanes). Combined yield: 
25.6 mg, 57%. α:β = 2:1. 
132α: colorless oil. [α]D
21 +42.9 (c 0.34, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 




1H), 4.88 – 4.79 (m, 3H), 4.77 – 4.70 (m, 2H), 4.61 (d, J = 12.2 Hz, 1H), 4.59 (d, J = 3.7 
Hz, 1H), 4.52 – 4.46 (m, 3H), 4.43 (d, J = 10.8 Hz, 1H), 4.23 (d, J = 12.1 Hz, 1H), 4.06 
(t, J = 9.1 Hz, 1H), 3.90 (t, J = 9.3 Hz, 1H), 3.85 (dd, J = 10.4, 8.3 Hz, 1H), 3.77 (ddd, J 
= 9.8, 4.4, 2.0 Hz, 1H), 3.71 (dd, J = 11.1, 4.5 Hz, 1H), 3.68 – 3.60 (m, 3H), 3.56 (dd, J 
= 9.6, 3.5 Hz, 1H), 3.50 (dd, J = 10.7, 2.5 Hz, 1H), 3.37 (s, 3H), 3.31 (dd, J = 10.8, 1.7 
Hz, 1H), 3.27 (dd, J = 10.4, 3.9 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 138.6, 138.1, 
138.0, 137.94, 137.91, 137.7, 128.5, 128.44, 128.35 (2 carbons), 128.32, 128.28, 128.2, 
128.0 (3 carbons), 127.8 (2 carbons), 127.74, 127.69, 127.6, 127.5, 127.4, 127.2, 
97.73, 97.70, 82.0, 80.5, 80.1, 78.0, 75.3, 75.0, 74.9, 73.5, 73.3 (2 carbons), 73.2, 71.4, 
69.4, 69.2, 67.8, 63.3, 55.3. HRMS (ESI-TOF) m/z: Calcd. for C55H59O10N3Na ([M + 
Na]+): 944.4098; found: 944.4088. 
132β: colorless oil. [α]D
21 -6.5 (c 0.16, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 7.48 
– 7.10 (m, 30H), 5.01 (d, J = 11.4 Hz, 1H), 4.83 – 4.72 (m, 5H), 4.66 (d, J = 12.1 Hz, 
1H), 4.60 – 4.56 (m, 2H), 4.53 (d, J = 10.9 Hz, 1H), 4.46 (d, J = 12.1 Hz, 1H), 4.40 – 
4.32 (m, 2H), 4.23 (d, J = 8.1 Hz, 1H), 3.95 (t, J = 9.4 Hz, 1H), 3.91 (dd, J = 11.2, 3.6 
Hz, 1H), 3.88 (t, J = 9.3 Hz, 1H), 3.77 (dt, J = 10.0, 2.5 Hz, 1H), 3.69 (dd, J = 10.9, 2.0 
Hz, 1H), 3.63 – 3.56 (m, 2H), 3.51 – 3.44 (m, 2H), 3.37 (s, 3H), 3.30 (dd, J = 9.9, 8.1 
Hz, 1H), 3.22 (t, J = 9.4 Hz, 1H), 3.17 (ddd, J = 9.9, 4.4, 1.9 Hz, 1H). 13C NMR (151 
MHz, CDCl3) δ 139.5, 138.33, 138.28, 138.0, 137.9, 137.8, 128.5, 128.44, 128.37, 
128.3, 128.2, 128.1 (2 carbons), 127.99, 127.97, 127.9, 127.8, 127.73, 127.72, 127.66 
(2 carbons), 127.5, 127.4, 127.0, 100.9, 98.3, 83.3, 80.3, 79.0, 77.9, 76.8, 75.4, 75.3, 
75.2, 74.8, 73.53, 73.46, 73.3, 69.7, 68.5, 68.2, 66.9, 55.3. HRMS (ESI-TOF) m/z: 
Calcd. for C55H59O10N3Na ([M + Na]




Benzyl 2-deoxy-4,6-O-isopropylidene-α-D-glucopyranoside (155). 
A mixture of 2-deoxy-D-glucose 154 (800 mg, 4.87 mmol), benzyl alcohol (8 mL) 
and acetyl chloride (0.35 mL, 4.87 mmol) was heated to 50 oC for 10 min. The reaction 
was quenched by adding triethylamine and the excess benzyl alcohol was removed by 
concentration under reduced pressure. Chromatographic purification (9% 
methanol/dichloromethane) afforded benzyl 2-deoxy-α-D-glucopyranoside as a white 
solid (1.16 g, 94%), with spectral data consistent with the literature.279 To a stirred 
solution of this glycoside (1.16 g, 4.56 mmol) and (1S)-(+)-10-camphorsulfonic acid 
(211.9 mg, 0.9 mmol) in DMF (12 mL) at room temperature was added 2,2-
dimethoxypropane (5.6 mL, 45.6 mmol). The reaction mixture was stirred for 5 h before 
it was diluted with ethyl acetate, washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure. Chromatographic purification (30% ethyl 
acetate/hexanes) afforded the title compound as a colorless oil (155, 1.10 g, 82%): 
[α]D
21 80.9 (c 1.08, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.27 (m, 5H), 4.97 (dd, 
J = 3.9, 1.1 Hz, 1H), 4.67 (d, J = 11.9 Hz, 1H), 4.44 (d, J = 11.9 Hz, 1H), 4.08 (ddd, J = 
11.2, 9.0, 5.2 Hz, 1H), 3.83 (dd, J = 10.0, 5.2 Hz, 1H), 3.76 (t, J = 10.0 Hz, 1H), 3.69 
(ddd, J = 10.0, 9.0, 5.2 Hz, 1H), 3.52 (t, J = 9.0 Hz, 1H), 2.23 (ddd, J = 13.3, 5.2, 1.1 Hz, 
1H), 1.76 (ddd, J = 13.3, 11.2, 3.9 Hz, 1H), 1.52 (s, 3H), 1.42 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 137.4, 128.4 (2 Cs), 127.84 (2 Cs), 127.78, 99.9, 97.2, 76.4, 69.0, 66.3, 
63.7, 62.4, 37.4, 29.2, 19.2. HRMS (ESI-TOF) m/z: Calcd. for C16H22O5Na ([M + Na]
+): 







A solution of benzyl 2-deoxyglucoside 155 (1.10 g, 3.73 mmol), tert-
butyldimethylsilyl chloride (1.69 g, 11.2 mmol) and imidazole (761 mg, 11.2 mmol) in 
DMF (15 mL) was stirred at room temperature for 8 h before it was diluted with ethyl 
acetate, washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure. The crude silylated product (1.57 g) was dissolved in ethyl acetate (11 mL), 
treated with Pd/C (274 mg) and stirred at room temperature under a hydrogen 
atmosphere (1 atm) for 4 h. The solution was filtered through Celite and the filtrate was 
concentrated under reduced pressure to dryness. Chromatographic purification (20% 
ethyl acetate/hexanes) afforded the hemiacetal 156 as a mixture of anomers (1.02 g, 
86%, : = 1.8:1). A mixture of the this product (2.18 g, 6.84 mmol), 4-
methylmorpholine N-oxide (1.20 g, 10.3 mmol) and activated 3 Å molecular siveves 
(829 mg) in dichloromethane (13 mL) was stirred at room temperature for 1 h before it 
was cooled to 0 oC. Tetra-n-propylammonium perruthenate (120 mg, 5 mol %) was 
added and the reaction mixture was stirred for a further 2 h at room temperature before 
it was concentrated under reduced pressure. Ethyl acetate was added to the residue 
and the mixture was then filtered through Celite. The filtrate was washed successively 
with 5% aqueous Na2SO3, saturated aqueous CuSO4, and brine, dried over Na2SO4 
and concentrated under reduced pressure. Chromatographic purification (10% ethyl 
acetate/hexanes) afforded the title lactone as a white solid (157, 1.90 g, 88%): [α]D
21 
7.7 (c 0.93, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 4.04 (td, J = 7.8, 5.8 Hz, 1H), 4.02 




(dd, J = 9.9, 7.8 Hz, 1H), 3.07 (dd, J = 18.0, 7.8 Hz, 1H), 2.58 (dd, J = 18.0, 5.8 Hz, 1H), 
1.50 (s, 3H), 1.42 (s, 3H), 0.87 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 169.0, 99.9, 74.1, 69.0, 68.0, 61.6, 39.3, 28.8, 25.6 (3 Cs), 18.8, 18.0, -4.5, -
5.1. HRMS (ESI-TOF) m/z: Calcd. for C15H28O5SiNa ([M + Na]




To a stirred solution of diisopropylamine (1.68 mL, 12.01 mmol) in THF (5.8 mL) 
at -78 oC was added n-butyllithium solution (2.5 M in hexanes, 4.8 mL, 12.01 mmol) 
dropwise. After stirring at the same temperature for 0.5 h, dimethyl methylphosphonate 
(1.30 mL, 12.0 mmol) was added dropwise. The reaction mixture was stirred for 0.5 h 
at -78 oC before a solution of the above lactone 157 (1.90 g, 6.00 mmol) in THF (10 mL) 
was added dropwise. After completion (2 h), saturated aqueous NH4Cl was added and 
the reaction mixture was allowed to warm to room temperature, and extracted with 
ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 
and concentrated under reduced pressure. Chromatographic purification (50% ethyl 
acetate/hexanes) afforded the title compound as a white solid (158, 2.54 g, 96%): [α]D
21 
9.1 (c 0.47, CHCl3). 
1H NMR (499 MHz, CDCl3) δ 4.04 (ddd, J = 10.8, 9.0, 5.2 Hz, 1H), 
3.88 (ddd, J = 10.6, 9.0, 5.2 Hz, 1H), 3.81 (dd, J = 10.3, 5.2 Hz, 1H), 3.78 – 3.67 (m, 
7H), 3.41 (t, J = 9.2 Hz, 1H), 2.24 – 2.08 (m, 3H), 1.54 (dd, J = 13.0, 10.8 Hz, 1H), 1.48 
(s, 3H), 1.40 (s, 3H), 0.87 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 99.4, 96.5 (d, J = 8.4 Hz), 76.1, 67.4 (d, J = 5.4 Hz), 64.9, 62.5, 53.5 (d, J = 5.7 Hz), 




19.1, 18.2, -4.4, -4.9. 31P NMR (162 MHz, CDCl3) δ 30.51. HRMS (ESI-TOF) m/z: 
Calcd. for C18H37O8PSiNa ([M + Na]
+): 463.1893; found: 463.1875. 
(4R,10R)-4-((tert-Butyldimethylsilyl)oxy-6,6-dimethyl-5,7-dioxa-Δ1,9-octalin-2-one 
(161). 
To a stirred solution of the above phosphonate 158 (2.54 g, 5.77 mmol) in THF 
(15 mL) at room temperature was added sodium borohydride (654 mg, 17.3 mmol). 
The reaction mixture was stirred at room temperature for 4 h before it was concentrated 
to dryness, diluted with ethyl acetate and washed with water, and brine, dried over 
Na2SO4 and concentrated under reduced pressure to give a crude diol 159 (2.55 g) 
which was directly used for next step without purification. A solution of dimethyl 
sulfoxide (2.46 mL, 34.6 mmol) in dichloromethane (12 mL) at -78 oC was treated 
dropwise with a solution of trifluoroacetic anhydride (3.20 mL, 23.1 mmol) in 
dichloromethane (12 mL) and stirred at -78 oC for 2 h, before a solution of the diol 159 
(2.55 g) in dichloromethane (24 mL) was added dropwise. After stirring for 2 h at the 
same temperature triethylamine (6.43 mL, 46.1 mmol) was added dropwise and stirring 
continued at -78 oC for another 1 h, before the reaction mixture was allowed to warm to 
room temperature and diluted with dichloromethane. The mixture was washed with 
brine, dried over Na2SO4 and concentrated under reduced pressure to give a crude 
diketone 160 (2.79 g), which was taken up in toluene (20 mL), treated with 18-crown-6 
(76.2 mg, 0.29 mmol) and potassium carbonate (2.39 g, 17.30 mmol), and stirred at 
room temperature for 18 h before it was concentrated under reduced pressure. 
Chromatographic purification (7% ethyl acetate/hexanes) of the residue afforded the 
title compound as a light yellow oil (161, 1.17 g, 65%): [α]D





NMR (400 MHz, CDCl3) δ 5.76 (m, 1H), 4.48 – 4.39 (m, 3H), 4.05 (ddd, J = 12.2, 8.1, 
5.1 Hz, 1H), 2.68 (ddd, J = 16.4, 5.1, 1.2 Hz, 1H), 2.47 (dd, J = 16.4, 12.2 Hz, 1H), 1.49 
(s, 3H), 1.41 (s, 3H), 0.88 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ 196.6, 159.0, 122.1, 100.4, 72.8, 71.3, 61.5, 46.2, 25.7 (4 Cs), 22.2, 18.1, -4.5, -5.0. 
HRMS (ESI-TOF) m/z: Calcd. for C16H28O4SiNa ([M + Na]




To a stirred solution of enone 161 (1.21 g, 3.87 mmol) and cerium (III) chloride 
heptahydrate (1.73 g, 4.65 mmol) in MeOH (20 mL) at -20 oC was added sodium 
borohydride (220 mg, 5.81 mmol). After stirring at -20 oC for 1 h, the reaction was 
quenched by addition of saturated aqueous NH4Cl. The reaction mixture was allowed 
to warm to room temperature, a mixture of water and ethyl acetate was added and the 
resulting mixture was filtered through Celite. The filtrate was extracted with ethyl 
acetate, and the combined organic layers were washed with brine, dried over Na2SO4 
and concentrated under reduced pressure. Chromatographic purification (25% ethyl 
acetate/hexanes) afforded the title compound as a colorless oil (165, 901.1 mg, 74%): 
[α]D
21 -63.5 (c 0.48, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 5.50 (br s, 1H), 4.43 (dd, J = 
13.8, 1.7 Hz, 1H), 4.39 (br s, 1H), 4.25 (d, J = 7.0 Hz, 1H), 4.09 (d, J = 13.8 Hz, 1H), 
3.75 (ddd, J = 12.0, 7.0, 3.6 Hz, 1H), 2.20 (dddd, J = 12.3, 5.3, 3.6, 1.4 Hz, 1H), 1.64 – 
1.56 (m, 1H), 1.49 (s, 3H), 1.37 (s, 3H), 0.88 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H). 13C 




Cs), 20.0, 18.2, -4.5, -5.0. HRMS (ESI-TOF) m/z: Calcd. for C16H30O4SiNa ([M + Na]
+): 
337.1811; found: 337.1816. 
(2R,4R,10R)-4-((tert-Butyldimethylsilyl)oxy-6,6-dimethyl-5,7-dioxa-Δ1,9-octalin-2-yl 
Benzoate (166). 
To a stirred solution of 165 (125.8 mg, 0.40 mmol), triphenyl phosphine (125.9 
mg, 0.48 mmol) and benzoic acid (58.6 mg, 0.48 mmol) in THF (2 mL) at 0 oC was 
added a solution of diisopropyl azodicarboxylate (97.1 mg, 0.48 mmol) in THF (0.7 mL) 
dropwise. The reaction mixture was stirred at room temperature for 10 h before it was 
concentrated to dryness under reduced pressure. Chromatographic purification (5% 
ethyl acetate/hexanes) afforded the title compound as a colorless oil (166, 128.6 mg, 
77%): [α]D
21 137.5 (c 1.14, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 7.7 Hz, 
2H), 7.57 (t, J = 7.7 Hz, 1H), 7.45 (t, J = 7.7 Hz, 2H), 5.69 – 5.62 (m, 1H), 5.53 (br s, 
1H), 4.42 (dd, J = 14.3, 1.7 Hz, 1H), 4.23 (d, J = 7.6 Hz, 1H), 4.19 (d, J = 14.3 Hz, 1H), 
4.12 (ddd, J = 11.8, 7.6, 3.9 Hz, 1H), 2.11 (ddt, J = 14.4, 3.9, 1.8 Hz, 1H), 1.95 (ddd, J 
= 14.4, 11.8, 4.4 Hz, 1H), 1.51 (s, 3H), 1.41 (s, 3H), 0.90 (s, 9H), 0.11 (s, 3H), 0.10 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 166.0, 138.2, 133.0, 130.2, 129.6 (2 Cs), 128.4 (2 
Cs), 117.8, 99.3, 73.2, 68.4, 68.3, 62.5, 36.0, 27.8, 25.8 (3 Cs), 20.3, 18.3, -4.5, -4.8. 
HRMS (ESI-TOF) m/z: Calcd. for C23H34O5SiNa ([M + Na]




To a stirred solution of ester 166 (500 mg, 1.19 mmol) in MeOH (2 mL) at room 




temperature for 12 h, the reaction mixture was neutralized with Amberlyst 15 hydrogen 
form and then filtered. The filtrate was concentrated under reduced pressure to give a 
residue, chromatographic purification (25% ethyl acetate/hexanes) of which afforded 
the title compound as a colorless oil (164, 335.8 mg, 89%): [α]D
21 25.8 (c 0.55, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 5.56 – 5.52 (m, 1H), 4.39 (dd, J = 14.2, 1.7 Hz, 1H), 4.29 
(br s, 1H), 4.18 – 4.11 (m, 2H), 3.99 (ddd, J = 11.9, 7.3, 4.0 Hz, 1H), 1.98 (ddt, J = 13.9, 
4.0, 1.8 Hz, 1H), 1.77 (ddd, J = 13.9, 11.9, 4.4 Hz, 1H), 1.48 (s, 3H), 1.39 (s, 3H), 0.89 
(s, 9H), 0.09 (s, 3H), 0.08 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 135.7, 121.5, 99.2, 
73.5, 67.8, 65.2, 62.6, 38.8, 28.0, 25.8 (3 Cs), 20.2, 18.2, -4.4, -4.8. HRMS (ESI-TOF) 
m/z: Calcd. for C16H30O4SiNa ([M + Na]
+): 337.1811; found: 337.1822. 
(1R,2R,5R)-1,2-Dihydroxy-3-(hydroxymethyl)cyclohexen-5-yl Benzoate (172) and 
(1R,2R,5R)-1-((tert-Butyldimethylsilyl)oxy)-2-hydroxy-3-
(hydroxymethyl)cyclohexen-5-yl Benzoate (173). 
To a solution of 166 (1.14 g, 2.72 mmol) in MeOH (2 mL) was added a solution 
of iodine in MeOH (1%, 20 mL). After stirring at room temperature for 3 h, the reaction 
was quenched by addition of saturated aqueous Na2S2O3 (50 mL) and extracted with 
ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 
and concentrated under reduce pressure. Chromatographic purification (33% ethyl 
acetate/hexanes) afforded the silyl ether 173 as a colorless oil (708.7 mg, 69%) and 
then the triol 172 as a colorless solid (185 mg, 26%). 
Silyl ether 173: [α]D
21 176.7 (c 0.09, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 8.02 (d, 
J = 7.6 Hz, 2H), 7.57 (t, J = 7.6 Hz, 1H), 7.44 (t, J = 7.6 Hz, 2H), 5.92 – 5.86 (m, 1H), 




Hz, 1H), 2.13 (dtd, J = 13.9, 3.6, 1.0 Hz, 1H), 1.98 (ddd, J = 13.9, 10.3, 4.8 Hz, 1H), 
0.91 (s, 9H), 0.13 (s, 3H), 0.12 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 165.9, 142.3, 
133.0, 130.2, 129.6 (2 Cs), 128.4 (2 Cs), 122.6, 74.1, 71.0, 68.1, 64.7, 34.6, 25.8 (3 
Cs), 18.1, -4.5, -4.7. HRMS (ESI-TOF) m/z: Calcd. for C20H30O5SiNa ([M + Na]
+): 
401.1760; found: 401.1778. 
Triol 172: [α]D
21 114.6 (c 0.24, MeOH). 1H NMR (400 MHz, CD3OD) δ 8.00 (d, J 
= 7.6 Hz, 2H), 7.60 (t, J = 7.6 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 5.97 – 5.90 (m, 1H), 
5.63 (m, 1H), 4.26 – 4.15 (m, 2H), 4.03 – 3.95 (m, 2H), 2.19 – 2.11 (m, 1H), 2.08 – 1.98 
(m, 1H). 13C NMR (101 MHz, CD3OD) δ 166.0, 144.2, 132.8, 130.2, 129.0 (2 Cs), 128.1 
(2 Cs), 120.2, 71.2, 69.5, 68.2, 61.8, 33.1. HRMS (ESI-TOF) m/z: Calcd. for 
C14H16O5Na ([M + Na]
+): 287.0895; found: 287.0896. 
(1R,2R,5R)-1-((tert-Butyldimethylsilyl)oxy)-2-(methoxymethoxy)-3-
((methoxymethoxy)methyl)cyclohexen-5-yl Benzoate (174). 
A stirred solution of diol 173 (441.8 mg, 1.17 mmol) in N,N-diisopropylethylamine 
(5 mL) at 0 oC was treated with chloromethyl methyl ether (1.77 mL, 23.34 mmol), and 
stirred at room temperature for 24 h before it was diluted with ethyl acetate, and 
washed with 1 N HCl, and brine, dried over Na2SO4 and concentrated under reduced 
pressure. Chromatographic purification (10% ethyl acetate/hexanes) afforded the title 
compound as a colorless oil (174, 473.8 mg, 87%): [α]D
21 67.6 (c 0.46, CHCl3). 
1H NMR 
(400 MHz, CDCl3) δ 8.04 (d, J = 7.4 Hz, 2H), 7.55 (t, J = 7.4 Hz, 1H), 7.43 (t, J = 7.4 Hz, 
2H), 6.03 (br s, 1H), 5.73 (m, 1H), 4.82 (d, J = 6.8 Hz, 1H), 4.73 (d, J = 6.8 Hz, 1H), 
4.67 (d, J = 6.5 Hz, 1H), 4.61 (d, J = 6.5 Hz, 1H), 4.22 (ddd, J = 5.6, 4.1, 2.3 Hz, 1H), 




12.8, 5.6 Hz, 1H), 2.02 (ddd, J = 12.8, 8.0, 2.3 Hz, 1H), 0.90 (s, 9H), 0.12 (s, 3H), 0.10 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 166.0, 136.5, 132.9, 130.4, 129.6 (2 Cs), 128.3 
(2 Cs), 126.5, 97.8, 95.3, 75.6, 69.3, 68.1, 67.4, 56.0, 55.4, 32.3, 25.7 (3 Cs), 18.0, -4.9 
(2 Cs). HRMS (ESI-TOF) m/z: Calcd. for C24H38O7SiNa ([M + Na]




A stirred solution of benzoate 174 (269.2 mg, 0.58 mmol) in MeOH (3 mL) at 
room temperature was treated with sodium methoxide (46.7 mg, 0.87 mmol) and stirred 
at room temperature for 12 h. The reaction mixture was neutralized with Amberlyst 15 
hydrogen form, filtered, and concentrated under reduced pressure. Chromatographic 
purification (33% ethyl acetate/hexanes) afforded the title compound as a colorless oil 
(175, 202.5 mg, 97%): [α]D
21 3.7 (c 0.62, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 5.97 – 
5.94 (m, 1H), 4.76 (d, J = 6.8 Hz, 1H), 4.70 (d, J = 6.8 Hz, 1H), 4.66 (d, J = 6.5 Hz, 1H), 
4.59 (d, J = 6.5 Hz, 1H), 4.42 (m, 1H), 4.17 – 4.10 (m, 2H), 4.06 (d, J = 12.8 Hz, 1H), 
3.78 (d, J = 3.6 Hz, 1H), 3.41 (s, 3H), 3.37 (s, 3H), 2.08 (dtt, J = 12.6, 5.5, 1.1 Hz, 1H), 
1.74 (ddd, J = 12.6, 8.7, 2.2 Hz, 1H), 0.86 (s, 9H), 0.09 (s, 3H), 0.07 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 133.9, 131.5, 97.6, 95.0, 75.2, 69.1, 67.5, 64.4, 55.9, 55.3, 35.6, 
25.7 (3 Cs), 17.9, -4.9 (2 Cs). HRMS (ESI-TOF) m/z: Calcd. for C17H34O6SiNa ([M + 







dioxadecalin-2-one (163) by Catalytic Hydrogenation of Enone 161. 
A solution of enone 161 (11.7 mg, 0.04 mmol) in THF (0.5 mL) was treated with 
Pd/C (4.0 mg), and stirred at room temperature under a hydrogen atmosphere (1 atm) 
for 8 h, then filtered through Celite. The filtrate was concentrated under reduced 
pressure to dryness to give a residue (11.6 mg) that was judged by integration of its 1H 
NMR spectrum to be a 1.1:1 mixture of 162 and 163. Chromatographic purification (8% 
ethyl acetate/hexanes) afforded 163 (3.4 mg, 29%) as a colorless oil. Further elution 
(12% ethyl acetate/hexanes) gave 162 (3.8 mg, 32%) as a colorless oil. 
trans-Fused ketone 162: [α]D
21 -5.0 (c 0.10, CHCl3). 
1H NMR (600 MHz, CDCl3) 
δ 3.80 (ddd, J = 10.8, 8.9, 5.7 Hz, 1H), 3.76 (dd, J = 11.4, 4.7 Hz, 1H), 3.71 (dd, J = 
10.6, 8.9 Hz, 1H), 3.67 (t, J = 11.4 Hz, 1H), 2.67 (ddd, J = 14.7, 5.7, 2.5 Hz, 1H), 2.45 
(dd, J = 14.7, 10.8 Hz, 1H), 2.15 (ddd, J = 14.3, 4.0, 2.5 Hz, 1H), 2.03 (t, J = 14.3 Hz, 
1H), 1.80 – 1.69 (m, 1H), 1.48 (s, 3H), 1.41 (s, 3H), 0.85 (s, 9H), 0.06 (s, 3H), 0.05 (s, 
3H). 13C NMR (151 MHz, CDCl3) δ 205.6, 99.2, 76.4, 72.0, 64.4, 49.5, 40.5, 33.9, 29.6, 
25.7 (3 Cs), 19.0, 18.2, -4.4, -5.1. HRMS (ESI-TOF) m/z: Calcd. for C16H34O4NSi ([M + 
NH4]
+): 332.2257; found: 332.2268. 
cis-Fused ketone 163: [α]D
21 4.7 (c 0.17, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 
4.22 – 4.14 (m, 2H), 3.97 (t, J = 2.2 Hz, 1H), 3.54 (dd, J = 11.9, 1.3 Hz, 1H), 2.97 (dd, J 
= 14.1, 12.0 Hz, 1H), 2.75 (dd, J = 14.0, 2.8 Hz, 1H), 2.24 (dt, J = 14.0, 2.4 Hz, 1H), 
2.21 – 2.06 (m, 2H), 1.52 (s, 3H), 1.44 (s, 3H), 0.85 (s, 9H), 0.07 (s, 3H), 0.05 (s, 3H). 




(3 Cs), 19.0, 17.9, -4.9, -5.0. HRMS (ESI-TOF) m/z: Calcd. for C16H34O4NSi ([M + 
NH4]
+): 332.2257; found: 332.2268. 
Preparation of Ketone 163 by Reduction of Enone 161 with Stryker’s Reagent 
To a stirred solution of triphenylphosphinecopper (I) hydride hexamer (6.3 mg, 5 
mol %) in toluene (0.25 mL) at room temperature was added phenylsilane (11.8 μL, 
0.10 mmol), followed by a solution of 161 (20.0 mg, 0.06 mmol) in toluene (0.2 mL). 
After stirring at room temperature for 48 h, the reaction mixture was diluted with ethyl 
acetate, washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure. Chromatographic purification (8% ethyl acetate/hexanes) afforded 163 (6.0 
mg, 30%) as a colorless oil with spectral data identical to the above sample.  Further 




To a stirred solution of 164 (112.7 mg, 0.36 mmol) in EtOH (0.5 mL) at room 
temperature was added a suspension of Raney nickel (20.0 mg, slurry in H2O) in EtOH 
(1 mL). The reaction mixture was stirred at room temperature under a hydrogen 
atmosphere (1 atm) for 10 h before it was filtered through Celite and the filtrate 
concentrated under reduced pressure to dryness (113.3 mg). Examination of the crude 
reaction mixture by 1H NMR spectroscopy revealed a 2:1 ratio of 167 and 168. 
Chromatographic purification eluting with 17% ethyl acetate in hexanes, afforded 168 
(21.7 mg, 19%) as a white solid. Further elution with 20% ethyl acetate in hexanes 




trans-Fused alcohol 167: [α]D
21 -9.0 (c 1.35, CHCl3). 
1H NMR (400 MHz, CDCl3) 
δ 4.18 (app p, J = 2.9 Hz, 1H), 3.90 (ddd, J = 11.2, 8.6, 5.0 Hz, 1H), 3.67 (dd, J = 11.2, 
4.9 Hz, 1H), 3.58 (t, J = 11.2 Hz, 1H), 3.35 (dd, J = 10.5, 8.6 Hz, 1H), 2.12 – 1.98 (m, 
2H), 1.58 – 1.46 (m, 2H), 1.44 (s, 3H), 1.38 (s, 3H), 1.17 (td, J = 13.5, 2.9 Hz, 1H), 0.86 
(s, 9H), 0.07 (s, 3H), 0.05 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 98.9, 78.1, 68.9, 66.5, 
64.6, 41.2, 32.6, 32.5, 29.8, 25.8 (3 Cs), 19.2, 18.3, -4.3, -4.9. HRMS (ESI-TOF) m/z: 
Calcd. for C16H33O4Si ([M + H]
+): 317.2148; found: 317.2159. 
cis-Fused alcohol 168: [α]D
21 21.7 (c 0.65, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 
4.12 (dd, J = 11.7, 2.6 Hz, 1H), 4.00 (tt, J = 11.3, 4.2 Hz, 1H), 3.88 (app q, J = 3.0 Hz, 
1H), 3.75 (t, J = 3.0 Hz, 1H), 3.56 (dd, J = 11.7, 1.0 Hz, 1H), 1.98 (dd, J = 11.7, 11.3 Hz, 
1H), 1.90 – 1.80 (m, 1H), 1.75 – 1.52 (m, 3H), 1.45 (s, 3H), 1.39 (s, 3H), 0.87 (s, 9H), 
0.06 (s, 3H), 0.04 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 98.5, 70.6, 69.4, 65.9, 64.7, 
37.5, 33.4, 30.3, 29.8, 25.7 (3 Cs), 18.9, 17.9, -4.9, -5.1. HRMS (ESI-TOF) m/z: Calcd. 
for C16H32O4SiNa ([M + Na]
+): 339.1968; found: 339.1975. 
(5R,7S,10R)-5-((tert-Butyldimethylsilyl)oxy-3,3-dimethyl-2,4-dioxa-Δ1,9-octalin-7-ol 
(169) 
A solution of 164 (14.6 mg, 0.05 mmol) and Crabtree’s catalyst (0.8 mg, 2 
mmol %) in dichloromethane (0.3 mL) was stirred at 0 oC under a hydrogen 
atmosphere (1 atm) for 3 h before it was concentrated under reduced pressure. 
Chromatographic purification (12% ethyl acetate/hexanes) afforded the title compound 
as a colorless oil (169, 9.7 mg, 66%): [α]D
21 9.6 (c 0.49, CHCl3). 
1H NMR (400 MHz, 
CDCl3) δ 6.29 – 6.27 (m, 1H), 4.07 (m, 1H), 3.94 – 3.82 (m, 2H), 2.23 (d, J = 14.7 Hz, 




3H), 0.88 (s, 9H), 0.08 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 137.7, 107.0, 99.2, 74.1, 
70.7, 66.3, 40.0, 34.9, 27.8, 25.8 (3 Cs), 21.3, 18.3, -4.4, -4.9. HRMS (ESI-TOF) m/z: 
Calcd. for C16H30O4SiNa ([M + Na]
+): 337.1811; found: 337.1816. 
(1R,2R,3S,5S)-1-((tert-Butyldimethylsilyl)oxy)-2-hydroxy-3-methylcyclohexan-5-yl 
Benzoate (176). 
A solution of 173 (8.5 mg, 0.02 mmol) in EtOH (0.4 mL) was treated with 
Pd(OH)2/C (3.0 mg, 20 wt %) and stirred at room temperature under a hydrogen 
atmosphere (1 atm) for 0.5 h before it was filtered through Celite. The filtrate was 
concentrated under reduced pressure and chromatographic purification of the residue 
(3% ethyl acetate/hexanes) afforded the title compound as a colorless oil (176, 4.6 mg, 
56%): [α]D
21 19.1 (c 0.23, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 7.4 Hz, 2H), 
7.57 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 7.4 Hz, 2H), 5.34 (app p, J = 2.9 Hz, 1H), 3.88 (ddd, 
J = 11.6, 9.0, 6.0 Hz, 1H), 3.11 (t, J = 9.0 Hz, 1H), 2.22 (ddd, J = 14.1, 6.0, 2.9 Hz, 1H), 
2.05 – 1.89 (m, 2H), 1.64 (ddd, J = 14.1, 11.6, 2.9 Hz, 1H), 1.38 (ddd, J = 14.3, 12.2, 
2.9 Hz, 1H), 1.08 (d, J = 6.3 Hz, 3H), 0.89 (s, 9H), 0.09 (s, 3H), 0.06 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 165.6, 133.0, 130.5, 129.5 (2 Cs), 128.4 (2 Cs), 80.4, 72.8, 70.3, 
37.6, 36.9, 31.9, 25.8 (3 Cs), 18. 0, 17.9, -4.2, -4.7. HRMS (ESI-TOF) m/z: Calcd. for 
C20H32O4SiNa ([M + Na]
+): 387.1968; found: 387.1966. 
(1R,2R,3R,5S)-1-((tert-Butyldimethylsilyl)oxy)-2-(methoxymethyloxy)-3-
((methoxymethoxy)methyl)cyclohexan-5-ol (177). 
A solution of 175 (371.7 mg, 1.03 mmol) in EtOH (2 mL) was treated with a 
suspension of Raney nickel (40.0 mg, slurry in H2O) in EtOH (2.5 mL), and stirred at 




through Celite. The filtrate was concentrated under reduced pressure to dryness, and 
chromatographic purification (33% ethyl acetate/hexanes) of the residue afforded the 
title compound as a colorless oil (177, 343.9 mg, 92%): [α]D
21 44.0 (c 1.48, CHCl3). 
1H 
NMR (400 MHz, CDCl3) δ 4.89 (d, J = 6.7 Hz, 1H), 4.66 (d, J = 6.7 Hz, 1H), 4.62 (s, 
2H), 4.14 (m, 1H), 3.99 (ddd, J = 10.1, 7.8, 4.4 Hz, 1H), 3.69 (dd, J = 9.5, 3.6 Hz, 1H), 
3.61 (dd, J = 9.5, 6.6 Hz, 1H), 3.40 (s, 3H), 3.35 (s, 3H), 3.28 (dd, J = 9.3, 7.8 Hz, 1H), 
2.18 – 2.07 (m, 1H), 1.95 (dtd, J = 13.5, 4.4, 2.4 Hz, 1H), 1.86 (dtd, J = 14.1, 4.4, 2.4 
Hz, 1H), 1.61 (ddd, J = 14.1, 11.2, 3.0 Hz, 1H), 1.55 (ddd, J = 13.5, 10.1, 2.9 Hz, 1H), 
0.88 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 98.4, 96.7, 81.2, 
71.9, 68.5, 65.7, 56.1, 55.1, 40.6, 37.1, 34.8, 25.8 (3 Cs), 17.9, -4.7 (2 Cs). HRMS 
(ESI-TOF) m/z: Calcd. for C17H36O6SiNa ([M + Na]
+): 387.2179; found: 387.2180. 
(1R,2R,3R,5S)-1-((tert-Butyldimethylsilyl)oxy)-2-(methoxymethyloxy)-3-
((methoxymethoxy)methyl)-5-(naphthalen-2-ylmethoxy)cyclohexane (178). 
To a stirred solution of 177 (373.8 mg, 1.03 mmol) in DMF (3 mL) at 0 oC was added 
sodium hydride (102.5 mg, 60% suspension in mineral oil, 2.56 mmol). After stirring at 
0 oC for 30 min, tetrabutylammonium iodide (37.9 mg, 0.10 mmol) and 2-
(bromomethyl)naphthalene (566.7 mg, 2.56 mmol) were added. The resulting mixture 
was stirred at room temperature for 16 h. After completion, ethyl acetate was added, 
and the reaction mixture was washed with brine 3 times, dried over Na2SO4 and 
concentrated under reduced pressure. Chromatographic purification (9% ethyl 
acetate/hexanes) afforded the title compound as a colorless oil (178, 475.7 mg, 92%): 
[α]D
21 32.4 (c 0.33, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.84 – 7.76 (m, 4H), 7.50 – 




2H), 4.04 (ddd, J = 10.9, 8.1, 4.4 Hz, 1H), 3.81 (app p, J = 3.2 Hz, 1H), 3.69 (dd, J = 
9.5, 3.3 Hz, 1H), 3.64 (dd, J = 9.5, 5.8 Hz, 1H), 3.42 (s, 3H), 3.35 (s, 3H), 3.31 (dd, J = 
9.8, 8.2 Hz, 1H), 2.24 – 2.04 (m, 3H), 1.57 – 1.42 (m, 2H), 0.89 (s, 9H), 0.10 (s, 3H), 
0.09 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 136.4, 133.3, 132.9, 128.0, 127.8, 127.7, 
126.0, 125.8, 125.7, 125.5, 98.7, 96.7, 81.7, 72.5, 72.4, 70.0, 68.6, 56.2, 55.1, 38.0, 
37.3, 31.9, 25.8 (3 Cs), 17.9, -4.59, -4.62. HRMS (ESI-TOF) m/z: Calcd. for 
C28H44O6SiNa ([M + Na]
+): 527.2805; found: 527.2806. 
(1R,2R,3R,5S)-2-(Methoxymethoxy)-3-((methoxymethoxy)methyl)-5-(naphthalen-
2-ylmethoxy)cyclohexan-1-ol (179). 
A mixture of 178 (475.7 mg, 0.94 mmol) and tetrabutylammonium fluoride (1.0 M in 
THF, 1.1 mL, 1.13 mmol) in THF (2 mL) was heated to reflux for 2 h. After cooling to 
room temperature, the reaction was concentration under reduced pressure. 
Chromatographic purification (40% ethyl acetate/hexanes) afforded the title compound 
as a colorless oil (179, 301.4 mg, 82%): [α]D
21 -29.7 (c 0.39, CHCl3). 
1H NMR (400 MHz, 
CDCl3) δ 7.85 – 7.75 (m, 4H), 7.50 – 7.42 (m, 3H), 4.80 (d, J = 6.7 Hz, 1H), 4.73 – 4.63 
(m, 3H), 4.63 – 4.58 (m, 2H), 4.37 (s, 1H), 3.96 – 3.82 (m, 2H), 3.72 (dd, J = 9.4, 4.7 Hz, 
1H), 3.53 (dd, J = 9.4, 2.7 Hz, 1H), 3.47 (s, 3H), 3.35 (s, 3H), 3.24 (dd, J = 10.5, 8.6 Hz, 
1H), 2.44 (ddt, J = 13.8, 5.6, 3.1 Hz, 1H), 2.21 – 2.11 (m, 1H), 2.06 (dq, J = 14.2, 3.3 
Hz, 1H), 1.53 (td, J = 14.0, 2.6 Hz, 1H), 1.39 (ddd, J = 14.1, 11.7, 2.6 Hz, 1H). 13C NMR 
(101 MHz, CDCl3) δ 136.2, 133.3, 132.9, 128.1, 127.8, 127.7, 126.04, 125.97, 125.7, 
125.6, 98.5, 96.7, 87.5, 72.5, 70.0, 69.3, 68.0, 55.8, 55.2, 36.6, 35.8, 32.0. HRMS (ESI-
TOF) m/z: Calcd. for C22H30O6Na ([M + Na]






A mixture of 179 (281.4 mg, 0.72 mmol), Dess-Martin periodinane (1.22 g, 2.88 mmol) 
and sodium bicarbonate (484.3 mg, 5.77 mmol) in DCM (5 mL) was stirred at room 
temperature for 12 h before it was filtered through a pad of Celite. The filtrate was 
concentrated under reduced pressure. Chromatographic purification (33% ethyl 
acetate/hexanes) afforded the title compound as a colorless oil (180, 253.3 mg, 91%): 
[α]D
21 71.0 (c 0.31, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.84 – 7.70 (m, 4H), 7.50 – 
7.40 (m, 3H), 4.79 (d, J = 6.9 Hz, 1H), 4.74 – 4.69 (m, 2H), 4.64 (s, 2H), 4.60 (d, J = 
12.1 Hz, 1H), 4.26 (d, J = 11.1 Hz, 1H), 4.13 (app p, J = 3.2 Hz, 1H), 3.77 (dd, J = 9.5, 
4.3 Hz, 1H), 3.62 (dd, J = 9.5, 2.7 Hz, 1H), 3.44 (s, 3H), 3.37 (s, 3H), 2.85 (dt, J = 13.9, 
3.1 Hz, 1H), 2.56 – 2.46 (m, 2H), 2.23 (dq, J = 14.3, 3.4 Hz, 1H), 2.01 (ddd, J = 14.7, 
12.7, 2.5 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 206.9, 135.4, 133.2, 132.9, 128.2, 
127.8, 127.7, 126.2, 126.1, 125.9, 125.7, 96.8, 96.5, 79.5, 74.2, 70.0, 67.6, 56.2, 55.4, 





To a stirred solution of 180 (253.3 mg, 0.65 mmol) in THF (3 mL) at -78 oC was added 
a solution of L-Selectride in THF (1.0 M, 1.96 mL, 1.96 mmol). The reaction mixture 
was stirred at the same temperature for 5.5 h before it was quenched by adding 
methanol. After warming to room temperature, the volatile was removed by 




acetate/hexanes) afforded the title compound as a colorless oil (181, 241.2 mg, 95%): 
[α]D
21 23.0 (c 0.27, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.73 (m, 4H), 7.51 – 
7.42 (m, 3H), 4.80 (d, J = 6.8 Hz, 1H), 4.77 – 4.70 (m, 2H), 4.67 (dd, J = 11.9, 0.8 Hz, 
1H), 4.61 (s, 2H), 4.13 (app q, J = 3.4 Hz, 1H), 3.88 (app p, J = 3.3 Hz, 1H), 3.69 (dd, J 
= 9.4, 5.3 Hz, 1H), 3.62 (dd, J = 9.4, 3.3 Hz, 1H), 3.51 (dd, J = 10.3, 2.7 Hz, 1H), 3.43 
(s, 3H), 3.34 (s, 3H), 2.46 – 2.35 (m, 1H), 2.30 (dq, J = 14.6, 3.6 Hz, 1H), 2.20 (dq, J = 
14.3, 3.6 Hz, 1H), 1.66 (dt, J = 14.6, 3.0 Hz, 1H), 1.56 (ddd, J = 14.4, 11.8, 2.8 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 135.2, 133.2, 133.0, 128.3, 127.8, 127.7, 126.3, 126.2, 
126.0, 125.6, 96.7, 96.1, 78.4, 73.8, 70.8, 68.7, 68.4, 55.6, 55.2, 34.3, 32.8, 31.4. 
HRMS (ESI-TOF) m/z: Calcd. for C22H30O6Na ([M + Na]
+): 413.1940; found: 413.1956. 
(1S,2R,3R,5S)-2-(Methoxymethoxy)-3-((methoxymethoxy)methyl)-5-(naphthalen-2-
ylmethoxy)cyclohexyl Methanesulfonate (182). 
To a stirred solution of 181 (242.3 mg, 0.62 mmol) in pyridine (2 mL) at room 
temperature was added methanesulfonyl chloride (0.24 mL, 3.10 mmol). The reaction 
mixture was stirred at the same temperature for 24 h before it was diluted with ethyl 
acetate, washed with 1 N HCl and brine, dried over Na2SO4, and concentrated under 
reduced pressure. Chromatographic purification (33% ethyl acetate/hexanes) afforded 
the title compound as a colorless oil (182, 245.3 mg, 84%): [α]D
21 9.9 (c 1.22, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.86 – 7.78 (m, 4H), 7.47 (ddd, J = 9.3, 5.9, 1.7 Hz, 3H), 
5.10 (dt, J = 6.2, 3.1 Hz, 1H), 4.78 (d, J = 6.9 Hz, 1H), 4.76 – 4.69 (m, 2H), 4.66 (d, J = 
11.9 Hz, 1H), 4.59 (s, 2H), 3.83 – 3.75 (m, 2H), 3.64 (dd, J = 9.6, 4.9 Hz, 1H), 3.54 (dd, 
J = 9.6, 4.1 Hz, 1H), 3.44 (s, 3H), 3.32 (s, 3H), 2.98 (s, 3H), 2.56 – 2.42 (m, 2H), 2.14 – 




1H). 13C NMR (101 MHz, CDCl3) δ 136.0, 133.3, 132.9, 128.1, 127.8, 127.7, 126.2, 
126.1, 125.8, 125.7, 96.6, 96.2, 77.7, 75.2, 71.4, 70.2, 68.0, 56.0, 55.3, 39.0, 34.5, 32.7, 
31.4. HRMS (ESI-TOF) m/z: Calcd. for C23H32O8SNa ([M + Na]
+): 491.1716; found: 
491.1718. 
S-((1R,2R,3R,5S)-2-(Methoxymethoxy)-3-((methoxymethoxy)methyl)-5-
(naphthalen-2-ylmethoxy)cyclohexyl) Thioacetate (183) and (1S,2R,4S)-1-
(Methoxymethoxy)-2-((methoxymethoxy)methyl)-4-(naphthalen-2-
ylmethoxy)cyclohex-5-ene (184). 
A mixture of 182 (68.9 mg, 0.15 mmol) and cesium thioacetate (611.7 mg, 2.94 mmol) 
in DMF (0.6 mL) was heated to 100 oC by irridation with microwave for 1 h. After 
cooling to room temperature, the reaction mixture was diluted with ethyl acetate, 
washed with water and brine, dried over Na2SO4, and concentrated under reduced 
pressure. Chromatographic purification (14% ethyl acetate/hexanes) afforded 183 as a 
light yellow oil (28.4 mg, 43%): [α]D
21 0.7 (c 0.55, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 
7.88 – 7.78 (m, 4H), 7.57 – 7.41 (m, 3H), 4.84 (d, J = 11.9 Hz, 1H), 4.74 – 4.69 (m, 2H), 
4.66 – 4.57 (m, 3H), 3.96 (ddd, J = 12.6, 10.5, 4.0 Hz, 1H), 3.76 (app p, J = 3.0 Hz, 1H), 
3.69 (dd, J = 9.6, 4.5 Hz, 1H), 3.53 (dd, J = 9.6, 2.9 Hz, 1H), 3.48 (t, J = 10.3 Hz, 1H), 
3.43 (s, 3H), 3.34 (s, 3H), 2.46 (dq, J = 14.1, 3.5 Hz, 1H), 2.35 (s, 3H), 2.31 – 2.21 (m, 
1H), 2.05 (dq, J = 14.1, 3.4 Hz, 1H), 1.68 – 1.56 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
195.1, 136.1, 133.3, 132.9, 128.1, 127.9, 127.7, 126.3, 126.0, 125.9, 125.7, 98.3, 96.7, 
79.0, 71.8, 69.9, 68.2, 56.5, 55.3, 44.4, 39.3, 35.8, 32.8, 30.9. HRMS (ESI-TOF) m/z: 
Calcd. for C24H32O6SNa ([M + Na]




184 (25.7 mg, 47%) was also obtained from the same reaction as a light yellow oil (11% 
ethyl acetate/hexanes): [α]D
21 -37.2 (c 0.95, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.86 
– 7.76 (m, 4H), 7.52 – 7.41 (m, 3H), 6.03 – 5.88 (m, 2H), 4.80 – 4.68 (m, 4H), 4.62 (s, 
2H), 4.02 (d, J = 8.4 Hz, 1H), 3.96 (app q, J = 4.0 Hz, 1H), 3.64 (dd, J = 9.5, 5.4 Hz, 
1H), 3.58 (dd, J = 9.5, 4.1 Hz, 1H), 3.42 (s, 3H), 3.34 (s, 3H), 2.30 – 2.19 (m, 1H), 2.11 
(dt, J = 13.4, 3.1 Hz, 1H), 1.73 (ddd, J = 14.1, 11.5, 4.4 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 136.3, 133.3, 132.9, 132.4, 128.3, 128.1, 127.8, 127.7, 126.2, 126.0, 125.8, 
125.7, 96.7, 96.2, 73. 8, 70.7, 69.9, 68.4, 55.6, 55.2, 36.2, 29.3. HRMS (ESI-TOF) m/z: 
Calcd. for C22H28O5Na ([M + Na]
+): 395.1834; found: 395.1839. 
(5S)-5-((Methoxymethoxy)methyl)cyclohex-2-en-1-one (197). 
A stirred solution of enone 196258 (1.0 g, 7.93 mmol) in N,N-diisopropylethylamine (2 
mL) and DCM (2 mL) at 0 oC was treated with chloromethyl methyl ether (1.2 mL, 15.85 
mmol), and stirred at room temperature for 6 h before it was diluted with ethyl acetate, 
washed with 1 N HCl and brine, dried over Na2SO4, and concentrated under reduced 
pressure. Chromatographic purification (33% ethyl acetate/hexanes) afforded the title 
compound as a colorless oil (197, 1.27 g, 94%): [α]D
21 73.0 (c 1.15, CHCl3). 
1H NMR 
(400 MHz, CDCl3) δ 6.96 (ddd, J = 10.1, 5.4, 2.7 Hz, 1H), 6.06 – 5.95 (m, 1H), 4.60 (s, 
2H), 3.52 – 3.41 (m, 2H), 3.33 (s, 3H), 2.55 – 2.18 (m, 5H). 13C NMR (101 MHz, CDCl3) 
δ 199.1, 149.3, 129.7, 96.5, 70.6, 55.2, 41.0, 35.5, 28.9. HRMS (ESI-TOF) m/z: Calcd. 
for C9H14O3Na ([M + Na]






(3R,5R)-3-(Ethylthio)-5-((methoxymethoxy)methyl)cyclohexan-1-one (198) and 
(3S,5R)-3-(Ethylthio)-5-((methoxymethoxy)methyl)cyclohexan-1-one (199). 
To a stirred solution of 197 (300 mg, 1.76 mmol) in MeOH (3.5 mL) at room 
temperature was added sodium ethanethiolate (444.8 mg, 5.29 mmol). The reaction 
mixture was stirred at the same temperature for 25 min before it was diluted with ethyl 
acetate, washed with brine, dried over Na2SO4, and concentrated under reduced 
pressure. Chromatographic purification (18% ethyl acetate/hexanes) afforded the title 
compound as a colorless oil (198, 265.2 mg, 56%): [α]D
21 58.6 (c 0.63, CHCl3). 
1H NMR 
(400 MHz, CDCl3) δ 4.59 (s, 2H), 3.49 – 3.39 (m, 2H), 3.33 (s, 3H), 2.93 (tt, J = 12.7, 
4.0 Hz, 1H), 2.68 (ddt, J = 14.1, 4.2, 2.0 Hz, 1H), 2.58 (q, J = 7.4 Hz, 2H), 2.42 (ddt, J = 
13.9, 3.9, 2.0 Hz, 1H), 2.33 – 2.21 (m, 2H), 2.16 (t, J = 13.4 Hz, 1H), 2.10 – 1.98 (m, 
1H), 1.51 (app q, J = 12.3 Hz, 1H), 1.24 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 208.2, 96.5, 71.3, 55.3, 48.2, 44.0, 40.9, 37.8, 35.8, 24.4, 14.9. HRMS (ESI-TOF) m/z: 
Calcd. for C11H20O3SNa ([M + Na]
+): 255.1031; found: 255.1036. 
Further elution (25% ethyl acetate/hexanes) gave 199 as a colorless oil (147.8 mg, 
31%): [α]D
21 -22.9 (c 0.89, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 4.59 (s, 2H), 3.52 – 
3.41 (m, 3H), 3.34 (s, 3H), 2.68 (ddd, J = 14.7, 4.7, 0.9 Hz, 1H), 2.59 – 2.42 (m, 5H), 
2.23 (ddd, J = 14.3, 9.7, 1.2 Hz, 1H), 2.03 – 1.98 (m, 2H), 1.24 (t, J = 7.4 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 208.3, 96.5, 70.9, 55.3, 46.5, 43.9, 40.1, 34.3, 33.1, 24.7, 
14.5. HRMS (ESI-TOF) m/z: Calcd. for C11H20O3SNa ([M + Na]








To a stirred solution of 198 (252.6 mg, 1.09 mmol) in THF (3 mL) at -78 oC was added 
a solution of L-Selectride in THF (1.0 M, 3.26 mL, 3.26 mmol). The reaction mixture 
was stirred at the same temperature for 5 h before it was warmed to room temperature. 
The reaction was quenched by adding MeOH and the mixture was concentrated under 
reduced pressure. Chromatographic purification (33% ethyl acetate/hexanes) afforded 
the title compound as a colorless oil (200, 188.6 mg, 74%): [α]D
21 -12.5 (c 1.06, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 4.59 (s, 2H), 4.23 (app p, J = 3.0 Hz, 1H), 3.40 – 3.34 (m, 
2H), 3.34 (s, 3H), 3.07 (tt, J = 12.5, 3.6 Hz, 1H), 2.58 (q, J = 7.4 Hz, 2H), 2.18 – 2.05 
(m, 3H), 1.82 (ddt, J = 13.8, 3.4, 1.3 Hz, 1H), 1.44 (td, J = 13.2, 2.7 Hz, 1H), 1.29 – 
1.19 (m, 4H), 1.05 (q, J = 12.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 96.5, 72.6, 66.7, 
55.1, 39.9, 37.1, 36.8, 35.6, 32.2, 24.0, 15.1. HRMS (ESI-TOF) m/z: Calcd. for 
C11H22O3SNa ([M + Na]
+): 257.1187; found: 257.1189. 
(1R,3R,5R)-3-(Ethylthio)-5-((methoxymethoxy)methyl)cyclohexyl 
Methanesulfonate (201). 
To a stirred solution of 200 (167.4 mg, 0.71 mmol) in pyridine (2 mL) at room 
temperature was added methanesulfonyl chloride (0.28 mL, 3.57 mmol). The reaction 
mixture was stirred at the same temperature for 11 h before it was diluted with ethyl 
acetate, washed with 1 N HCl and brine, dried over Na2SO4, and concentrated under 
reduced pressure. Chromatographic purification (25% ethyl acetate/hexanes) afforded 
the title compound as a colorless oil (201, 204.4 mg, 92%): [α]D
21 -1.3 (c 1.19, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 5.11 (app p, J = 2.9 Hz, 1H), 4.58 (s, 2H), 3.37 (d, J = 5.4 




3.7, 2.0 Hz, 1H), 2.17 – 2.03 (m, 3H), 1.52 (ddd, J = 14.8, 12.6, 2.5 Hz, 1H), 1.35 (t, J = 
13.7 Hz, 1H), 1.24 (t, J = 7.4 Hz, 3H), 1.12 (app q, J = 13.3, 12.9 Hz, 1H). 13C NMR 
(101 MHz, CDCl3) δ 96.5, 78.7, 71.8, 55.2, 38.6, 38.2, 36.6, 36.1, 33.7, 32.5, 24.1, 15.0. 
HRMS (ESI-TOF) m/z: Calcd. for C12H24O5S2Na ([M + Na]




A mixture of 201 (60.0 mg, 0.19 mmol) and cesium thioacetate (798.9 mg, 3.84 mmol) 
in DMF (0.6 mL) was heated to 100 oC by irridation with microwave for 1 h. After 
cooling to room temperature, the reaction mixture was diluted with ethyl acetate, 
washed with brine, dried over Na2SO4, and concentrated under reduced pressure. 
Chromatographic purification (6% ethyl acetate/hexanes) afforded the title compound 
as a light yellow oil (202, 23.0 mg, 41%): [α]D
21 -24.3 (c 0.68, CHCl3). 
1H NMR (400 
MHz, CDCl3) δ 4.58 (s, 2H), 3.44 (tt, J = 12.7, 3.9 Hz, 1H), 3.36 (d, J = 6.1 Hz, 2H), 
3.34 (s, 3H), 2.75 (tt, J = 12.2, 3.7 Hz, 1H), 2.58 (q, J = 7.4 Hz, 2H), 2.32 – 2.24 (m, 
4H), 2.09 (ddq, J = 11.1, 3.5, 1.7 Hz, 1H), 2.02 (ddq, J = 12.7, 3.7, 1.9 Hz, 1H), 1.90 – 
1.77 (m, 1H), 1.32 (q, J = 12.4 Hz, 1H), 1.24 (t, J = 7.4 Hz, 3H), 1.10 (q, J = 12.5 Hz, 
1H), 1.03 (q, J = 12.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 195.4, 96.5, 72.0, 55.2, 
41.5, 40.9, 39.9, 38.5, 36.0, 35.4, 30.7, 24.2, 15.0. HRMS (ESI-TOF) m/z: Calcd. for 
C13H24O3S2Na ([M + Na]








5-((methoxymethoxy)methyl)cyclohexan-1-one (203) and (3S,5R)-3-(((1S,3R,5S)-3-
(Ethylthio)-5-((methoxymethoxy)methyl)cyclohexyl)thio)-5-
((methoxymethoxy)methyl)cyclohexan-1-one (204). 
To a stirred solution of 202 (378.6 mg, 1.29 mmol) in MeOH (2 mL) at room 
temperature was added sodium methoxide (139.9 mg, 2.59 mmol). After stirring at 
room temperature for 30 min, the reaction mixture was diluted with ethyl acetate, 
washed with 1 N HCl and brine, dried over Na2SO4, and concentrated under reduced 
pressure to give the free thiol (328.2 mg). To a solution of the free thiol and enone 197 
(330.5 mg, 1.94 mmol) in 2,2,2-trifluoroethanol (3 mL) at room temperature was added 
a solution of DBU (197.1 mg, 1.29 mmol) in  2,2,2-trifluoroethanol (0.5 mL). After 
stirring at room temperature for 30 min, the reaction mixture was concentrated under 
reduced pressure at 40 oC. Chromatographic purification (33% ethyl acetate/hexanes) 
afforded the title compound as a colorless oil (203, 300.0 mg, 55%):  [α]D
21 19.6 (c 0.25, 
CHCl3). 
1H NMR (600 MHz, CDCl3) δ 4.59 (s, 2H), 4.58 (s, 2H), 3.47 – 3.41 (m, 2H), 
3.37 – 3.33 (m, 5H), 3.33 (s, 3H), 3.01 (tt, J = 12.6, 4.0 Hz, 1H), 2.74 (tt, J = 12.2, 3.7 
Hz, 1H), 2.70 – 2.61 (m, 2H), 2.57 (q, J = 7.4 Hz, 2H), 2.42 (ddt, J = 14.0, 4.0, 1.9 Hz, 
1H), 2.29 (t, J = 13.6 Hz, 1H), 2.26 – 2.18 (m, 2H), 2.16 (t, J = 13.6 Hz, 1H), 2.10 – 
2.01 (m, 3H), 1.76 – 1.68 (m, 1H), 1.51 (app q, J = 12.5 Hz, 1H), 1.29 (app q, J = 12.4 
Hz, 1H), 1.23 (t, J = 7.4 Hz, 3H), 1.07 – 0.98 (m, 2H). 13C NMR (151 MHz, CDCl3) δ 
208.0, 96.5 (2 Cs), 72.1, 71.2, 55.3, 55.2, 48.9, 44.0, 41.6, 41.1, 40.9, 39.8, 38.5, 37.8, 
36.8, 36.3 (2 Cs), 24.0, 15.0. HRMS (ESI-TOF) m/z: Calcd. for C20H36O5S2Na ([M + 




Further elution (40% ethyl acetate/hexanes) gave 204 as a colorless oil (177.2 mg, 
33%): [α]D
21 -28.6 (c 0.21, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 4.59 (s, 2H), 4.58 (s, 
2H), 3.57 (app p, J = 5.1 Hz, 1H), 3.48 – 3.42 (m, 2H), 3.36 – 3.33 (m, 5H), 3.33 (s, 3H), 
2.71 – 2.60 (m, 3H), 2.57 (q, J = 7.4 Hz, 2H), 2.55 – 2.49 (m, 1H), 2.45 (m, 2H), 2.28 – 
2.19 (m, 2H), 2.09 (ddt, J = 12.8, 3.6, 1.9 Hz, 1H), 2.06 – 1.94 (m, 3H), 1.78 – 1.68 (m, 
1H), 1.29 (app q, J = 12.3 Hz, 1H), 1.23 (t, J = 7.4 Hz, 3H), 1.08 – 0.98 (m, 2H). 13C 
NMR (151 MHz, CDCl3) δ 208.2, 96.51, 96.49, 72.1, 70.9, 55.3, 55.2, 47.1, 43.8, 41.6, 
41.1, 40.8, 38.9, 38.5, 36.4, 36.3, 34.4, 33.7, 24.0, 15.0. HRMS (ESI-TOF) m/z: Calcd. 
for C20H36O5S2Na ([M + Na]




To a stirred solution of 203 (20.0 mg, 0.05 mmol) in MeOH (0.3 mL) at room 
temperature was added sodium borohydride (5.4 mg, 0.14 mmol). The reaction mixture 
was stirred at room temperature for 20 min before it was diluted with ethyl acetate, 
washed with 1 N HCl and brine, dried over Na2SO4, and concentrated under reduced 
pressure. Chromatographic purification (50% ethyl acetate/hexanes) afforded the title 
compound as a colorless oil (205, 15.7 mg, 78%): [α]D
21 -17.8 (c 0.32, CHCl3). 
1H NMR 
(600 MHz, CDCl3) δ 4.60 (s, 2H), 4.59 (s, 2H), 3.65 (tt, J = 10.9, 4.3 Hz, 1H), 3.41 – 
3.37 (m, 2H), 3.37 – 3.35 (m, 2H), 3.34 (s, 3H), 3.33 (s, 3H), 2.79 – 2.71 (m, 2H), 2.66 
(tt, J = 12.2, 3.7 Hz, 1H), 2.58 (q, J = 7.4 Hz, 2H), 2.30 – 2.23 (m, 2H), 2.12 – 1.99 (m, 
4H), 1.77 – 1.68 (m, 2H), 1.52 (d, J = 4.8 Hz, 1H), 1.30 (app q, J = 12.3 Hz, 1H), 1.26 – 




72.1, 69.6, 55.2 (2 Cs), 43.1, 41.7, 41.1, 40.7, 38.6, 38.5, 38.4, 36.9, 36.7, 36.4 (2 Cs), 





A mixture of alcohol 205 (22.6 mg, 0.05 mmol), MeOH (1 mL) and concentrated HCl 
(10 µL) was heated to 60 oC for 6 h. After cooling to room temperature, the reaction 
mixture was concentrated under reduced pressure. Chromatographic purification (9% 
methanol/dichloromethane) afforded the title compound as a colorless oil (206, 15.5 mg, 
87%): [α]D
21 -16.4 (c 0.14, CH3OH). 
1H NMR (600 MHz, CD3OD) δ 3.58 (tt, J = 11.1, 4.2 
Hz, 1H), 3.44 – 3.35 (m, 4H), 2.84 – 2.74 (m, 2H), 2.70 (tt, J = 12.1, 3.6 Hz, 1H), 2.57 
(q, J = 7.4 Hz, 2H), 2.26 (dtd, J = 14.4, 3.6, 1.7 Hz, 1H), 2.23 – 2.18 (m, 1H), 2.08 – 
1.99 (m, 3H), 1.99 – 1.93 (m, 1H), 1.66 – 1.54 (m, 2H), 1.22 (t, J = 7.4 Hz, 3H), 1.20 – 
1.10 (m, 2H), 0.96 – 0.83 (m, 4H). 13C NMR (151 MHz, CD3OD) δ 68.9, 66.33, 66.31, 
42.9, 41.4 (2 Cs), 40.6, 40.5, 38.6, 38.5, 37.5, 36.6, 36.6, 36.0, 23.4, 14.0. HRMS (ESI-
TOF) m/z: Calcd. for C16H30O3S2Na ([M + Na]




To a stirred solution of 203 (277.7 mg, 0.66 mmol) in THF (3 mL) at -78 oC was added 
a solution of L-Selectride in THF (1.0 M, 1.98 mL, 1.98 mmol). The reaction mixture 
was stirred at the same temperature for 4 h before it was warmed to room temperature. 




reduced pressure. Chromatographic purification (15% acetone/hexanes) afforded the 
title compound as a colorless oil (207, 228.1 mg, 82%): [α]D
21 -22.2 (c 0.36, CHCl3). 
1H 
NMR (600 MHz, CDCl3) δ 4.58 (s, 2H), 4.57 (s, 2H), 4.22 (app p, J = 2.9 Hz, 1H), 3.38 
– 3.30 (m, 10H), 3.15 (tt, J = 12.4, 3.7 Hz, 1H), 2.74 (tt, J = 12.1, 3.7 Hz, 1H), 2.65 (tt, J 
= 12.1, 3.6 Hz, 1H), 2.57 (q, J = 7.5 Hz, 2H), 2.30 (dtd, J = 14.6, 3.6, 1.7 Hz, 1H), 2.17 
– 2.01 (m, 5H), 1.80 (dtt, J = 13.9, 3.7, 2.1 Hz, 1H), 1.77 – 1.68 (m, 1H), 1.42 (td, J = 
13.3, 2.7 Hz, 1H), 1.28 (app q, J = 12.5 Hz, 1H), 1.25 – 1.20 (m, 4H), 1.09 – 0.98 (m, 
3H). 13C NMR (151 MHz, CDCl3) δ 96.50, 96.47, 72.5, 72.2, 66.7, 55.2, 55.1, 41.7, 41.3, 
40.7, 40.5, 38.6, 37.7, 36.9, 36.4, 36.0, 35.6, 32.2, 24.0, 15.0. HRMS (ESI-TOF) m/z: 
Calcd. for C20H38O5S2Na ([M + Na]
+): 445.2058; found: 445.2066. 
(1R,3R,5R)-3-(((1S,3R,5S)-3-(Ethylthio)-5-
((methoxymethoxy)methyl)cyclohexyl)thio)-5-
((methoxymethoxy)methyl)cyclohexyl Methanesulfonate (208). 
To a stirred solution of 207 (88.4 mg, 0.21 mmol) in pyridine (2 mL) at room 
temperature was added methanesulfonyl chloride (80.9 µL, 1.05 mmol). The reaction 
mixture was stirred at the same temperature for 20 h before it was diluted with ethyl 
acetate, washed with 1 N HCl and brine, dried over Na2SO4, and concentrated under 
reduced pressure. Chromatographic purification (40% ethyl acetate/hexanes) afforded 
the title compound as a colorless oil (208, 95.9 mg, 92%): [α]D
21 -11.6 (c 0.56, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 5.08 (app p, J = 3.0 Hz, 1H), 4.57 (s, 2H), 4.56 (s, 2H), 
3.37 – 3.33 (m, 4H), 3.32 (s, 3H), 3.31 (s, 3H), 3.07 (tt, J = 12.4, 3.7 Hz, 1H), 3.01 (s, 
3H), 2.74 (tt, J = 12.2, 3.7 Hz, 1H), 2.65 (tt, J = 12.2, 3.6 Hz, 1H), 2.57 (q, J = 7.4 Hz, 




2.02 (m, 5H), 1.77 – 1.68 (m, 1H), 1.51 (ddd, J = 14.8, 12.6, 2.5 Hz, 1H), 1.37 – 1.25 
(m, 2H), 1.23 (t, J = 7.4 Hz, 3H), 1.12 (app q, J = 12.9 Hz, 1H), 1.06 – 0.98 (m, 2H). 13C 
NMR (151 MHz, CDCl3) δ 96.5 (2 Cs), 78.6, 72.1, 71.8, 55.20, 55.17, 41.6, 41.1, 41.0, 
38.8, 38.7, 38.5, 36.9, 36.8, 36.3, 35.7, 33.6, 32.5, 24.0, 15.0. HRMS (ESI-TOF) m/z: 
Calcd. for C21H40O7S3Na ([M + Na]
+): 523.1834; found: 523.1841. 
S-((1S,3R,5S)-3-(((1S,3R,5S)-3-(Ethylthio)-5-
((methoxymethoxy)methyl)cyclohexyl)thio)-5-
((methoxymethoxy)methyl)cyclohexyl) Thioacetate (209). 
A mixture of 208 (10.0 mg, 0.02 mmol) and cesium thioacetate (12.5 mg, 0.06 mmol) in 
DMF (0.05 mL) was heated to 100 oC by irridation with microwave for 50 min. After 
cooling to room temperature, the reaction mixture was diluted with ethyl acetate, 
washed with brine, dried over Na2SO4, and concentrated under reduced pressure. 
Chromatographic purification (14% ethyl acetate/hexanes) afforded the title compound 
as a light yellow oil (209, 4.5 mg, 47%): [α]D
21 -16.7 (c 0.18, CHCl3). 
1H NMR (600 MHz, 
CDCl3) δ 4.59 (s, 2H), 4.57 (s, 2H), 3.42 (tt, J = 12.6, 3.9 Hz, 1H), 3.37 – 3.33 (m, 7H), 
3.32 (s, 3H), 2.81 (tt, J = 12.1, 3.8 Hz, 1H), 2.72 (tt, J = 12.2, 3.7 Hz, 1H), 2.66 (tt, J = 
12.2, 3.6 Hz, 1H), 2.57 (q, J = 7.4 Hz, 2H), 2.29 (s, 3H), 2.27 – 2.20 (m, 2H), 2.11 – 
1.97 (m, 4H), 1.88 – 1.78 (m, 1H), 1.77 – 1.69 (m, 1H), 1.36 – 1.26 (m, 2H), 1.24 (t, J = 
7.4 Hz, 3H), 1.12 – 0.97 (m, 4H). 13C NMR (151 MHz, CDCl3) δ 195.3, 96.52 (2 Cs), 
96.50, 72.2, 72.0, 55.2, 41.7, 41.1, 40.9, 40.8, 40.6, 40.5, 38.5 (2 Cs), 37.0, 36.6, 36.3, 
35.4, 30.7, 24.0, 15.0. HRMS (ESI-TOF) m/z: Calcd. for C22H40O5S3Na ([M + Na]
+): 











To a stirred solution of 209 (24.6 mg, 0.05 mmol) in MeOH (0.6 mL) at room 
temperature was added sodium methoxide (5.5 mg, 0.10 mmol). After stirring at room 
temperature for 25 min, the reaction mixture was diluted with ethyl acetate, washed 
with 1 N HCl and brine, dried over Na2SO4, and concentrated under reduced pressure 
to give the free thiol (21.8 mg). To a solution of the free thiol and enone 197 (10.5 mg, 
0.06 mmol) in 2,2,2-trifluoroethanol (0.6 mL) was added a solution of DBU (7.8 mg, 
0.05 mmol) in  2,2,2-trifluoroethanol (0.1 mL). After stirring at room temperature for 30 
min, the reaction mixture was concentrated under reduced pressure at 40 oC. 
Chromatographic purification (40% ethyl acetate/hexanes) afforded the title compound 
as a colorless oil (210, 15.4 mg, 49%): [α]D
21 13.6 (c 0.39, CHCl3). 
1H NMR (600 MHz, 
CDCl3) δ 4.59 (s, 2H), 4.58 (s, 2H), 4.57 (s, 2H), 3.48 – 3.41 (m, 2H), 3.38 – 3.29 (m, 
13H), 3.01 (tt, J = 12.6, 4.1 Hz, 1H), 2.78 – 2.70 (m, 3H), 2.70 – 2.62 (m, 2H), 2.57 (q, J 
= 7.4 Hz, 2H), 2.42 (ddt, J = 14.0, 3.9, 1.9 Hz, 1H), 2.33 – 2.12 (m, 5H), 2.10 – 2.01 (m, 
5H), 1.77 – 1.67 (m, 2H), 1.52 (app q, J = 12.5 Hz, 1H), 1.33 – 1.20 (m, 5H), 1.07 – 
0.97 (m, 4H). 13C NMR (151 MHz, CDCl3) δ 208.0, 96.5 (3 Cs), 72.2, 72.0, 71.2, 55.3, 




36.94, 36.86, 36.7, 36.32, 36.28, 24.0, 15.0. HRMS (ESI-TOF) m/z: Calcd. for 
C29H52O7S3Na ([M + Na]
+): 631.2773; found: 631.2780. 
Further elution (50% ethyl acetate/hexanes) gave 211 as a colorless oil (9.4 mg, 30%): 
[α]D
21 -18.3 (c 0.30, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 4.60 – 4.56 (m, 6H), 3.57 
(app p, J = 5.1 Hz, 1H), 3.50 – 3.42 (m, 2H), 3.40 – 3.28 (m, 13H), 2.78 – 2.62 (m, 5H), 
2.57 (q, J = 7.4 Hz, 2H), 2.55 – 2.48 (m, 1H), 2.48 – 2.41 (m, 2H), 2.29 – 2.17 (m, 3H), 
2.11 – 1.92 (m, 6H), 1.78 – 1.67 (m, 2H), 1.32 – 1.20 (m, 5H), 1.07 – 0.97 (m, 4H). 13C 
NMR (151 MHz, CDCl3) δ 208.2, 96.53, 96.52, 96.49, 72.2, 72.0, 70.9, 55.3, 55.2 (2 
Cs), 47.1, 43.8, 41.6, 41.2, 41.13, 41.09, 40.6, 40.5, 39.0, 38.53, 38.49, 37.0, 36.9, 
36.33, 36.26, 34.4, 33.7, 24.0, 15.0. HRMS (ESI-TOF) m/z: Calcd. for C29H52O7S3Na 





To a stirred solution of 210 (5.7 mg, 0.009 mmol) in MeOH (0.1 mL) at room 
temperature was added sodium borohydride (1.1 mg, 0.03 mmol). The reaction mixture 
was stirred at room temperature for 20 min before it was diluted with ethyl acetate, 
washed with 1 N HCl and brine, dried over Na2SO4, and concentrated under reduced 
pressure. Chromatographic purification (20% acetone/hexanes) afforded the title 
compound as a colorless oil (212, 3.5 mg, 61%): [α]D
21 -11.4 (c 0.14, CHCl3). 
1H NMR 
(600 MHz, CDCl3) δ 4.62 – 4.55 (m, 6H), 3.65 (tt, J = 11.1, 4.2 Hz, 1H), 3.43 – 3.29 (m, 




– 2.20 (m, 3H), 2.11 – 1.97 (m, 6H), 1.78 – 1.68 (m, 3H), 1.34 – 1.20 (m, 6H), 1.08 – 
0.94 (m, 6H). 13C NMR (151 MHz, CDCl3) δ 96.54 (2 Cs), 96.51, 72.22, 72.16, 72.1, 
69.6, 55.22 (2 Cs), 55.19, 43.3, 41.70, 41.65, 41.1, 40.8, 40.6, 40.5, 38.7, 38.6, 38.5, 
38.3, 36.92, 36.89, 36.8, 36.7, 36.4, 36.3, 24.0, 15.0. HRMS (ESI-TOF) m/z: Calcd. for 
C29H54O7S3Na ([M + Na]




A mixture of alcohol 212 (5.2 mg, 0.009 mmol), MeOH (0.5 mL) and concentrated HCl 
(5 µL) was heated to 60 oC for 5 h. After cooling to room temperature, the reaction 
mixture was concentrated under reduced pressure. Chromatographic purification (9% 
methanol/dichloromethane) afforded the title compound as a colorless oil (213, 3.1 mg, 
76%): [α]D
21 -11.4 (c 0.07, CH3OH). 
1H NMR (600 MHz, CD3OD) δ 3.58 (tt, J = 10.9, 4.1 
Hz, 1H), 3.45 – 3.35 (m, 6H), 2.88 – 2.75 (m, 4H), 2.72 (tt, J = 12.1, 3.6 Hz, 1H), 2.58 
(q, J = 7.4 Hz, 2H), 2.31 – 2.23 (m, 2H), 2.20 (dtt, J = 12.1, 4.0, 2.1 Hz, 1H), 2.11 – 
1.99 (m, 5H), 1.96 (d, J = 12.1 Hz, 1H), 1.73 – 1.52 (m, 3H), 1.22 (t, J = 7.4 Hz, 3H), 
1.20 – 1.11 (m, 3H), 1.01 – 0.78 (m, 6H). 13C NMR (151 MHz, CD3OD) δ 68.9, 66.3 (3 
Cs), 42.8, 42.0, 41.44, 41.42, 40.6, 40.52, 40.51, 40.47 (2 Cs), 38.6, 38.5, 37.4, 36.64, 
36.56 (2 Cs), 36.5, 35.9, 23.4, 14.1. HRMS (ESI-TOF) m/z: Calcd. for C23H42O4S3Na 










To a stirred solution of 210 (14.9 mg, 0.02 mmol) in THF (0.3 mL) at -78 oC was added 
a solution of L-Selectride in THF (1.0 M, 73.4 µL, 0.07 mmol). The reaction mixture was 
stirred at the same temperature for 12 h before it was warmed to room temperature. 
The reaction was quenched by adding MeOH and the mixture was concentrated under 
reduced pressure. Chromatographic purification (14% acetone/hexanes) afforded the 
title compound as a colorless oil (214, 11.8 mg, 79%): [α]D
21 -18.7 (c 0.47, CHCl3). 
1H 
NMR (600 MHz, CDCl3) δ 4.59 (s, 2H), 4.58 (s, 2H), 4.57 (s, 2H), 4.22 (br s, 1H), 3.42 – 
3.28 (m, 15H), 3.14 (tt, J = 12.4, 3.7 Hz, 1H), 2.78 – 2.69 (m, 3H), 2.66 (tt, J = 12.2, 3.6 
Hz, 1H), 2.57 (q, J = 7.4 Hz, 2H), 2.31 – 2.22 (m, 2H), 2.17 – 1.99 (m, 7H), 1.80 (dtd, J 
= 14.1, 3.6, 1.8 Hz, 1H), 1.77 – 1.69 (m, 2H), 1.42 (td, J = 13.5, 2.6 Hz, 1H), 1.33 – 
1.18 (m, 6H), 1.10 – 0.94 (m, 5H). 13C NMR (151 MHz, CDCl3) δ 96.51 (2 Cs), 96.47, 
72.5, 72.21, 72.19, 66.6, 55.2 (2 Cs), 55.1, 41.9, 41.7, 41.2, 40.9, 40.7, 40.6 (2 Cs), 
38.6, 38.5, 37.8, 37.0, 36.92, 36.85, 36.3, 36.2, 35.5, 32.2, 24.0, 15.0. HRMS (ESI-TOF) 
m/z: Calcd. for C29H54O7S3Na ([M + Na]











((methoxymethoxy)methyl)cyclohexyl Methanesulfonate (215). 
To a stirred solution of 214 (10.5 mg, 0.02 mmol) in pyridine (0.25 mL) at room 
temperature was added methanesulfonyl chloride (6.7 µL, 0.09 mmol). The reaction 
mixture was stirred at the same temperature for 11 h before it was diluted with ethyl 
acetate, washed with 1 N HCl and brine, dried over Na2SO4, and concentrated under 
reduced pressure. Chromatographic purification (45% ethyl acetate/hexanes) afforded 
the title compound as a colorless oil (215, 11.4 mg, 96%): [α]D
21 -9.0 (c 0.41, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 5.09 (br s, 1H), 4.60 – 4.56 (m, 6H), 3.43 – 3.28 (m, 15H), 
3.07 (tt, J = 12.4, 3.6 Hz, 1H), 3.01 (s, 3H), 2.80 – 2.70 (m, 3H), 2.67 (tt, J = 12.2, 3.6 
Hz, 1H), 2.57 (q, J = 7.4 Hz, 2H), 2.38 (dd, J = 14.2, 3.7 Hz, 1H), 2.30 – 2.20 (m, 2H), 
2.16 – 2.00 (m, 7H), 1.79 – 1.69 (m, 2H), 1.51 (ddd, J = 14.8, 12.7, 2.5 Hz, 1H), 1.34 (t, 
J = 13.5 Hz, 1H), 1.31 – 1.25 (m, 2H), 1.23 (t, J = 7.4 Hz, 3H), 1.12 (app q, J = 12.7 Hz, 
1H), 1.07 – 0.97 (m, 4H). 13C NMR (151 MHz, CDCl3) δ 96.52, 96.51 (2 Cs), 78.6, 72.2, 
72.1, 71.8, 55.20 (2 Cs), 55.19, 41.63, 41.59, 41.1, 41.0, 40.6, 40.5, 38.9, 38.7, 38.49, 
38.47, 37.0, 36.9 (2 Cs), 36.8, 36.4, 35.7, 33.6, 32.6, 24.0, 15.0. HRMS (ESI-TOF) m/z: 
Calcd. for C30H56O9S4Na ([M + Na]










((methoxymethoxy)methyl)cyclohexyl) Thioacetate (216). 
A mixture of 215 (11.4 mg, 0.02 mmol) and cesium thioacetate (10.3 mg, 0.05 mmol) in 
DMF (0.1 mL) was heated to 100 oC by irridation with microwave for 35 min. After 
cooling to room temperature, the reaction mixture was diluted with ethyl acetate, 
washed with brine, dried over Na2SO4, and concentrated under reduced pressure. 
Chromatographic purification (22% ethyl acetate/hexanes) afforded the title compound 
as a light yellow oil (216, 4.5 mg, 41%): [α]D
21 -16.1 (c 0.18, CHCl3). 
1H NMR (600 MHz, 
CDCl3) δ 4.59 (m, 4H), 4.57 (s, 2H), 3.43 (tt, J = 12.6, 3.9 Hz, 1H), 3.39 – 3.29 (m, 15H), 
2.81 (tt, J = 12.9, 4.1 Hz, 1H), 2.77 – 2.70 (m, 3H), 2.67 (tt, J = 12.2, 4.0 Hz, 1H), 2.58 
(q, J = 7.4 Hz, 2H), 2.29 (s, 3H), 2.28 – 2.19 (m, 3H), 2.12 – 1.96 (m, 6H), 1.89 – 1.79 
(m, 1H), 1.79 – 1.69 (m, 2H), 1.36 – 1.25 (m, 3H), 1.24 (t, J = 7.4 Hz, 3H), 1.09 (app q, 
1H), 1.06 – 0.97 (m, 5H). 13C NMR (151 MHz, CDCl3) δ 195.3, 96.54 (2 Cs), 96.51, 
72.22, 72.16, 72.0, 55.21, 55.19 (2 Cs), 41.7, 41.5, 41.1, 40.83, 40.80, 40.5 (4 Cs), 
38.5 (3 Cs), 36.98, 36.96, 36.9, 36.6, 36.4, 35.3, 30.7, 24.0, 15.0. HRMS (ESI-TOF) 
m/z: Calcd. for C31H56O7S4Na ([M + Na]


















To a stirred solution of 216 (3.3 mg, 0.005 mmol) in MeOH (0.2 mL) at room 
temperature was added sodium methoxide (0.5 mg, 0. 01 mmol). After stirring at room 
temperature for 10 min, the reaction mixture was diluted with ethyl acetate, washed 
with 1 N HCl and brine, dried over Na2SO4, and concentrated under reduced pressure 
to give the free thiol (4.5 mg). To a solution of the free thiol and enone 197 (1.0 mg, 
0.006 mmol) in 2,2,2-trifluoroethanol (0.1 mL) was added a solution of DBU (750 µg, 
0.005 mmol) in  2,2,2-trifluoroethanol (10 µL). After stirring at room temperature for 30 
min, the reaction mixture was concentrated under reduced pressure at 40 oC. 
Chromatographic purification (45% ethyl acetate/hexanes) afforded the title compound 
as a colorless oil (217, 2.1 mg, 53%): [α]D
21 2.0 (c 0.15, CHCl3). 
1H NMR (600 MHz, 
CDCl3) δ 4.61 – 4.58 (m, 8H), 3.49 – 3.41 (m, 2H), 3.41 – 3.30 (m, 18H), 3.02 (tt, J = 
12.6, 4.1 Hz, 1H), 2.81 – 2.71 (m, 5H), 2.71 – 2.63 (m, 2H), 2.58 (q, J = 7.4 Hz, 2H), 




(t, J = 13.7 Hz, 1H), 2.13 – 2.00 (m, 7H), 1.79 – 1.69 (m, 3H), 1.52 (t, J = 12.5 Hz, 1H), 
1.32 – 1.22 (m, 6H), 1.09 – 0.97 (m, 6H). 13C NMR (151 MHz, CDCl3) δ 208.0, 96.6, 
96.5 (3 Cs), 72.20, 72.17, 72.0, 71.2, 55.3, 55.23 (2 Cs), 55.20, 48.9, 44.0, 41.7, 41.5, 
41.3, 41.2, 41.1, 40.6 (2 Cs), 40.54, 40.46, 39.8, 38.53, 38.49, 38.47, 37.8, 36.94 (3 
Cs), 36.88, 36.8, 36.4, 36.3, 24.0, 15.0. HRMS (ESI-TOF) m/z: Calcd. for 
C38H68O9S4Na ([M + Na]
+): 819.3644; found: 819.3643. 
Further elution (50% ethyl acetate/hexanes) gave 218 as a colorless oil (1.1 mg, 28%): 
[α]D
21 -10.9 (c 0.11, CHCl3). 
1H NMR (600 MHz, CDCl3) δ 4.62 – 4.56 (m, 8H), 3.58 
(app p, J = 4.9 Hz, 1H), 3.50 – 3.42 (m, 2H), 3.42 – 3.30 (m, 18H), 2.81 – 2.62 (m, 7H), 
2.58 (q, J = 7.4 Hz, 2H), 2.56 – 2.49 (m, 1H), 2.48 – 2.41 (m, 2H), 2.32 – 2.17 (m, 4H), 
2.13 – 1.93 (m, 8H), 1.80 – 1.69 (m, 3H), 1.34 – 1.21 (m, 6H), 1.09 – 0.96 (m, 6H). 13C 
NMR (151 MHz, CDCl3) δ 208.2, 96.6, 96.54 (2 Cs), 96.50, 72.20, 72.17, 72.1, 70.9, 
55.3, 55.23, 55.22, 55.21, 47.1, 43.8, 41.7, 41.5, 41.2, 41.14, 41.08, 40.6 (2 Cs), 40.53, 
40.46, 39.0, 38.53 (2 Cs), 38.48, 37.1, 37.0, 36.9 (2 Cs), 36.4, 36.3, 34.4, 33.7, 24.0, 
15.0. HRMS (ESI-TOF) m/z: Calcd. for C38H68O9S4Na ([M + Na]







To a stirred solution of 217 (4.9 mg, 0.006 mmol) in MeOH (0.1 mL) at room 




mixture was stirred at room temperature for 20 min before it was diluted with ethyl 
acetate, washed with 1 N HCl and brine, dried over Na2SO4, and concentrated under 
reduced pressure. Chromatographic purification (25% acetone/hexanes) afforded the 
title compound as a colorless oil (219, 2.7 mg, 54%): [α]D
21 -10.0 (c 0.11, CHCl3). 
1H 
NMR (600 MHz, CDCl3) δ 4.61 – 4.57 (m, 8H), 3.65 (tt, J = 10.9, 3.8 Hz, 1H), 3.44 – 
3.31 (m, 20H), 2.80 – 2.70 (m, 6H), 2.66 (tt, J = 12.2, 3.6 Hz, 1H), 2.58 (q, J = 7.4 Hz, 
2H), 2.32 – 2.19 (m, 4H), 2.13 – 1.98 (m, 8H), 1.79 – 1.69 (m, 4H), 1.34 – 1.20 (m, 7H), 
1.09 – 0.94 (m, 8H). 13C NMR (151 MHz, CDCl3) δ 96.6, 96.54 (2 Cs), 96.51, 72.20 (2 
Cs), 72.16, 72.1, 69.6, 55.3, 55.22, 55.20, 55.19, 43.3, 41.8, 41.7, 41.5, 41.2, 40.8, 
40.60, 40.57 (3 Cs), 40.5, 38.8, 38.6, 38.54, 38.50, 38.3, 37.0, 36.92 (2 Cs), 36.88, 
36.7, 36.37, 36.36, 24.0, 15.0. HRMS (ESI-TOF) m/z: Calcd. for C38H70O9S4Na ([M + 




A mixture of alcohol 219 (2.2 mg, 0.003 mmol), MeOH (0.3 mL) and concentrated HCl 
(3 µL) was heated to 60 oC for 6 h. After cooling to room temperature, the reaction 
mixture was concentrated under reduced pressure. Chromatographic purification (11% 
methanol/dichloromethane) afforded the title compound as a colorless oil (220, 1.3 mg, 
76%): [α]D
21 -22.5 (c 0.04, CH3OH). 
1H NMR (600 MHz, CD3OD) δ 3.62 – 3.55 (m, 1H), 
3.44 – 3.35 (m, 8H), 2.88 – 2.75 (m, 6H), 2.72 (tt, J = 12.2, 3.6 Hz, 1H), 2.58 (q, J = 7.4 
Hz, 2H), 2.30 – 2.23 (m, 3H), 2.21 (d, J = 11.9 Hz, 1H), 2.10 – 1.99 (m, 7H), 1.96 (d, J 




– 0.83 (m, 8H). 13C NMR (151 MHz, CD3OD) δ 68.9, 66.3 (4 Cs), 42.9, 42.09, 42.05, 
42.0, 41.5, 41.4, 40.54 (4 Cs), 40.48 (4 Cs), 38.7, 38.5, 37.4, 36.7, 36.6 (4 Cs), 36.0, 




A solution of alcohol 196 (3.0 g, 23.78 mmol), tert-butyldimethylsilyl chloride (7.17 g, 
47.56 mmol) and imidazole (3.24 g, 47.56 mmol) in DMF (30 mL) was stirred at room 
temperature for 3.5 h before it was diluted with ethyl acetate, washed with brine, dried 
over Na2SO4, and concentrated under reduced pressure. Chromatographic purification 
(6% ethyl acetate/hexanes) afforded the title compound as a colorless oil (221, 3.28 g, 
57%): [α]D
21 44.5 (c 0.82, CHCl3).
 1H NMR (400 MHz, CDCl3) δ 7.03 – 6.92 (m, 1H), 
6.01 (d, J = 10.0 Hz, 1H), 3.63 – 3.47 (m, 2H), 2.54 – 2.17 (m, 5H), 0.89 (s, 9H), 0.04 (s, 
6H). 13C NMR (101 MHz, CDCl3) δ 199.8, 149.7, 129.7, 66.1, 40.9, 37.7, 28.6, 25.9 (3 
Cs), 18.3, -5.46, -5.49. HRMS (ESI-TOF) m/z: Calcd. for C13H24O2SiNa ([M + Na]
+): 
263.1443; found: 263.1442. 
(5R,6R)-5-((Methoxymethoxy)methyl)-6-hydroxycyclohex-2-en-1-one (229). 
To a stirred solution of diisopropylamine (53.5 µL, 0.38 mmol) in THF (0.5 mL) at -78 oC 
was added n-butyllithium solution (2.5 M in hexanes, 0.15 mL, 0.38 mmol) dropwise. 
After stirring at the same temperature for 15 min, a solution of 197 (50.0 mg, 0.29 mmol) 
in THF (0.5 mL) was added dropwise. The reaction mixture was stirred for a further 40 
min at -78 oC before (1S)-(+)-(10-camphorsulfonyl)oxaziridine 234 (101.0 mg, 6.00 
mmol) was added. The reaction mixture was allowed to warm to room temperature 




mixture was extracted with ethyl acetate. The combined organic layers were washed 
with brine, dried over Na2SO4, and concentrated under reduced pressure. 
Chromatographic purification (25% ethyl acetate/hexanes) afforded the title compound 
as a colorless oil (229, 26.3 mg, 48%): [α]D
21 78.2 (c 0.49, CHCl3).
 1H NMR (400 MHz, 
CDCl3) δ 7.04 (ddd, J = 10.0, 4.9, 3.5 Hz, 1H), 6.15 – 6.07 (m, 1H), 4.70 – 4.63 (m, 2H), 
4.16 (dd, J = 12.7, 1.9 Hz, 1H), 3.79 (dd, J = 9.7, 5.4 Hz, 1H), 3.74 – 3.68 (m, 2H), 3.38 
(s, 3H), 2.63 – 2.54 (m, 2H), 2.28 – 2.16 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 200.3, 
151.2, 126.5, 96.7, 73.3, 67.4, 55.3, 43.4, 29.3. HRMS (ESI-TOF) m/z: Calcd. for 
C9H14O4Na ([M + Na]
+): 209.0790; found: 209.0786. 
229 Was also obtained by the oxidation of enone 197 with 233: To a stirred solution of 
potassium bis(trimethylsilyl)amide (0.5 M in toluene, 0.71 mL, 0.35 mmol) in THF (1 mL) 
at -78 oC was added a solution of 197 (50.0 mg, 0.29 mmol) in THF (0.6 mL) dropwise. 
After stirring at the same temperature for 30 min, a solution of oxaziridine 233 (121.3 
mg, 0.44 mmol) in THF (0.6 mL) was added. The reaction mixture was stirred for a 
further 15 min at -78 oC before saturated aqueous NH4Cl was added. After warming to 
room temperature, the reaction mixture was extracted with ethyl acetate. The combined 
organic layers were washed with brine, dried over Na2SO4, and concentrated under 
reduced pressure. Chromatographic purification (25% ethyl acetate/hexanes) afforded 









To a stirred solution of diisopropylamine (17.5 µL, 0.12 mmol) in THF (0.1 mL) at -78 oC 
was added n-butyllithium solution (2.5 M in hexanes, 50 µL, 0.12 mmol) dropwise. After 
stirring at the same temperature for 10 min, a solution of 221 (20.0 mg, 0.08 mmol) in 
THF (0.13 mL) was added dropwise. The reaction mixture was stirred for a further 30 
min at -78 oC before the saccharin-derived oxaziridine 235 (32.8 mg, 0.17 mmol) was 
added. After completion (1.5 h), saturated aqueous NH4Cl was added and the reaction 
mixture was allowed to warm to room temperature, and extracted with ethyl acetate. 
The combined organic layers were washed with brine, dried over Na2SO4, and 
concentrated under reduced pressure. Chromatographic purification (4% ethyl 
acetate/hexanes) afforded the title compound as a colorless oil (trans-238, 8.2 mg, 
38%): [α]D
21 51.2 (c 0.26, CHCl3).
 1H NMR (400 MHz, CDCl3) δ 7.04 (ddd, J = 9.9, 5.5, 
2.7 Hz, 1H), 6.10 (ddd, J = 9.9, 2.9, 1.1 Hz, 1H), 4.13 (dd, J = 12.6, 1.7 Hz, 1H), 3.88 
(dd, J = 10.1, 5.1 Hz, 1H), 3.77 (dd, J = 10.1, 3.0 Hz, 1H), 3.66 (d, J = 1.7 Hz, 1H), 2.66 
– 2.44 (m, 2H), 2.19 – 2.06 (m, 1H), 0.91 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 200.7, 151.6, 126.3, 73.1, 62.7, 45.3, 28.7, 25.9 (3 Cs), 18.3, -5.47, 
-5.49. HRMS (ESI-TOF) m/z: Calcd. for C26H48O6Si2Na ([2M + Na]
+): 535.2887; found: 
535.2889. 
Further elution (6% ethyl acetate/hexanes) gave cis-238 as a colorless oil (6.7 mg, 
31%): [α]D
21 46.3 (c 0.24, CHCl3).
 1H NMR (400 MHz, CDCl3) δ 6.91 – 6.81 (m, 1H), 




3.8 Hz, 1H), 3.64 (d, J = 2.3 Hz, 1H), 3.57 (dd, J = 10.1, 7.6 Hz, 1H), 2.80 – 2.53 (m, 
3H), 0.85 (s, 9H), 0.00 (s, 3H), -0.01 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 199.1, 
149.2, 127.0, 74.0, 60.2, 42.2, 28.0, 25.8 (3 Cs), 18.2, -5.6, -5.7. HRMS (ESI-TOF) m/z: 
Calcd. for C26H48O6Si2Na ([2M + Na]
+): 535.2887; found: 535.2896. 
trans-238 Was also obtained by the oxidation of enone 221 with 236: To a stirred 
solution of diisopropylamine (17.5 µL, 0.12 mmol) in THF (0.1 mL) at -78 oC was added 
n-butyllithium solution (2.5 M in hexanes, 50 µL, 0.12 mmol) dropwise. After stirring at 
the same temperature for 10 min, a solution of 221 (20.0 mg, 0.08 mmol) in THF (0.13 
mL) was added dropwise. The reaction mixture was stirred for a further 30 min at -78 
oC before the saccharin-derived oxaziridine 236 (39.8 mg, 0.17 mmol) was added. The 
reaction mixture was allowed to warm to room temperature slowly. After completion 
(3.5 h), saturated aqueous NH4Cl and saturated aqueous Na2S2O3 were added, and 
the reaction mixture was extracted with ethyl acetate. The combined organic layers 
were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. 
Chromatographic purification (4% ethyl acetate/hexanes) afforded trans-238 as a 
colorless oil (13.7 mg, 64%). 
(5R,6R)-5-((Methoxymethoxy)methyl)-6-(methoxymethoxy)cyclohex-2-en-1-one 
(240). 
A stirred solution of 229 (28.9 mg, 0.16 mmol) in N,N-diisopropylethylamine (0.3 mL) 
and DCM (0.3 mL) at room temperature was treated with chloromethyl methyl ether 
(47.2 µL, 0.62 mmol), and stirred at room temperature for 16 h before it was diluted 
with ethyl acetate, washed with 1 N HCl and brine, dried over Na2SO4, and 




acetate/hexanes) afforded the title compound as a colorless oil (240, 32.1 mg, 90%): 
[α]D
21 184.6 (c 1.25, CHCl3).
 1H NMR (600 MHz, CDCl3) δ 6.90 (ddd, J = 10.0, 5.3, 2.8 
Hz, 1H), 5.98 (ddd, J = 10.0, 2.8, 1.1 Hz, 1H), 4.88 (d, J = 6.8 Hz, 1H), 4.77 (d, J = 6.8 
Hz, 1H), 4.62 (s, 2H), 4.19 (d, J = 12.2 Hz, 1H), 3.70 – 3.65 (m, 2H), 3.42 (s, 3H), 3.35 
(s, 3H), 2.63 – 2.50 (m, 2H), 2.43 – 2.34 (m, 1H). 13C NMR (151 MHz, CDCl3) δ 198.5, 
148.8, 128.3, 97.2, 96.7, 77.5, 67.3, 56.3, 55.4, 41.5, 29.4. HRMS (ESI-TOF) m/z: 
Calcd. for C11H18O5Na ([M + Na]
+): 253.1052; found: 253.1062. 
(5R,6R)-5-(((tert-Butyldimethylsilyl)oxy)methyl)-6-((tert-
butyldimethylsilyl)oxy)cyclohex-2-en-1-one (241). 
To a stirred solution of trans-238 (95.2 mg, 0.37 mmol) in DCM (2.9 mL) at -78 oC was 
added 2,6-lutidine (0.13 mL, 1.11 mmol) and t-butyldimethylsilyl triflate (0.11 mL, 0.48 
mmol). The reaction mixture was stirred at the same temperature for 30 min before 
saturated aqueous NH4Cl was added. After warming to room temperature, the reaction 
mixture was extracted with DCM. The combined organic layers were washed with 1 N 
HCl and brine, dried over Na2SO4, and concentrated under reduced pressure. 
Chromatographic purification (2% ethyl acetate/hexanes) afforded the title compound 
as a colorless oil (241, 128.0 mg, 93%): [α]D
21 79.8 (c 1.15, CHCl3).
  1H NMR (400 MHz, 
CDCl3) δ 6.90 (ddd, J = 9.9, 4.8, 3.4 Hz, 1H), 5.96 (dt, J = 9.9, 1.7 Hz, 1H), 4.18 (d, J = 
11.9 Hz, 1H), 3.81 (dd, J = 10.0, 5.4 Hz, 1H), 3.72 (dd, J = 10.0, 3.2 Hz, 1H), 2.54 – 
2.40 (m, 2H), 2.28 – 2.14 (m, 1H), 0.92 (s, 9H), 0.90 (s, 9H), 0.21 (s, 3H), 0.06 (s, 3H), 
0.05 (s, 3H), 0.04 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 199.5, 148.8, 128.0, 75.3, 62.9, 
45.4, 29.0, 25.98 (3 Cs), 25.96 (3 Cs), 18.7, 18.4, -3.9, -5.3, -5.5, -5.7. HRMS (ESI-
TOF) m/z: Calcd. for C19H39O3Si2 ([M + H]





(ethylthio)cyclohexan-1-one (242) and (2R,3R,5S)-2-(Methoxymethoxy)-3-
((methoxymethoxy)methyl)-5-(ethylthio)cyclohexan-1-one (244). 
To a stirred solution of 240 (187.4 mg, 0.81 mmol) in MeOH (1.5 mL) at room 
temperature was added sodium ethanethiolate (205.4 mg, 2.44 mmol). The reaction 
mixture was stirred at the same temperature for 30 min before it was diluted with ethyl 
acetate, washed with brine, dried over Na2SO4, and concentrated under reduced 
pressure. Chromatographic purification (16% ethyl acetate/hexanes) afforded the title 
compound as a colorless oil (242, 124.7 mg, 52%): [α]D
21 124.3 (c 1.29, CHCl3).
 1H 
NMR (400 MHz, CDCl3) δ 4.73 (d, J = 6.8 Hz, 1H), 4.67 (d, J = 6.8 Hz, 1H), 4.63 (s, 
2H), 4.20 (d, J = 11.4 Hz, 1H), 3.71 – 3.61 (m, 2H), 3.39 (s, 3H), 3.36 (s, 3H), 2.91 (tt, J 
= 12.6, 4.0 Hz, 1H), 2.73 (dt, J = 13.1, 3.4 Hz, 1H), 2.59 (q, J = 7.4 Hz, 2H), 2.41 (t, J = 
13.1 Hz, 1H), 2.27 (dq, J = 13.5, 3.3 Hz, 1H), 2.06 – 1.94 (m, 1H), 1.87 (app q, J = 12.6 
Hz, 1H), 1.24 (t, J = 7.4, 3H). 13C NMR (101 MHz, CDCl3) δ 206.1, 96.7, 96.4, 79.0, 
67.5, 56.2, 55.4, 47.6, 44.1, 41.2, 35.1, 24.7, 14.8. HRMS (ESI-TOF) m/z: Calcd. for 
C13H24O5SNa ([M + Na]
+): 315.1242; found: 315.1247. 
Further elution (20% ethyl acetate/hexanes) gave 244 as a colorless oil (46.0 mg, 19%): 
[α]D
21 73.1 (c 0.32, CHCl3).
 1H NMR (400 MHz, CDCl3) δ 4.76 (d, J = 6.9 Hz, 1H), 4.70 
(d, J = 6.9 Hz, 1H), 4.63 (s, 2H), 4.14 (d, J = 10.4 Hz, 1H), 3.71 (dd, J = 9.6, 4.7 Hz, 
1H), 3.61 (dd, J = 9.6, 3.1 Hz, 1H), 3.51 (app p, J = 7.8, 3.6 Hz, 1H), 3.41 (s, 3H), 3.37 
(s, 3H), 2.74 (dd, J = 14.0, 5.0 Hz, 1H), 2.61 (ddd, J = 14.0, 3.8, 2.4 Hz, 1H), 2.58 – 
2.46 (m, 3H), 2.24 (ddd, J = 14.9, 11.3, 3.8 Hz, 1H), 2.09 (dtd, J = 14.3, 4.1, 2.4 Hz, 




56.2, 55.4, 45.0, 40.9, 40.6, 32.1, 24.8, 14.4. HRMS (ESI-TOF) m/z: Calcd. for 
C13H24O5SNa ([M + Na]
+): 315.1242; found: 315.1253. 
(2R,3R,5R)-2-((tert-Butyldimethylsilyl)oxy)-3-(((tert-
butyldimethylsilyl)oxy)methyl)-5-(ethylthio)cyclohexan-1-one (243) and 
(2R,3R,5S)-2-((tert-Butyldimethylsilyl)oxy)-3-(((tert-butyldimethylsilyl)oxy)methyl)-
5-(ethylthio)cyclohexan-1-one (245). 
To a stirred solution of 241 (880.0 mg, 2.37 mmol) in MeOH (10 mL) at room 
temperature was added sodium ethanethiolate (599.1 mg, 7.12 mmol). The reaction 
mixture was stirred at the same temperature for 20 min before it was diluted with ethyl 
acetate, washed with brine, dried over Na2SO4, and concentrated under reduced 
pressure. Chromatographic purification (2% ethyl acetate/hexanes) afforded the title 
compound as a colorless oil (243, 600.0 mg, 58%): [α]D
21 86.6 (c 1.52, CHCl3).
 1H NMR 
(400 MHz, CDCl3) δ 4.16 (d, J = 10.0 Hz, 1H), 3.79 (dd, J = 9.8, 4.0 Hz, 1H), 3.69 (dd, 
J = 9.8, 2.2 Hz, 1H), 2.92 (tt, J = 12.6, 4.0 Hz, 1H), 2.71 (ddd, J = 13.2, 4.1, 2.8 Hz, 1H), 
2.58 (q, J = 7.4 Hz, 2H), 2.36 (t, J = 13.2 Hz, 1H), 2.15 (dt, J = 10.1, 3.3 Hz, 1H), 1.87 – 
1.71 (m, 2H), 1.25 (t, J = 7.4 Hz, 3H), 0.90 (s, 18H), 0.14 (s, 3H), 0.06 (s, 3H), 0.05 (s, 
3H), -0.01 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 207.3, 76.7, 62.9, 47.6, 47.2, 41.2, 
34.6, 26.0 (3 Cs), 25.9 (3 Cs), 24.6, 18.5, 18.4, 14.9, -4.2, -5.3, -5.5, -5.7. HRMS (ESI-
TOF) m/z: Calcd. for C21H48O3NSSi2 ([M + NH4]
+): 450.2893; found: 450.2911. 
Further elution (3% ethyl acetate/hexanes) gave 245 as a white solid (195.2 mg, 19%): 
[α]D
21 17.7 (c 0.79, CHCl3).
 1H NMR (400 MHz, CDCl3) δ 4.10 (d, J = 9.6 Hz, 1H), 3.82 
(dd, J = 10.0, 4.5 Hz, 1H), 3.62 (dd, J = 10.0, 3.2 Hz, 1H), 3.47 (app p, J = 4.2 Hz, 1H), 




3.9 Hz, 2H), 2.32 – 2.23 (m, 1H), 2.12 (ddd, J = 14.1, 10.7, 3.8 Hz, 1H), 1.99 (dtd, J = 
14.1, 4.2, 2.1 Hz, 1H), 1.23 (t, J = 7.4 Hz, 3H), 0.92 – 0.88 (m, 18H), 0.13 (s, 3H), 0.05 
(s, 3H), 0.04 (s, 3H), -0.00 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 207.4, 76.8, 62.8, 
44.6, 44.5, 40.7, 31.6, 25.94 (3 Cs), 25.88 (3 Cs), 24.8, 18.5, 18.3, 14.5, -4.2, -5.3, -5.5 
(2 Cs). HRMS (ESI-TOF) m/z: Calcd. for C21H48O3NSSi2 ([M + NH4]




 To a stirred solution of 242 (124.7 mg, 0.43 mmol) in THF (1.5 mL) at -78 oC was 
added a solution of L-Selectride in THF (1.0 M, 1.28 mL, 1.28 mmol). The reaction 
mixture was stirred at the same temperature for 3 h before it was quenched by adding 
methanol. After warming to room temperature, the volatile was removed by 
concentration under reduced pressure. Chromatographic purification (25% ethyl 
acetate/hexanes) afforded the title compound as a colorless oil (246, 89.0 mg, 71%): 
[α]D
21 13.0 (c 1.28, CHCl3).
 1H NMR (400 MHz, CDCl3) δ 4.72 (d, J = 6.7 Hz, 1H), 4.65 
(d, J = 6.7 Hz, 1H), 4.59 (s, 2H), 4.14 (app q, J = 3.0 Hz, 1H), 3.58 (dd, J = 9.4, 2.9 Hz, 
1H), 3.54 (dd, J = 9.4, 5.1 Hz, 1H), 3.48 (dd, J = 10.6, 3.0 Hz, 1H), 3.39 (s, 3H), 3.34 (s, 
3H), 3.06 (tt, J = 12.3, 3.4 Hz, 1H), 2.57 (q, J = 7.4 Hz, 2H), 2.26 (dq, J = 14.1, 3.5 Hz, 
1H), 2.15 – 2.03 (m, 2H), 1.43 (ddd, J = 14.1, 12.7, 2.6 Hz, 1H), 1.34 (app q, J = 13.2 
Hz, 1H), 1.24 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 96.7, 96.1, 78.3, 68.4, 
67.9, 55.9, 55.2, 37.6, 37.2, 35.9, 35.5, 24.4, 15.1. HRMS (ESI-TOF) m/z: Calcd. for 
C13H26O5SNa ([M + Na]






To a stirred solution of 243 (263.2 mg, 0.61 mmol) in THF (2 mL) at -78 oC was added 
a solution of L-Selectride in THF (1.0 M, 1.82 mL, 1.82 mmol). The reaction mixture 
was stirred at the same temperature for 7 h before it was warmed to room temperature. 
The reaction was quenched by adding MeOH and the mixture was concentrated under 
reduced pressure. Chromatographic purification (3% ethyl acetate/hexanes) afforded 
the title compound as a colorless oil (247, 46.6 mg, 17%): [α]D
21 22.7 (c 0.44, CHCl3).
  
1H NMR (400 MHz, CDCl3) δ 3.88 (app q, J = 3.2 Hz, 1H), 3.62 – 3.59 (m, 2H), 3.56 
(dd, J = 10.3, 3.2 Hz, 1H), 3.06 (tt, J = 12.5, 3.7 Hz, 1H), 2.57 (q, J = 7.4 Hz, 2H), 2.45 
(d, J = 2.1 Hz, 1H), 2.27 (dq, J = 14.0, 3.5 Hz, 1H), 1.98 (dq, J = 13.1, 3.5 Hz, 1H), 1.90 
– 1.78 (m, 1H), 1.41 (ddt, J = 14.0, 12.7, 2.1 Hz, 1H), 1.32 – 1.19 (m, 4H), 0.90 (s, 9H), 
0.89 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 72.2, 70.3, 63.5, 40.7, 37.6, 36.2, 34.9, 26.0 (3 Cs), 25.8 (3 Cs), 24.2, 18.4, 
18.0, 15.1, -4.4, -4.9, -5.3, -5.5. HRMS (ESI-TOF) m/z: Calcd. for C21H47O3SSi2 ([M + 
H]+): 435.2784; found: 435.2774. 
(1S,2R,3R,5R)-2-(Methoxymethoxy)-3-((methoxymethoxy)methyl)-5-
(ethylthio)cyclohexyl Methanesulfonate (248). 
To a stirred solution of 246 (125.1 mg, 0.42 mmol) in pyridine (2 mL) at room 
temperature was added methanesulfonyl chloride (0.16 mL, 2.12 mmol). The reaction 
mixture was stirred at the same temperature for 20 h before it was diluted with ethyl 
acetate, washed with 1 N HCl and brine, dried over Na2SO4, and concentrated under 




the title compound as a colorless oil (248, 141.0 mg, 89%): [α]D
21 49.1 (c 1.37, CHCl3).
 
1H NMR (400 MHz, CDCl3) δ 5.14 (dt, J = 4.4, 2.2 Hz, 1H), 4.75 (d, J = 6.7 Hz, 1H), 
4.62 (d, J = 6.7 Hz, 1H), 4.59 (s, 2H), 3.63 – 3.53 (m, 3H), 3.40 (s, 3H), 3.34 (s, 3H), 
3.09 (s, 3H), 3.03 (tt, J = 13.1, 3.4 Hz, 1H), 2.57 (q, J = 7.4 Hz, 2H), 2.45 (dtd, J = 14.5, 
3.9, 2.7 Hz, 1H), 2.18 – 2.03 (m, 2H), 1.59 (ddd, J = 14.5, 12.6, 2.0 Hz, 1H), 1.45 (app 
q, J = 12.5 Hz, 1H), 1.24 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 96.7, 96.2, 
79.8, 75.4, 67.7, 56.1, 55.4, 39.0, 37.9, 37.7, 35.8, 35.2, 24.5, 14.9. HRMS (ESI-TOF) 
m/z: Calcd. for C14H28O7S2Na ([M + Na]
+): 395.1174; found: 395.1161. 
(1S,2R,3R,5R)-2-((tert-Butyldimethylsilyl)oxy)-3-(((tert-
butyldimethylsilyl)oxy)methyl)-5-(ethylthio)cyclohexyl Methanesulfonate (249). 
To a stirred solution of 247 (46.6 mg, 0.11 mmol) in pyridine (0.8 mL) at room 
temperature was added methanesulfonyl chloride (41.5 µL, 0.54 mmol). The reaction 
mixture was stirred at the same temperature for 11 h before it was diluted with ethyl 
acetate, washed with 1 N HCl and brine, dried over Na2SO4, and concentrated under 
reduced pressure. Chromatographic purification (5% ethyl acetate/hexanes) afforded 
the title compound as a colorless oil (249, 39.0 mg, 71%): [α]D
21 50.0 (c 0.52, CHCl3).
 
1H NMR (400 MHz, CDCl3) δ 4.92 (app p, J = 2.1 Hz, 1H), 3.65 – 3.61 (m, 2H), 3.58 
(dd, J = 10.5, 2.7 Hz, 1H), 3.12 – 3.01 (m, 4H), 2.57 (q, J = 7.4 Hz, 2H), 2.49 (dq, J = 
14.5, 3.7 Hz, 1H), 2.07 (dq, J = 13.1, 3.6 Hz, 1H), 1.99 – 1.88 (m, 1H), 1.56 (ddd, J = 
14.5, 12.3, 2.0 Hz, 1H), 1.33 (app q, J = 13.1 Hz, 1H), 1.25 (t, J = 7.4 Hz, 3H), 0.91 (s, 
9H), 0.89 (s, 9H), 0.12 (s, 3H), 0.09 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H). 13C NMR (101 




24.5, 18.4, 18.1, 15.0, -4.0, -5.1, -5.3, -5.4. HRMS (ESI-TOF) m/z: Calcd. for 
C22H52O5NS2Si2 ([M + NH4]
+): 530.2825; found: 530.2833. 
S-((1R,2R,3R,5R)-2-(Methoxymethoxy)-3-((methoxymethoxy)methyl)-5-
(ethylthio)cyclohexyl) Thioacetate (250). 
A mixture of 248 (10.0 mg, 0.03 mmol) and cesium thioacetate (111.7 mg, 0.54 mmol) 
in DMF (0.1 mL) was heated to 100 oC by irridation with microwave for 1 h. After 
cooling to room temperature, the reaction mixture was diluted with ethyl acetate, 
washed with brine, dried over Na2SO4, and concentrated under reduced pressure. 
Chromatographic purification (16% ethyl acetate/hexanes) afforded the title compound 
as a light yellow oil (250, 5.0 mg, 53%): [α]D
21 -27.0 (c 0.30, CHCl3).
 1H NMR (400 MHz, 
CDCl3) δ 4.71 – 4.65 (m, 2H), 4.60 (s, 2H), 3.63 – 3.57 (m, 2H), 3.57 – 3.49 (m, 2H), 
3.40 (s, 3H), 3.35 (s, 3H), 2.78 (tt, J = 12.3, 3.7 Hz, 1H), 2.57 (q, J = 7.4 Hz, 2H), 2.38 – 
2.30 (m, 4H), 2.12 (dq, J = 13.4, 3.4 Hz, 1H), 1.87 – 1.75 (m, 1H), 1.53 (app q, J = 12.7 
Hz, 1H), 1.45 (app q, J = 12.7 Hz, 1H), 1.25 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 194.8, 98.5, 96.7, 79.0, 68.1, 56.6, 55.3, 48.1, 44.8, 40.8, 40.2, 35.5, 30.8, 




butyldimethylsilyl)oxy)methyl)-5-(ethylthio)cyclohexyl) Thioacetate (251). 
A mixture of 249 (10.0 mg, 0.02 mmol) and cesium thioacetate (12.2 mg, 0.06 mmol) in 
DMF (0.08 mL) was heated to 100 oC by irridation with microwave for 30 min. After 
cooling to room temperature, the reaction mixture was diluted with ethyl acetate, 




Chromatographic purification (3% ethyl acetate/hexanes) afforded the title compound 
as a light yellow oil (251, 4.0 mg, 42%): [α]D
21 -30.0 (c 0.20, CHCl3).
 1H NMR (600 MHz, 
CDCl3) δ 3.64 – 3.58 (m, 2H), 3.48 – 3.40 (m, 2H), 2.77 (tt, J = 12.4, 3.6 Hz, 1H), 2.54 
(q, J = 7.4 Hz, 2H), 2.33 – 2.23 (m, 4H), 2.03 (dq, J = 13.4, 3.6 Hz, 1H), 1.65 – 1.57 (m, 
1H), 1.48 (app q, J = 12.4 Hz, 1H), 1.29 (app q, J = 12.8 Hz, 1H), 1.23 (t, J = 7.4 Hz, 
3H), 0.88 (s, 9H), 0.84 (s, 9H), 0.10 (s, 3H), 0.05 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H). 13C 
NMR (151 MHz, CDCl3) δ 195.0, 71.8, 63.6, 49.6, 48.1, 40.9, 40.8, 35.2, 30.8, 26.1 (3 
Cs), 25.9 (3 Cs), 24.3, 18.4, 18.3, 15.0, -3.3, -3.6, -5.2, -5.4. HRMS (ESI-TOF) m/z: 
Calcd. for C23H52O3NS2Si2 ([M + NH4]
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As one of the four major classes of macromolecule in living systems, the roles of 
carbohydrates as energy storage substances and structural components have long 
been recognized. However, the unique role of carbohydrates in cellular recognition 
processes has only been scrutinized since the 1960s, thanks to the progress in the 
research in both cell surface carbohydrates and carbohydrate-binding proteins (lectins). 
The advances in the research of such process demand the use of carbohydrates as 
basic tools. Therefore, the primary goal of glycochemistry has been to obtain complex 
carbohydrates and their analogs effectively. One common approach to the problem 
involves the chemical synthesis of carbohydrates, with glycosylation as the key reaction. 
The glycosylation reaction enables the attachment of a carbohydrate moiety to a non-
carbohydrate carrier or another carbohydrate molecule and is currently under extensive 
research. An indirect approach to the problem uses rationally designed structural 
analogs to mimic the natural carbohydrates. The work conducted in this study is related 




Chapter one surveys the background to the research. It starts with a brief 
introduction of the structure and energy-related functions of carbohydrates. Then cell 
surface carbohydrates, lectins, and the nature of their interactions are introduced. 
Chapter one also introduces the implications of carbohydrates in drug development. 
Progress in oligosaccharide synthesis, the general mechanism of glycosylation 
reactions, and neighboring group participation are briefly discussed at the end of the 
chapter. 
Chapter two describes the use of a series of 2-O-alkoxylcarbonylmethyl ether 
protected mannopyranosyl donors as probes for the stereodirecting participation of 
ester functionalities through six-membered rings. The preparation of these 
mannopyranosyl donors, their glycosylation reactions, and the deprotection of the 
protecting groups are described. The results are discussed in the context of the 
possibilities of participation by these functionalities through six-membered cyclic 
intermediates. On the basis of a conformational analysis of the putative dioxenium ions, 
DFT calculations allow the comparison of the cyclization of the 
2-O-alkoxylcarbonylmethyl ether systems with hypothetical remote participation by an 
ester group at the 3-O position. 
In chapter three, the general mechanisms and the progress in the development 
of photocatalytic glycosylation reactions are discussed. In order to solve the problems 
associated with the current methods, and inspired by an interesting method of 
generating simple alkyl cabocations, chapter three next describes the development of a 
new blue light photocatalytic glycosylation reaction employing stable and readily 




generally clean reaction profiles establish the effectiveness of this method. The modest 
donor-dependent stereoselectivities are discussed in terms of partially concerted 
reaction mechanisms. 
In chapter four, the design and synthesis of a series of oligomeric 
thioether-linked cabasugars as β-glucan mimetics are presented. The 4-deoxy series of 
mimetics are prepared efficiently via a method featuring a thiol-Michael addition 
reaction. Results of biological tests are presented, which indicate that the oligomeric 
thioether-linked cabasugars are able to bind to the common β-glucan receptors CR3 
and Dectin-1, and that they stimulate phagocytosis. The results suggest that the 
enhanced interaction between the ligands and the receptors is due to the increased 
hydrophobicity of the α-faces of the ligand molecules, which is consistent with the 
conclusions drawn from the previous studies in the Crich laboratory. 
The thesis ends with a conclusion chapter and complete experimental details for 








08 / 2012 – Present: Ph.D. in Organic Chemistry, advisor: Prof. David Crich 
Department of Chemistry, Wayne State University, Detroit, Michigan, USA 
08 / 2009 – 06 / 2012: M.S., Biochemical engineering, advisor: Prof. Qun Lu 
School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 
China 
08 / 2005 – 06 / 2009: B.S., Bioengineering 
School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 
China 
Publications 
 “The Experimental Evidence in Support of Glycosylation Mechanisms at the SN1‐SN2 
Interface” 
Philip O Adero, Harsha Amarasekara, Peng Wen, Luis Bohé, and David Crich, Chem. 
Rev. accepted. 
 “Allylic Strain as a Stereocontrol Element in the Hydrogenation of 3-Hydroxymethyl-
cyclohex-3-en-1,2,5-triol Derivatives. Synthesis of the Carbasugar Pseudo-2-deoxy-α-D-
glucopyranose” 
Peng Wen and David Crich, Tetrahedron, accepted. 
 “Blue Light  hotocatalytic Glycosylation without Electrophilic Additives”  
Peng Wen and David Crich, Org. Lett. 2017, 19, 2402 - 2405. 
 “Absence of Stereodirecting  articipation by 2-O-Alkoxycarbonylmethyl Ethers in 4, 6-
O-Benzylidene-Directed Mannosylation”  
Peng Wen and David Crich, J. Org. Chem. 2015, 80, 12300 - 12310. 
 “ ovel Synthesis of  aricalcitol by Chem-Biotransformation” 
Yang Wan; Peng Wen; Pan Zhang and Qun Lu, Chin. J. Org. Chem. 2012, 32, 1988 
- 1992. 
Presentations 
 “Synthesis and Evaluation of Thioether-Based β(1→3)Glucan Mimetics” 
Oral presentation at the 252nd American Chemical Society National Meeting & 
Exposition 
Philadelphia, PA, August 21st ‐ 25th, 2016 
 “2-O-Alkoxycarbonylmethyl Ethers: Non-Participating Protecting Groups in 4,6-O-
Benzylidene-Directed Mannosylation” 
Oral presentation at the 17th Annual Chemistry Graduate Research Symposium 
Wayne State University, Detroit, MI, October 17th, 2015 
